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A virtual reality (VR) is a simulated environment generated by a computer (see figure 
1.1). Virtual environments are well known from gaming, where you can create a virtual 
character and go on adventures in a virtual environment. Technically, the term virtual 
reality could also be applied to two-dimensional programs displayed on a traditional 
computer monitor, but in this thesis, VR specifically refers to the use of a head mounted 
display (HMD) presenting the user with immersive 3D environments in a first-person 
perspective (figure 1.2). The HMD contains two small displays that show slightly 
Figure 1.1. Simulated environment generated by a computer. 
Source: CleVR.net
Figure 1.2. Head mounted display. 
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different images to the left and right eye, creating a 3D effect for the user. The HMD 
is equipped with sensors that track the movement of the user. This information is sent 
back to the computer and used to update the virtual environment. If the user turns 
their head to the left, the computer generates the left part of the virtual environment 
for them to see. This adaptation of the virtual environment happens so fast that it seems 
instantaneous to the user, giving them a sense of continued presence. Usually, the user 
can interact with the virtual environment by using a keyboard or controllers.
While the technology of VR has been around for decades, it has now become more 
affordable, available and user-friendly than before. Immersive VR environments give 
people a sense of presence, of ‘being there’, while simultaneously being aware that the 
virtual environment is not real1. While this double awareness is tolerated by most people, 
some develop cybersickness. Cybersickness is the experience of motion sickness-like 
symptoms such as nausea while being exposed to a VR environment2 and it diminishes 
the sense of presence3. Immersive VR makes it possible to bring real-life situations into 
the therapy or research room by using 3D VR-glasses, in a safe and controlled manner.
VR in psychology
Research on the use of VR in psychology includes work on assessing psychiatric disorders 
through VR4, using VR environments to explore working mechanisms of symptoms and 
VR therapy5,6. VR therapy research has been conducted for over two decades7 and has 
focused mainly on treating anxiety disorders5. Virtual reality exposure therapy produces 
significant behavior changes in real-life situations8. Exposure to feared stimuli and 
reducing safety behaviors is an essential part of treating anxiety. VR technology allows 
therapists to expose people to their feared stimuli in VR or ‘in virtuo’ to help them deal 
with these stimuli in their daily lives. 
VR treatment of social anxiety disorder shows that interactive virtual social environments 
can enable people to effectively confront their fears about being rejected by other people9. 
A similar approach could be used for people suffering from unfounded anticipation of 
intentional harm inflicted by other people. Studies have shown that virtual experiences 
were safe and acceptable for patients suffering from psychosis10 and for patients assessed 
with an at risk mental state for developing psychosis11, opening up possibilities for further 
research. A more recent review study confirms the safety and acceptability of using 
virtual reality with people experiencing psychotic symptoms12. Their attitude towards 
virtual reality was positive and they completed the tasks that were given to them13. 
People with paranoid ideation are constantly on the lookout for other people wanting to 
hurt them14. They either avoid social situations or endure them with high levels of stress 
using situational safety behaviors such as avoiding eye contact and remaining silent15. 








neglect, abuse or bullying; i.e. of being hurt by other people16. Traumatic experiences 
should be discussed with the patient at the start of treatment. When PTSD-classification 
is met, trauma-focused therapy should be conducted first as this improves both PTSD 
symptoms and psychotic symptoms17. The safety behaviors and avoidance strategies 
they’ve adopted prevent them from having any corrective positive or neutral experiences 
with other people to reduce their paranoid fears18. VR therapy using interactive social 
environments would be a valuable first step in gaining these experiences. 
Psychosis and paranoid ideation
Some people are vulnerable to developing psychotic symptoms, in the same way that 
others are vulnerable to developing anxiety or depression. Psychotic symptoms exist 
on a continuum across the general population19. Many people have psychotic-like 
experiences, such as hearing your phone ringing when it didn’t or thinking that, when 
you hear people laughing, they are laughing at you. There is a small group of people that 
experiences many of these psychotic experiences at once. Or they experience them more 
strongly, for instance hearing voices that others can’t hear or thinking the people they 
hear laughing are plotting to hurt them. If these experiences become too much for a 
person to bear and start to interfere with their ability to function, we call the symptoms 
a disorder. The current diagnostical classification manual used in the Netherlands is the 
DSM-520, which defines psychotic disorders according to abnormalities in one or more 
of the following five domains: delusions, hallucinations, disorganized thinking (speech), 
grossly disorganized or abnormal motor behavior (including catatonia), and negative 
symptoms21. A common experience is paranoid ideation, with regular experiences such 
as mistrust, interpersonal sensitivity and ideas of reference on one end of the continuum, 
and full persecutory delusions on the other end22. Paranoid ideation is exponentially 
distributed and hierarchically arranged across the human population. Persecutory 
delusions are reported by 70%23 to 90%18 of people diagnosed with a psychotic disorder 
to some degree. If you fear that other people want to hurt or even kill you, it is an 
understandable response to avoid social situations. While avoidance helps to feel safe in 
the short term, it leads to social withdrawal, isolation and loneliness in the long term. 
We see that people diagnosed with a psychotic disorder spend more time alone than 
people without a psychotic disorder24. Their social networks are generally limited, and 
many do not have a partner relationship25. Unemployment rates are high26. 
Environmental factors in psychosis
Psychology is a relatively young science, and at the cutting edge of interacting biological, 
social and psychological factors. Social factors have both a developmental influence and 
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a real-time influence on how we perceive social situations. Experiencing adverse life 
events during developmental years, such as childhood trauma, is related to an increased 
risk of developing psychotic disorders27. Later in life, stress sensitivity and learned threat 
anticipation increase chances for a psychotic evaluation of everyday life events and 
stressors28. Social context is thus inextricably bound up with psychotic experiences such as 
paranoid ideation, and research on mechanisms of paranoid ideation should incorporate 
social context. Research has shown that when exposed to a social environment, people 
with persecutory delusions report an increase in levels of anxiety and paranoid ideation29. 
Scientific research in real-life social environments is complicated by the fact that social 
environments are always changing, and each participant will inevitably encounter 
different people. VR can present the same social environments and stimuli to multiple 
subjects, enabling scientific experimentation.
Other studies have used the Experience Sampling Method (ESM) to incorporate social 
context in their design30. With ESM, participants wear technology in their daily life that 
beeps at random intervals, at which time a brief questionnaire can be answered. But 
ESM data still poses a challenge, as social contexts are continually changing and there 
is an interaction effect between the participant and other people. For research purposes, 
full control and repeatability of social contexts (while still being as realistic as possible) 
are necessary to better understand the mechanisms of paranoid ideation. 
Antipsychotic treatment with medication
According to The National Institute for Health and Care Excellence (NICE) guidelines, 
treatment of psychotic symptoms consists of antipsychotic medication and added 
cognitive behavioral therapy for psychosis (CBTp)31.The NICE guidelines for psychosis 
and schizophrenia also mention that the patient and the healthcare professional should 
make the choice for pharmacotherapeutic treatment together. Antipsychotic medication 
can help reduce psychotic symptoms, but effect sizes are small to moderate32. The 
conditioned social avoidance resulting from paranoid ideation and anxiety does not 
always improve with antipsychotic medication18. The use of antipsychotic medication 
does not always prevent relapse (27% within one year)33. First episode psychosis even has 
78% relapses in 24 months34. Besides the benefits, there is also a risk of side effects when 
using antipsychotic medication35. Common side effects include motor disturbances like 
parkinsonism, breast milk production in male, weight gain, decreased sexual libido and 
dysphoria. Since such side effects can negatively impact quality of life, patients often opt 










Cognitive behavioral therapy for psychosis is the most effective psychotherapy in treating 
paranoid ideation37, and the NICE guidelines recommend at least sixteen individual 
sessions31. There is robust evidence for the effects on delusions and hallucinations38. 
Recent research also indicates that CBTp is effective for people who do not use 
antipsychotic medication39. 
A vast amount of scientific research publications has demonstrated the treatment effect of 
exposure therapy40. Exposure is the core component of any anxiety treatment, including 
paranoid anxiety. In exposure sessions, people are confronted with feared stimuli to test 
the accuracy of their expected negative outcome. When they are exposed to the feared 
stimuli but the expected negative outcome does not occur, they start to develop a more 
realistic outcome expectancy, and their anxiety drops. 
There are several challenges with exposure therapy to which VR could offer solutions. 
Since VR is not real, the threshold to start exposure therapy is expected to be low. 
Furthermore, some individuals do not benefit from exposure treatment and others 
experience a recurrence of fear after treatment. A core mechanism believed to underlie 
exposure therapy is inhibitory learning41. Several exposure optimization strategies are 
proposed to strengthen the effect of inhibitory learning41. VR is expected to contribute 
to several of these, because of the extended level of control over the virtual exposure 
conditions. Two enhancement possibilities that VR offers are ‘variability’ and ‘multiple 
contexts’. By varying the stimuli and contexts in which exposure takes place, the 
retrievability of newly learned information increases. Recurrence of fear after treatment 
is expected to decline. Furthermore, VR can be used to maximize expectancy violation. 
Stimuli can be added during exposure and negative outcome scenarios can be created, 
for instance, a virtual social rejection scenario in which a person can experience that, 
while social rejection is an unpleasant experience, they are able to handle it and do not 
experience the anticipated negative consequences.
Virtual reality-based cognitive behavioral therapy (VR-CBT)
Using VR to enhance CBT for people suffering from paranoid ideation has several 
advantages. Many of these patients see it as a more acceptable start of therapy because 
it is not real. An added advantage of in virtuo is that exercises can take place in the 
privacy of the therapy room, with the full support of the attendant therapist. During 
in virtuo exercises in the therapy room, all thoughts, feelings and behaviors can be 
discussed in real-time. Another advantage of VR is the opportunity for the therapist 
to use positive affirmation when the patient is taking important steps and performing 
difficult tasks. At the same time, it can sometimes be useful to correct unhelpful behavior. 
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Another important advantage of in virtuo therapy is that learning environments can be 
personalized and controlled by the therapist. Interactive environments can be created 
based on the individual paranoid expectations of the patient. Finally, the exercises can be 
repeated as many times as patient and therapist want. The virtual people will not react 
any differently the fourth or even twentieth time a patient does an exercise.
The core of VR-CBT is reducing safety behaviors while actively testing harm expectancies 
during behavioral experiments. Safety behaviors get in the way of having corrective 
experiences. A patient who feels safe because they do not make eye contact with other 
people will never learn that they are still safe when they do make eye contact with 
people. During therapy, patients are actively testing their paranoid expectancies. They 
expose themselves to virtual social situations while reducing their safety behaviors such 
as avoiding eye contact, escaping from the situation, showing obedience to avatars, 
seeking aid from others or turning to aggression. While being exposed to the social 
situation, they actively test harm expectancies such as: ‘If I make eye contact with 
other people, they will react aggressively towards me’. The outcome of this particular 
behavioral experiment will likely be: ‘If I make eye contact with people, they will just 
look away after a few seconds and do nothing’. 
In addition to experiencing corrective neutral or positive social situations, VR can also 
be used to test harm expectancies in negative social situations. This usually takes place 
in a later stage of the therapy, and never without consent. For example, many patients 
fear that other people will think of them as being ‘weird’. That also raises the interesting 
question of what ‘normal’ even is and why a person would want to strive for it. Neutral 
or positive interpersonal experiences are what most everyday social interactions look 
like. But what if you do encounter an unpleasant person? A bully? What if someday, 
somebody will call you weird? VR offers an opportunity to test this situation. The patient 
can even experiment with different healthy reactions to being called ‘weird’. What 
patients learn through this experience, is that being called ‘weird’, however unlikely, is 
unpleasant but tolerable; they can handle it.  
Many people suffering from paranoid ideation have cognitive biases that interfere with 
a healthy perception of social situations. The cognitive bias ‘jumping to conclusions’, for 
instance, blocks the corrective experience that making eye contact is harmless and common 
behavior between people. Therefore, patients who jump to conclusions are trained to think 
of several alternative (neutral or positive) explanations while in a VR social environment 
with the misinterpreted stimuli present (making eye contact). Another common example 
is the ‘attention to threat’ bias. All attention is focused on the one guy who frowns, who is 
therefore identified as a potential threat. Patients who have a selective attention to threat 
are trained to divide their attention more equally over all stimuli present in the VR social 
environment; positive, neutral, negative and task-related. Since the occurrence and type 








Outline of  the thesis
This thesis focusses on VR for research and treatment of psychosis. Before VR can be 
used in the treatment of paranoid ideation, the VR environments must be ecologically 
validated. To test this validity, 170 people with different levels of psychosis liability, and 
with different levels of paranoia and anxiety in daily life were exposed to interactive virtual 
social environments. Paranoid ideation and anxiety in response to several stressors in the 
virtual social environments were measured. The test of ecological validity is described 
in chapter 2. VR could help to better explore mechanisms and interaction effects in 
paranoid ideation. As mentioned, paranoid ideation needs to be studied in a social 
context. Factors such as cognitive biases do not exist in a vacuum, but are problematic 
because they negatively interact with the perception of social situations. If you see 
someone looking at you, this only becomes problematic if you jump to the conclusion 
that they know who you are and want to hurt you. The moderation of cognitive biases 
between social stress and paranoid ideation is investigated in chapter 3.
A common side effect of VR is the experience of cybersickness (CS): the occurrence 
of motion sickness-like symptoms when using VR. The occurrence of cybersickness is 
related to treatment dropout in VR therapy. The possible overlap between symptoms of 
CS and anxiety complicates findings. Research done on cybersickness sometimes seems 
contradictive and raises several questions. Chapter 4 investigates whether: (a) gender 
differences in CS can be replicated, (b) differences in anxiety and CS symptoms between 
patients and controls can be replicated, and (c) whether the relationship between 
exposure to VR and CS symptoms is mediated by anxiety.
The development of Virtual Reality-based Cognitive Behavioral Therapy (VR-CBT) and 
trial protocol can be found in chapter 5. We conducted a large multicenter randomized 
controlled trial to study VR-CBT treatment compared to standard treatment. A 116 
patients with psychotic disorder suffering from paranoid ideation volunteered to 
participate in the study. Psychologists in seven Dutch mental health centers were trained 
in the VR-CBT protocol and provided with supervision. Since we wanted to measure 
the generalization of treatment effects on the daily life of the participants, ESM was used 
as primary outcome measure. The treatment effects of VR-CBT can be found in chapter 
6. The cost-effectiveness and cost-utility analyses are presented in chapter 7.
Finally, in a general discussion chapter, we will summarize results, compare them to 
current literature and developments, reflect on strengths and limitations, and explore 
possible implications for the future.
2
Chapter 2
Environmental social stress, 
paranoia and psychosis liability: 
A virtual reality study
Wim Veling · Roos Pot-Kolder · Jacqueline Counotte · 
Jim van Os · Mark van der Gaag




The impact of social environments on mental states is difficult to assess, limiting 
the understanding of which aspects of the social environment contribute to the 
onset of psychotic symptoms and how individual characteristics moderate this 
outcome. This study aimed to test sensitivity to environmental social stress as 
a mechanism of psychosis using Virtual Reality (VR) experiments. Fifty-five 
patients with recent onset psychotic disorder, 20 patients at ultra-high risk for 
psychosis, 42 siblings of patients with psychosis, and 53 controls walked 5 times 
in a virtual bar with different levels of environmental social stress. Virtual social 
stressors were population density, ethnic density and hostility. Paranoia about 
virtual humans and subjective distress in response to virtual social stress exposures 
were measured with State Social Paranoia Scale (SSPS) and self-rated momentary 
subjective distress (SUD), respectively. Pre-existing (subclinical) symptoms were 
assessed with the Community Assessment of Psychic Experiences (CAPE), Green 
Paranoid Thoughts Scale (GPTS) and the Social Interaction Anxiety Scale (SIAS). 
Paranoia and subjective distress increased with degree of social stress in the 
environment. Psychosis liability and pre-existing symptoms, in particular negative 
affect, positively impacted the level of paranoia and distress in response to social 
stress. These results provide experimental evidence that heightened sensitivity to 










The social environment influences the risk of onset, as well as the course of psychotic 
disorders42. Urban birth, childhood social adversity, neighborhood ethnic density, and 
social disorganization are risk factors for onset of psychosis27,43-45. Social stress may 
mediate these associations, given that psychosocial stress is associated with both risk of 
onset and relapse of psychosis46,47. Current theories of psychosis suggest that psychosis 
liability impacts individual sensitivity to experiences of social stress48, in particular when 
the level of perceptual stimuli in the environment is high49 and when the stress involves 
negative judgment of others50. Pre-existing (subclinical) paranoia, social anxiety, and 
negative affect may fuel this sensitivity, culminating in increasingly strong, sensitized 
psychotic responses to social stress exposure48,51.
Experimental studies of patients with persecutory delusions found that paranoia 
increased when they entered a busy shopping street and that this effect was partly 
mediated by anxiety and depression29,52. Experience sampling studies showed associations 
between the occurrence of minor stressors in daily life and intensity of psychotic 
experiences in patients and, to a lesser extent, their first-degree relatives and the general 
population51,53,54. However, these approaches are not sufficient to investigate which 
aspects of the social environment contribute to the onset of psychotic symptoms and 
which individual characteristics moderate this outcome, as daily social environments 
are complex, never exactly the same, strongly influenced by the individual’s behavior 
or presence of an observer, and cannot be controlled. Arguably the only way to test 
the mechanism of sensitized psychotic responses to the social environment, and the 
moderators thereof, would be to randomize individuals to controlled experimental 
environments with varying degree of social stress, quantifying environmental effect 
sizes as a function of liability to psychosis and prior level of (minor) symptoms. Virtual 
Reality (VR) technology, i.e., substituting sense data from the natural world with sense 
data about a virtual world that change in response to the user’s actions, resulting in a 
“sense of presence” in an interactive 3-dimensional virtual world, offers the possibility 
to do so1,52. VR is relatively new in psychosis research, but several studies have shown 
that VR is feasible, safe and valid for psychotic disorders55,56. Recent studies found that 
paranoid response to a neutral virtual environment was higher in people at ultra-high 
risk for psychosis (UHR) than in healthy controls, and that paranoid ideations were 
associated with social defeat57 and a history of bullying victimization58.
In this study, we aimed to test social stress sensitivity as a mechanism of psychosis, 
by exposing individuals with different levels of liability to psychosis to 5 social stress 
environments in VR. We hypothesized that:




•	 Liability to psychosis, and (subclinical) psychotic and affective symptoms 
are associated with more paranoia and subjective distress in social 
environments; and
•	 Degree of environmental social stress interacts with psychosis liability and 
pre-existing symptoms on paranoia and subjective distress.
Methods
Participants 
Individuals aged 18–35 years with different levels of liability to psychosis were included. 
We defined a high-liability group based on phenotype, i.e., the experience of (subclinical) 
psychotic symptoms. This group had 2 categories: (1) Patients with psychotic disorder, 
whose first diagnosis of psychotic disorder was established within the last 5 years. DSM-
IV diagnosis was established with a semi-structured interview (SCAN; Schedules for 
Clinical Assessment in Neuropsychiatry59 or CASH; Comprehensive Assessment of 
Symptoms and History60). All psychotic disorders were included, except for substance-
induced psychotic disorder and psychotic disorder due to a medical condition; and 
(2) Patients at UHR for psychosis, according to the Comprehensive Assessment of At-
Risk Mental States (CAARMS) criteria61. The low psychosis liability group consisted 
of: (3) Siblings of patients with a psychotic disorder, who never had a psychotic 
episode themselves; and (4) Controls with a negative (first-degree family) history of 
any psychotic disorder. Exclusion criteria were a history of epilepsy, IQ lower than 75 
and poor command of the Dutch language. Psychosis, UHR and sibling groups were 
recruited from 5 psychiatric institutes in the Netherlands. Controls were recruited with 
flyers at schools for vocational or higher education and in dentist offices in The Hague, 
and among the staff of a psychiatric institute in The Hague. Written informed consent 
was obtained from all participants. The study was approved by the medical ethical 
committee of Leiden University Medical Center.
VR set-up
The virtual environment was a bar with an indoor and an outdoor part (figure 2.1), 
built by CleVR with Vizard software62. Participants were standing during experiments 
and could turn around 360degrees. In order to walk around in the virtual environment, 
they used a Logitech F310 Gamepad. They wore a Sony HMZ-T1 Head Mounted 
Display with a HD resolution of 1280×720 per eye, with 51.6 diagonal field of view, 
a 3DOF tracker for head rotation, and built in headphones. Virtual humans (avatars) 
were sitting or standing at a table, chatted and had drinks. Bar background noises were 









We created 3 sources of social stress in the virtual environment.
Population density: the number of avatars in the bar was variable, by which we could 
simulate population density and could manipulate level of perceptual stimuli. In the 
quiet, low stress condition, the number of avatars in the bar was 6. In the stressful, 
crowded situation, the number was 40.
Ethnic density: ethnic appearance of an avatar was Dutch or North African. In the 
low ethnic density condition, more than 80% of the avatars was Dutch for non-Dutch 
participants and North African for Dutch participants. In the high ethnic density 
condition, the ethnic distribution was the opposite.
Hostility: in the low-stress condition, avatars had a neutral facial expression. When 
participants approached, avatars looked only briefly at them, after which they resumed 
their activities. In the stressful condition, avatars looked in an angry, hostile fashion at 
participants for 5 seconds, as participants approached, and also at other, random, moments.
Experiments
All participants underwent 5 experiments of 4 minutes each, in a single session. In all 
experiments, they were instructed to explore the bar. Five avatars had a number (0–99) 
on their clothing. In order to engage participants in the experiment and to make them 
look at all avatars, they had to find these avatars, and to report the highest number and 
gender of the avatar with the highest number.
Figure 2.1. Screenshot of the virtual bar environment. Source: CleVR.
Chapter 2
22
Virtual social stress was introduced at 4 levels:
•	 No stress—quiet, high ethnic density and neutral avatars;
•	 One stressor—crowded;
•	 Two stressors—(1) crowded and low ethnic density, (2) crowded and 
hostile avatars;
•	 Three stressors—crowded, low ethnic density and hostile avatars.
High population density was part of all stress conditions, because ethnic density and 
hostility could only be simulated effectively with a high number of avatars. The order 




Sociodemographic characteristics included age and sex. Ethnicity was defined as Dutch 
if the subject and both parents were born in the Netherlands, and as non-Dutch in 
all other cases. Level of education was classified as no/ primary education, vocational 
education ((V)MBO), higher secondary education (HAVO/VWO), higher tertiary 
education (HBO/University). Paranoia was assessed with the Green Paranoid Thoughts 
Scale (GPTS)63, social anxiety with the Social Interaction Anxiety Scale (SIAS)64 and 
minor positive, negative and depressive symptoms with the Community Assessment of 
Psychic Experiences (CAPE)65.
During and after experiments
In order to assess how actively participants explored the virtual bar during the experiments, 
their position in the bar was recorded every second, and the distance between current 
and all other recorded positions was calculated. The average of these distance scores is 
an indication of distance covered during the experiments; the SD reflects the degree to 
which participants were at different positions in the bar.
After each experiment, participants were asked to rate their maximum momentary 
subjective distress during the experiment (SUD) in units on an analogue scale, with range 
0 (no distress at all) to 100 (worst possible distress). Paranoid thoughts about avatars 
were measured after each experiment with the State Social Paranoia Scale (SSPS)66.
Statistical analyses
All analyses were conducted with Stata version 11. Differences in sociodemographic 
characteristics and exploration behavior in the virtual bar between psychosis liability 








variables). For the analyses of the effects of virtual social stressors on paranoia and 
subjective distress, multilevel random intercept regression models were used, taking 
into account the repeated measure structure of the data. The B is the fixed regression 
coefficient of the predictor in the multilevel model. We analyzed the data using the 
multilevel random intercept XTREG procedure in Stata. First, effects of social stressors 
were investigated. For each subject, SSPS and SUD scores of experiments 3a and 3b 
(see Experiments) were summed together and divided by 2, in order to create average 
paranoia and distress scores for experiments with 2 stressors. Regression models were 
fitted with paranoia and peak subjective distress during experiments as dependent 
variables, number of stressors as independent variable and age, sex, level of education 
and psychosis liability as covariates. To estimate effect sizes of the separate stressors, Stata 
LINCOM procedure was used. Thus, the effect of population density was calculated 
by comparing stress level 2 with level 1, the ethnic density effect by comparing level 
3a with level 2, and the effect of hostility by comparing level 3b with level 2. Second, 
differences in paranoia and subjective distress in VR between psychosis liability groups 
were examined. Third, associations between baseline symptoms and paranoia and 
distress in VR were explored, irrespective of psychosis liability group. Symptom domains 
were analyzed separately, but also entered simultaneously in a regression model, to test 
which baseline symptoms contributed most to paranoia and distress in VR. Fourth, 
interaction terms between social stress on the one hand, and psychosis liability and 
baseline symptoms on the other were added to the models. B coefficients of the main 
effects and the interaction terms were compared using the MARGINS dydx procedure, 
estimating linear marginal effects at the different virtual social stress levels.
Results
Fifty-three healthy controls, 42 siblings, 20 patients at UHR for psychosis, and 55 
patients with psychotic disorder were included. Sociodemographic characteristics, 
baseline level of symptoms and use of psychotropic medication are shown in table 2.1. 
The UHR and psychosis groups had significantly higher levels of all symptoms than 
controls, and psychosis patients had a lower level of education. The proportion of males 
was much higher in the psychosis group than in the other groups.
ANOVA showed a difference between the psychosis liability groups in distance covered 
by participants during the experiments (F = 2.864, df = 3, P = .039). No statistically 
significant differences remained in post hoc Bonferroni corrected group comparisons 
(supplementary table S2.1). There was only a trend level significance of lower distance 
covered by the psychosis group compared to controls (mean difference 0.28, 95% 




Virtual social stress elicited paranoid thoughts and subjective distress in participants. 
Table 2.2 shows that both measures increased with increasing numbers of virtual 
stressors. The B of the linear effect of number of social stressors on paranoia, adjusted 
for age, sex, level of education and psychosis liability, was 2.74 (95% CI, 2.31–3.17, 
P < .0005). The adjusted B of the linear effect of social stressors on subjective distress 
was 2.26 (95% CI, 1.52–3.00, P < .0005). Of the specific virtual stressors, population 
density (linear combination of experiment 2 compared to 1) had a strong positive effect 
on both paranoia and distress (table 2.3). Hostility (linear combination of experiment 
3b compared to 2) was significantly and positively associated with paranoia, but not 
with subjective distress. Ethnic density (linear combination of experiment 3a compared 
to 2) was associated with neither paranoia nor distress.
Compared to subjects with low psychosis liability, those with high liability reported 
more paranoia and subjective distress in VR (table 2.3), B 3.62 (95% CI, 1.39–5.84) 
and 17.94 (10.99–24.90), respectively. Of the separate liability groups, only UHR 










Age 24.6 (4.4) 26.4 (4.8) 24.0 (4.5) 26.0 (4.7)
Male sex, n (%) 25 (47.2) 23 (54.8) 7 (35.0) 42 (76.4)a
Non-Dutch origin, n (%) 16 (30.2) 11 (26.2) 5 (25.0) 26 (47.3)
Level of education, n (%)
No/primary 0 (0.0) 0 (0.0) 0 (0.0) 3 (5.5)a
Vocational ((V)MBO) 13 (24.5) 11 (26.2) 8 (40.0) 25 (45.5)a
Higher secondary (HAVO/VWO) 10 (18.9) 4 (9.5) 5 (25.0) 10 (18.2)a
Higher tertiary (HBO/University) 30 (56.6) 26 (61.9) 7 (35.0) 17 (30.9)a
Symptomsb
Paranoid thoughts 37.5 (9.1) 36.1 (6.1) 69.0 (26.6)a 56.2 (30.6)a
Social anxiety 16.8 (11.6) 15.6 (10.4) 38.6 (19.7)a 28.3 (16.1)a
Depressive symptoms 12.5 (2.8) 12.3 (2.2) 20.4 (4.7)a 14.8 (3.4)a
Positive symptoms 24.3 (4.6) 23.6 (3.1) 31.7 (7.5)a 31.2 (8.8)a
Negative symptoms 21.5 (4.6) 21.2 (3.7) 32.4 (7.9)a 27.1 (6.3)a
Use of psychotropic medication, n (%)c
None 49 (94.2) 39 (92.9) 6 (30.0) 18 (32.7)
Antipsychotic 0 (0.0) 0 (0.0) 0 (0.0) 35 (63.6)
Antidepressant 1 (1.9) 1 (2.4) 12 (60.0) 5 (9.1)
Benzodiazepine 0 (0.0) 0 (0.0) 4 (20.0) 6 (10.9)
Other 2 (3.8) 2 (4.8) 5 (25.0) 2 (3.6)
Note. UHR, Ultra High Risk.
a P < .05, ANOVA or Chi-square test with post hoc comparisons, controls as comparison group.
b Paranoid thoughts assessed with Green Paranoid Thoughts Scale, Social Anxiety with Social Interaction Anxiety Scale, 









patients had significantly higher paranoia than healthy controls; the UHR and psychosis 
groups had higher levels of distress (figure 2.2).
Table 2.2. Paranoid thoughts and subjective distress in virtual reality, by degree and type of virtual social stress
Virtual social stress condition Mean (SD) B a 95% CI P-value
Paranoia
Number of stressors
No stress 13.60 (6.2) — — —
1 stressor 16.25 (8.1) 2.66 1.35–3.96 < .0005
2 stressors 16.78 (9.3) 3.17 1.85–4.49 < .0005
3 stressors 22.51 (11.4) 9.14 7.82–10.45 < .0005
Population density — 2.65 1.31–3.99 < .0005
Ethnic density — 0.55 -0.81–1.91 .426
Hostility — 6.01 4.66–7.36 < .0005
Subjective distress
Number of stressors
No stress 26.96 (24.4) — — —
1 stressor 32.81 (26.3) 5.41 3.11–7.71 < .0005
2 stressors 31.68 (25.0) 5.13 2.84–7.42 < .0005
3 stressors 34.48 (27.6) 7.60 5.30–9.90 < .0005
Population density — 5.38 3.01–7.74 < .0005
Ethnic density — -1.35 -3.75–1.04 .269
Hostility — 0.50 -1.87–2.89 .678
Note. a Multilevel random regression analysis regression coefficient B, adjusted for age, sex, ethnicity, level of education 
and psychosis liability; compared to the no stress condition. B coefficients of separate stressors calculated by comparisons 
of the linear effects of 2 conditions (see text).
Table 2.3. Paranoia and subjective distress in virtual reality, by psychosis liability group
Paranoia Subjective distress
Psychosis liability group B a 95% CI P-value B a 95% CI P-value
Lowb — — — — — —
High 3.62 1.39–5.84 .001 17.94 10.99–24.90 < .0005
Controls — — — — — —
Siblings -1.86 -4.72–1.00 .203 −4.09 -13.02–4.83 .369
UHR 3.80 0.24–7.37 .037 17.90 6.68–29.13 .002
Psychosis 2.36 -0.43–5.16 .097 15.37 6.60–24.14 .001
Note. a Multilevel random regression analysis regression coefficient B, adjusted for age, sex, ethnicity, level of education 
and virtual experiment. Low liability and controls as reference groups.
b Healthy controls and siblings classified as low psychosis liability, UHR and psychosis as high liability.
Baseline levels of paranoid thoughts, social anxiety, (minor) positive, negative and 
depressive symptoms were all strongly associated with both paranoia and subjective 
distress in VR, with B’s ranging from 0.13 to 2.68. When all baseline symptom domains 
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were entered simultaneously in the regression model, adjusted for age, sex, ethnicity, 
level of education and virtual experiment, paranoia in VR was predicted significantly 
only by depressive symptoms (B 0.60, 95% CI, 0.18–1.02, P = .005); subjective distress 
was associated only with social anxiety (B 0.39, 95% CI, 0.11–0.68, P = .007).
The effects of baseline symptoms on paranoia and subjective distress increased with level 
of virtual social stress. Adjusted interaction terms between social stress on the one hand 
and paranoid thoughts, social anxiety, positive, depressive and negative symptoms on the 
other, were all statistically significant, except for the interaction between social stress and 









paranoid thoughts on subjective distress (P = .057). Table 2.4 shows how B coefficients 
of the linear marginal effects of symptoms increased at the different levels of social stress 
exposure. Strongest interaction effects were found with depressive symptoms. There was 
no significant interaction between social stress exposure and psychosis liability group, 
except for a stronger increase in paranoia with increasing social stress for the UHR 
group compared to controls (B interaction term 1.59, 95% CI 0.15–3.02, P = .03; B’s 
of marginal effects UHR group compared to controls 1.56 [-2.57–5.69], 3.14 [-0.49–
6.77], 4.73 [1.07–8.39] and 6.32 [2.10–10.53] for 0–3 social stressors, respectively).










B a 95% CI B 95% CI B 95% CI B 95% CI B 95% CI
Paranoia
No stress 0.08 0.03–0.13 0.09 0.01–0.17 0.47 0.17–0.78 0.29 0.12–0.46 0.20 0.01–0.38
1 stressor 0.11 0.07–0.16 0.13 0.06–0.20 0.70 0.43–0.97 0.38 0.23–0.53 0.30 0.13–0.46
2 stressors 0.15 0.10–0.19 0.18 0.10–0.25 0.93 0.66–1.20 0.47 0.32–0.62 0.39 0.23–0.56
3 stressors 0.18 0.13–0.24 0.22 0.14–0.30 1.16 0.85–1.47 0.56 0.38–0.73 0.49 0.31–0.68
Subjective distress
No stress 0.42 0.27–0.57 0.62 0.39–0.85 2.13 1.22–3.03 1.19 0.69–1.68 1.17 0.64–1.71
1 stressor 0.45 0.30–0.59 0.68 0.46–0.89 2.49 1.62–3.36 1.34 0.86–1.82 1.30 0.79–1.81
2 stressors 0.48 0.33–0.62 0.73 0.51–0.95 2.86 1.99–3.73 1.49 1.02–1.97 1.42 0.91–1.93
3 stressors 0.51 0.35–0.66 0.79 0.56–1.02 3.22 2.32–4.13 1.65 1.15–2.15 1.54 1.01–2.08
Note.  a Multilevel random regression analysis,  B  coefficients, adjusted for age, sex, ethnicity and level of education, 
estimated using Stata margins dydx procedure, at the 4 levels of virtual social stress. All coefficients statistically significant 
(P < .05).
Discussion
This VR study provides experimental evidence of social stress sensitivity as a mechanism 
linking environment and psychosis. Paranoia and subjective distress increased with 
degree of social stress in the environment. High psychosis liability, pre-existing (minor) 
affective and, to a lesser degree, psychotic symptoms were associated with more paranoia 
and distress in social environments. Pre-existing symptoms had stronger impact on 
paranoia and distress when level of environmental social stress increased.
Strengths and limitations
The main strength of this study is the experimental design, using VR as a tool to study 
interactions between the individual and complex social environments. Environmental 
studies of psychosis are generally complicated by subjective retrospective information 
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about social environment and events. Momentary assessment studies are closer to the 
action, but cannot control occurrence of events and remain dependent on subjective 
information about the environment. This study was the first to expose individuals 
experimentally to controlled complex social environments with different degrees of 
social stressors. Environmental social stress exposures were identical for all participants, 
except for the ethnic appearance of avatars, which depended on the ethnicity of the 
participant. Type and degree of environmental stress were controlled. It should be noted 
that participants could avoid exposure to a certain degree, as they navigated through the 
environments themselves and were free to choose where to look. To minimize variation 
in exposure, participants had a simple task that required extensive exploration of the 
VR environment and the avatars. Recording data of the position of participants in the 
virtual bar during experiments suggest that distance and area covered did not differ 
substantially between psychosis liability groups.
The study had several limitations. The virtual environment was simulated, not photo-
realistic and evidently still less complex than real life, which may reduce ecological 
validity. Previous studies, however, using similar VR software and environments, showed 
that experiences in these environments were correlated to real life experiences and 
symptoms, that participants reported all kinds of thoughts and feelings about avatars, 
and that virtual environments are sufficiently realistic to practice social behavior56,67,68.
As there was no experiment without social stressors (e.g., noise), it cannot be ruled out 
that the amount of stimuli in VR was more important than the social nature of the 
stressors. The additional effect of avatars’ hostile looks compared to a similar environment 
with neutral avatars, however, suggests that the social aspect of stressors does matter.
While the psychosis group had significantly higher paranoid thoughts and other 
symptoms than controls and siblings, their level of symptoms was lower than that of 
the UHR group, suggesting that many had already partially recovered. The majority 
of the psychosis group and nobody in the UHR group reported using antipsychotic 
medication, which may have contributed to the higher symptom level in the UHR 
group, and may have led to underestimation of the psychosis liability effect on paranoia 
and distress in VR. Another limitation is that the number of participants in the separate 
groups was relatively small, in particular in the UHR group, implicating that the analyses 
of separate group should be interpreted with caution.
Environmental social stress and psychosis
Current theories of psychosis state that environmental social stress contributes to the 
onset of psychosis by a process of sensitization, in interaction with liability to psychosis 
and subclinical symptoms42,48,69. This liability can be caused by genetic factors, or by 
perinatal or childhood environmental insults. Subsequent experiences of social stress 








salience is assigned to environmental stimuli. Negative affect, dysfunctional cognitive 
schemas and more stress will build up70. This vicious circle of sensitization and dopamine 
dysregulation eventually may lead to a psychotic state of delusions, hallucinations and 
negative symptoms48. Our study supports these theories in several ways.
First, environmental social stress elicited paranoia and subjective distress in a dose-
response fashion. More VR stressors resulted in greater levels of paranoia and distress. 
Not all separate stressors, however, had the same impact. Population density and 
hostility were significantly associated with paranoia, and only population density with 
subjective distress. Ethnic density was related to neither outcome measure, possibly 
because the majority of the participants was Dutch (66%) and ethnic density effects 
have primarily been described among ethnic minorities71. In addition, our non-Dutch 
avatars had a North African appearance, whereas most non-Dutch participants had an 
ethnic background other than North African.
Second, paranoia and distress in VR were stronger in those with higher psychometric 
psychosis liability, phenotypically defined as having (subclinical) psychotic symptoms. 
Genetic risk for psychosis was not associated with paranoia and stress, as siblings had 
similar responses as controls. UHR patients had the strongest response to social stress 
exposure. Use of antipsychotic medication might explain the dampening of psychotic 
symptoms and distress in the FEP patients compared to the UHR group.
Third, minor negative, psychotic and in particular depressive symptoms predicted 
paranoia and distress in VR. Negative affective state was an important driver of the 
psychotic and stress response to social stress exposure. This is consistent with cognitive 
models of paranoia70 in which negative affect is a core component in the development 
of paranoid delusions. An “affective route” to psychosis has been proposed, in which 
daily social stressors negatively influence affect, and disturbed affect in turn worsens 
biased appraisal of events and dysfunctional externalizing cognitions, eventually leading 
to paranoid delusions and other psychotic experiences51. Experience sampling studies 
also show that momentary negative affect predicts momentary paranoia in daily life51.
Clinical implications
We have demonstrated that it is possible to expose patients with psychosis and UHR 
patients to complex virtual social environments, and that exposure to these environments 
leads to meaningful responses, which are associated with clinical symptom profile. 
Exposure therapy for paranoia can be envisioned, with gradual, controlled exposure 
to increasingly stressful and paranoia-inducing social situations simulated in VR. Our 
group is currently developing and testing such a VR exposure treatment. Several other 
pilot VR treatment studies have recently been published55, it can be expected that more 
applications will be developed over the next few years.
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The results of this study suggest that reactivity to daily social stress may be an important 
target for treatment in patients with high levels of psychosis liability. Reactivity may be 
modified by focusing on negative affect, biased appraisals and dysfunctional cognitive 
schemas in cognitive behavioral therapy, or by stress reduction techniques such as 
relaxation or meditation72,73. Preliminary VR stress management studies were published 
recently, suggesting that this may represent a promising approach for reducing stress 
reactivity74,75.
Supplementary material
Supplementary table S2.1. Distance and area covered during the virtual experiments, by psychosis liability group
N a Mean SD F-score (df = 3) P-value
Average distance Controls 36 7.03 0.37
Siblings 33 6.96 0.41
UHR 15 7.04 0.34 2.864 0.039
Psychosis 44 6.75 0.62
Standard deviation of 
distance score
Controls 36 4.63 0.24
Siblings 33 4.59 0.30
UHR 15 4.64 0.15 1.168 0.325
Psychosis 44 4.52 0.37
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Introduction: Cognitive biases are associated with psychosis liability and paranoid 
ideation. This study investigated the moderating relationship between pre-existing 
self-reported cognitive biases and the occurrence of paranoid ideation in response 
to different levels of social stress in a virtual reality environment.
Methods: This study included 170 participants with different levels of psychosis 
liability (55 recent onset psychosis, 20 ultrahigh risk for psychosis, 42 siblings 
of psychotic patients, and 53 controls). All participants were exposed to virtual 
environments with different levels of social stress. The level of experienced 
paranoia in the virtual environments was measured with the State Social Paranoia 
Scale. Cognitive biases were assessed with a self-report continuous measure. Also, 
cumulative number of cognitive biases was calculated using dichotomous measures 
of the separate biases, based on general population norm scores.
Results: Higher belief inflexibility bias (Z = 2.83, P < .001), attention to threat 
bias (Z = 3.40, P < .001), external attribution bias (Z = 2.60, P < .001), and 
data-gathering bias (Z = 2.07, P < .05) were all positively associated with reported 
paranoid ideation in the social virtual environments. Level of paranoid response 
increased with number of cognitive biases present (B = 1.73, P < .001). The effect of 
environmental stressors on paranoid ideation was moderated by attention to threat 
bias (Z = 2.78, P < .01) and external attribution bias (Z = 2.75, P < .01), whereas 
data-gathering bias and belief inflexibility did not moderate the relationship.
Conclusion: There is an additive effect of separate cognitive biases on paranoid 
response to social stress. The effect of social environmental stressors on paranoid 
ideation is further enhanced by attention to threat bias and external attribution 
bias.








There is a relationship between exposure to stressful social environments and risk 
for developing psychosis42,76. Associations with psychosis have been documented for 
childhood abuse77, recent stressful life events78, social defeat57, belonging to an ethnic 
minority group79,80, urban upbringing81, and being a victim of bullying58. As a result of 
long-term or repeated exposure to stressful social environments, cognitive biases, such 
as an increased attention for potential threat, may develop. Psychological models suggest 
that cognitive biases increase vulnerability to develop paranoid ideations or delusions 
when confronted with environmental social stress later in life48,82.
Psychotic disorders are characterized by both cognitive deficits83,84 and cognitive biases82. 
Cognitive deficits are impairments in cognitive functioning, such as problems with verbal 
memory83. Cognitive biases represent selective processing of information, such as the 
tendency to attend to a certain type of stimulus or consistently interpret emotionally 
ambiguous information in a negative direction85. Cognitive biases are implicated in 
developing and maintaining paranoid ideation14. Paranoid ideation characterizes 90% of 
patients with psychotic disorder18. Psychotic patients with paranoid delusions anticipate 
intentional harm inflicted by other people. Cognitive models of paranoia propose that 
cognitive biases distort the processing of information from the social environment toward 
a more paranoid interpretation48. Several types of cognitive biases are associated with 
paranoid ideation82. Cognitive biases are measured with experimental tasks; only recently 
have self-report measures been developed and validated against experimental tasks86-88. 
“Data-gathering bias” (also known as “jumping to conclusions”) is a cognitive bias 
characterized by hasty decision making. “Belief inflexibility” is a cognitive bias that results 
in rigidity of beliefs when exposed to contradictory evidence; it overlaps with confirmatory 
bias and the bias against disconfirmatory evidence89. The tendency to attend selectively 
to threat-related information is known as “attention to threat bias.” “External attribution 
bias” is the tendency to blame other people for negative events. All of these four biases 
were found to be more prevalent in patients with a schizophrenia spectrum disorder82,90-93 
and in people with subclinical psychotic symptoms at ultrahigh risk for psychosis 
(UHR)94-97 than in healthy controls. They seem specifically related to the development 
and maintenance of paranoid delusions14. These findings suggest that the level of cognitive 
biases is associated with the level of paranoid ideation in response to social stressors in the 
environment, in particular in patients with a psychotic disorder and UHR.
Some evidence for this psychopathological mechanism is derived from experimental 
and time-sampling studies. In an experimental study, when patients with persecutory 
delusions were exposed to a crowded street in inner London, they reported an increase 
in paranoid ideation, auditory hallucinations, and in data-gathering bias52. Time-
sampling studies using observations in daily life found a temporal association between 
social contact and paranoid ideation53. However, due to the complexity of interactions 
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between personal and contextual factors, it is difficult to examine the context of 
paranoid ideation in daily life social environments. Ideally, the interaction between 
social environments, cognitive biases, and paranoid ideation should be explored using 
an experimental design, in which exposure to social stress is controlled.
Virtual reality (VR) allows systematic manipulation of social environments98. VR is a safe 
and valid method to investigate paranoia in healthy individuals, in UHR patients, and 
in patients with persecutory delusions56,62. Recent research has demonstrated that virtual 
social stressors were able to elicit paranoid ideation in VR social environments62,99,100 and 
psychosis liability and pre-existing negative affect moderated the levels of paranoia and 
distress100.
The present study manipulated the number of social stressors presented in the virtual 
environment. The moderating effect of cognitive biases on the association between the 
number of social stressors and paranoid ideation was examined in groups with a different 
liability to psychosis. Our hypothesis was that the level and number of cognitive biases 
present will be positively associated with the level of paranoid ideation when participants 
are exposed to increased social stress.
Methods
Participants 
Four groups of participants (aged 18–35 years) with different liability to psychosis were 
recruited. Namely, a group with high liability for psychosis consisting of (1) patients with 
recent onset psychotic disorder (N = 55) and (2) patients with an UHR status (N = 20); 
as well as a group with low liability for psychosis with (3) siblings of patients with a 
psychotic disorder, who had never had a psychotic episode themselves (N = 42), and (4) 
healthy controls without a history of psychotic disorder or a first-degree relative with a 
psychotic disorder (N = 53). The exclusion criteria were poor command of the Dutch 
language, a history of epilepsy, and an IQ ≤ 75.
This study was approved by the Medical Ethics Committee of the Leiden University 
Medical Centre (NL37356.058.12/P12.182). Written informed consent was obtained 
from all participants.
The psychotic group included individuals with a recent (< 5 years) diagnosis of a psychotic 
disorder according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth 
Edition (DSM-IV), with the exception of substance-induced psychotic disorder and 
psychotic disorder due to a medical condition. They were recruited from five participating 
mental health services. The UHR group included individuals with an UHR status, who 
were recruited among patients seeking help for nonpsychotic psychiatric symptoms at 







two mental health services. The siblings group included siblings of persons diagnosed 
with a psychotic disorder, who did not themselves have a personal history of psychotic 
disorder or meet UHR criteria. The healthy control group included persons recruited 
from the general population without a history of psychotic disorder or a first-degree 
relative with a psychotic disorder.
Measurement instruments
Diagnostic Instruments. The Comprehensive Assessment of At-Risk Mental States 
(CAARMS)61 was used to assess UHR status. The CAARMS identifies three inclusion 
groups: (1) people with a schizotypal personality disorder and/or a first-degree relative 
with psychosis; (2) people that experience attenuated positive psychotic symptoms, 
such as paranoid ideas and unusual perceptual experiences; and (3) people who have 
experienced a brief psychotic episode lasting ≤ 1 week and remitted without treatment 
with antipsychotic medication. Additional inclusion criteria were either a recent drop 
of 30% in social functioning as assessed with the Social and Occupational Functional 
Assessment Scale (SOFAS)101,102 or dropping below a score of 55 on the SOFAS.
Psychotic disorder was diagnosed with either the Comprehensive Assessment of 
Symptoms and History (CASH)60 or the Schedules for Clinical Assessment in 
Neuropsychiatry (SCAN)59. CASH and SCAN are similar semi structured interviews 
for diagnosing psychotic disorders, following DSM and ICD diagnostic criteria. Choice 
of instrument varied per participating mental health center.
Cognitive biases 
At baseline, the Davos Assessment of Cognitive Biases Scale (DACOBS) was 
administered to assess cognitive biases87. The DACOBS is a self-rating assessment scale, 
consisting of seven subscales (four cognitive biases, two assessing subjective deficits in 
cognition and social cognition, and one on safety behaviors). In this study, we used 
the four subscales that measure cognitive biases, i.e., (1) data-gathering bias, (2) belief 
inflexibility bias, (3) selective attention to threat bias, and (4) external attribution bias. 
The subscales had an acceptable reliability (Cronbach’s alpha ranging from .64 to .72) 
and an acceptable convergent validity (Spearman’s Rho ranging from .36 to .63). Factor 
analysis confirmed that the four cognitive biases are separate constructs87. All factors 
independently explained the variance (eigenvalues > 2) and total explained variance was 
45%. The DACOBS was cross-validated with correlations ranging from .360 to .627. 
The beads task, a probabilistic inference task103, was used as a validation test for the 
“Jumping to conclusions” subscale (r = -.360, P < .01). The Dogmatism scale, a self-report 
measurement, was used to validate the Belief inflexibility bias (r = .403, P < .01). The 
Green Paranoid Thoughts Scale, a self-report measurement, has two subscales. Subscale 
A measures ideas of social reference and subscale B measures paranoid thoughts. Part A 
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was used to validate the Attention to threat bias (r = .408, P < .01), whereas subscale B 
was used to validate the External attribution bias (r = .627, P < .01). The factor structure 
was replicated in an independent sample by confirmative factor analysis88.
A cognitive bias was considered to be present in a participant when the score was 
“above average,” “high,” or “very high” according to the norm scores for the normal 
control population87. The number of elevated cognitive biases was summed to create a 
cumulative cognitive biases variable.
State paranoia
Immediately after exposure to each virtual social environment, momentary paranoia was 
assessed using the Social State Paranoia Scale (SSPS). The SSPS is a valid (Spearman’s 
rho is .41) and reliable (Cronbach’s alpha is .91) measure of state persecutory ideation 
in virtual social environments66.
VR setting
The virtual environment used was a café with both indoor and outdoor areas. Participants 
could navigate in the virtual environment, using a Logitech F310 Gamepad. For VR 
display, participants used the Sony HMZ-T1 Head-Mounted Display with a HD 
resolution of 1280 × 720 (per eye), with 51.6 diagonal field of view, a 3DOF tracker 
for head rotation, and built-in headphones. The researcher controlled the VR system 
using a graphical user interface, whereby several actions could be activated within the 
virtual environment. Avatars could be placed in the café and chatted among themselves 
while sitting or standing at a table. Sounds and café noises were audio-played in the 
background. The avatars looked at participants for 5s when they were approached.
Experiments
The number of social stressors in the virtual social environments was manipulated by (1) 
the number of avatars in the virtual environment (6 or 40 avatars); (2) own ethnic or other 
ethnic identity of the avatars; and (3) neutral or hostile facial expressions by the avatars. 
Pre-existing cognitive biases were measured with a self-reported questionnaire before 
participants were exposed to the virtual environments with a varying number (0–3) 
of social stressors. Paranoid ideation was assessed after each exposure session of 4 min.
To engage participants in the virtual social environment, the computer randomly 
assigned a number (0–99) to five of the avatars. Participants were encouraged to explore 
the VR environment and to remember the number and sex of the avatar assigned 
the highest number. In a small pilot, patients reported that the task was easy and not 
stressful or distracting. All participants participated in four conditions with exposure to 
no, one, two, or three social stressors in the VR environment. The order of exposure to 
the different conditions was randomized.







Detailed information on the conditions have been published previously100.
Statistical analyses
Analysis was performed using Stata version 13. Differences in age between the 
psychosis liability groups were tested with one-way ANOVA. Group differences in the 
dichotomous variables sex, ethnic minority status, and education were tested using χ2 
tests. Multilevel random intercept regression analysis was conducted to test associations 
between cognitive biases and paranoid ideations in VR using the XTREG procedure 
in Stata. The study data have a hierarchical structure, with repeated measurements 
(level 1) nested within individuals (level 2). Multilevel analyses take into account that 
observations within an individual are more similar than those between individuals. The 
interaction effects between the number of virtual stressors and cognitive biases were 
added to the multilevel regression models to investigate a moderating relationship with 
sex, age, level of education, and psychosis liability as covariates. We examined whether 
the interaction between level of cognitive bias and level of social stress significantly 
predicted paranoid ideation. If moderation analysis found a significant interaction for 
different levels of cognitive biases, post hoc probing analysis was conducted to see how 
the different levels of cognitive biases (high vs low) affected the association between 
social stress and paranoid ideation104.
Results
Sociodemographic characteristics of the participants and level of cognitive biases are 
presented in table 3.1. Patients with psychosis had (on average) a lower level of education 
than siblings or the healthy controls. The proportion of males was high in the psychosis 
group (76%) and low in the UHR group (35%). Overall, males reported a higher level 
of data-gathering bias than females (M 25.5 vs F 22.9, P = .006). The covariate effect of 
sex was nonsignificant.
Participants with higher psychosis liability scored higher on attention to threat, belief 
inflexibility, and external attribution, while participants with lower psychosis liability 
scored average or below average. There was no psychosis liability effect on data-gathering 
bias, i.e., all groups scored average and showed no statistical differences; the results are 
shown in table 3.2.
The association between cognitive biases and paranoid ideation is shown in table 3.3. All 
four types of cognitive biases were significantly associated with higher levels of paranoid 
ideation experienced in the VR environments (table 3.3a).
Forty-four percent of the low-liability group had no cognitive biases, compared to only 
9% in the high-liability group. A significant effect was found for cumulative number of 
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Sex male, n (%) 25 (47.2) 23 (54.8) 7 (35) 42 (76.4) χ2 (3) = 14.5 .002
Age in years 25 (4) 26 (5) 24 (4) 26 (5) F (df ) = 2.1 (3) .097
Non-Dutch origin, n (%) 16 (30.2) 11 (26.2) 5 (25) 26 (47.3) χ2 (3) = 6.3 .099
Level of education, n (%) χ2 (9) = 19.7 .020
No/primary 0 (0.0) 0 (0.0) 0 (0.0) 3 (5.5)
Vocational ((V)MBO) 13 (24.5) 11 (26.2) 8 (40) 25 (45.5)
Higher secondary (HAVO/VWO) 10 (18.9) 4 (9.5) 5 (25) 10 (18.2)
Higher tertiary (HBO/University) 30 (56.6) 26 (61.9) 7 (35) 17 (30.9)
Medication usea, n (%)
None 49 (94.2) 39 (92.9) 6 (30.0) 18 (32.7)
Antipsychotic 0 (0.0) 0 (0.0) 0 (0.0) 35 (63.6)
Antidepressant 1 (1.9) 1 (2.4) 12 (60.0) 5 (9.1)
Benzodiazepine 0 (0.0) 0 (0.0) 4 (20.0) 6 (10.9)
Other 2 (3.8) 2 (4.8) 5 (25.0) 2 (3.6)
Note. Values are presented as mean (standard deviation; SD) or N (%). P-values are given from ANOVA (for continuous 
variables) and tested with Bonferroni correction, or χ2 tests (for categorical variables). UHR, patients with ultra-high risk 
for psychosis. Bold values are significant at < .05.
a Self-report.








N = 55 F (df ) P
Data-gathering bias (SD) 24.2 (6.1) 23.9 (6.7) 24.6 (5.4) 24.8 (6.3) 0.2 (3) .911
Belief inflexibility bias (SD) 14.2 (4.9) 13.3 (4.4) 18.1 (5.1) 19.7 (6.9) 14.2 (3) < .001
Attention to threat bias (SD) 17.8 (7.5) 16.1 (5.7) 28.8 (6.9) 22.8 (7.4) 13.5 (3) < .001
External attribution bias (SD) 14.1 (4.9) 12.3 (3.9) 23.2 (5.1) 19.8 (7.7) 25.3 (3) < .001
Note. DACOBS, Davos assessment of cognitive biases scale. DACOBS values are presented as mean (standard deviation; 
SD). P-values are given from ANOVA. Biases were tested with Bonferroni correction. Bold values are significant at < .05.
cognitive biases on reported paranoid ideation (B = 1.73, 95% CI: 0.93–2.53, P < .001). 
Effect of cumulative number of biases is shown in table 3.3b.
We found a significant interaction effect between the number of cognitive biases and 
the number of social stressors on paranoid ideation B = 0.52, 95% CI: 0.22–0.82, 
P = .001).
We found a significant interaction effect between attention to threat bias and the number 
of social stressors on paranoid ideation (P < .01) and also a significant interaction effect 
between external attribution bias and the number of social stressors on paranoid ideation 
in the VR environment (P < .01). The interaction results are shown in table 3.4.







Post hoc probing showed that both low and high levels of attention to threat bias 
significantly affected the association between social stress and paranoid ideation 
(low: B = 2.21, 95% CI: 1.62–2.80, P < .001; high: B = 3.43, 95% CI: 2.81–4.05, 
P < .001). Post hoc probing shows that both low and high levels of external attribution 
bias significantly affect the association between social stress and paranoid ideation (low: 
B = 2.19, 95% CI: 1.59–2.79, P < .001; high: B = 3.43, 95% CI: 2.81–4.06, P < .001). 
The effect of the difference in slopes is presented in figure 3.1. A high level of attention 
to threat bias showed a stronger paranoid response to an increase in social stressors. A 
high level of external attribution bias also showed a steeper paranoid response to an 
increase in social stressors.
Table 3.3. Effect of pre-existing self-reported cognitive biases, on paranoid ideations reported in virtual social 
stress environments
Paranoia SSPS Coefficienta Standard error Z P 95% Confidence Interval
Type of biasa
Data-gathering bias .183 .089 2.07 .039 .00948 .35649
Belief inflexibility bias .288 .101 2.83 .005 .08888 .48726
Attention to threat bias .262 .077 3.40 .001 .11113 .41379
External attribution bias .253 .097 2.60 .009 .06247 .44400
Cumulative number of biasesb
One .074 1.57 .05 .962 -3.0090 31.579
Two 3.056 1.56 1.96 .050 -.00493 61.162
Three 5.995 1.77 3.39 .001 25.256 94.636
Four 5.828 1.81 3.22 .001 22.843 93.714
Note. SSPS, Social State Paranoia Scale. Bold values are significant at < .05.
a B coefficient in multilevel random regression analysis (cognitive bias). Analyses were adjusted for sex, education, age, 
and psychosis liability.
b Calculated using dichotomous measures of the separate biases, based on general population norm scores, no cognitive 
biases as reference category.
Table 3.4. Interaction effect between cognitive biases and level of social stress, on paranoid ideations reported in 
virtual social stress environments
Paranoia SSPS Coefficienta Standard error Z P 95% Confidence Interval
Data-gathering bias .052 .036 1.45 .148 -.01842 .12231
Belief inflexibility bias .038 .036 1.05 .292 -.03271 .10861
Attention to threat bias .079 .028 2.78 .005 .02337 .13452
External attribution bias .090 .033 2.75 .006 .02583 .15366
Note. Bold values are significant at < .05.
a  B  coefficient in multilevel random regression analysis (cognitive bias × number of social stressors). Analyses were 




In this experimental VR study, higher psychosis liability was associated with higher levels 
of the cognitive biases attention to threat, belief inflexibility, and external attribution 
but not with data-gathering bias. Also, belief inflexibility, attention to threat, external 
attribution bias, and data-gathering bias all predicted paranoid ideation in controlled 
virtual social environments. When more cognitive biases were present that person 
showed a stronger paranoid response. Both attention to threat and external attribution 
bias moderated the paranoid response during exposure to social environmental stress 
(figure 3.1).
By using VR to fully control the level of exposure to social stressors, this study found 
experimental evidence to support current cognitive psychological models14,48 of the 
development and persistence of paranoid delusions. When people are exposed to 
social stress in the environment, higher levels of attention to threat bias and external 
attribution bias contribute to a more paranoid interpretation of the social environment. 
When multiple cognitive biases are present, this increases the paranoid interpretation.
In accordance with previous research, the present study found a positive relationship 
between the presence of cognitive biases and the experience of paranoid ideation. 
However, there was no significant difference in scores for data-gathering bias between 
Figure 3.1. The moderating effect of high versus low self-reported cognitive biases on the association between number 
of social stressors presented in virtual reality (0–3) and elicited paranoid ideation (Social State Paranoia Scale).
Note. Analyses were adjusted for sex, education, age. and psychosis liability.







the four groups with different psychosis liability. This may indicate poor sensitivity of 
the DACOBS subscale to measure data-gathering bias. Although the DACOBS data-
gathering bias subscale is validated against the beads task, their shared variance is limited87. 
Other explanations may be the fact that data-gathering bias may be difficult to measure 
using a self-report questionnaire, as those with the bias, compared with those without 
the bias, do not differ in the self-rated level of decisiveness105. Not finding different levels 
of data gathering in different liability groups is at odds with the literature, but finding a 
marginally significant effect of data gathering on paranoid ideation and no moderating 
effect is in accordance with the meta-analytical findings106. Our findings suggest that 
data-gathering biases may not be as relevant in the model of paranoid symptoms as was 
formerly expected.
Although we found a significant difference for belief inflexibility bias between the groups 
with different psychosis liability, there was no interaction effect between environmental 
social stress and belief inflexibility bias on paranoid ideation. Apparently, the relationships 
between specific cognitive biases and paranoid ideation differ. Cognitive biases describe 
selective processing of information in general; subdivision into more specific categories 
may improve our understanding of the cognitive processes involved in paranoid ideation.
Strengths and limitations
The main strength of this study is the use of VR to control the social environments 
and the social stressors the participants are exposed to. All participants were exposed 
to exactly the same environmental conditions, which would be impossible in a real-life 
social situation. The use of VR also prevents unintended effects of interactions between 
the participant and the social environment, allowing us to study the effect of cognitive 
biases on paranoid ideation. An additional strength is the variety of participants with 
different liability to psychosis, allowing to investigate the relationship between cognitive 
biases, social stress, and paranoid ideation over different levels of psychosis liability.
The study has several limitations. First, cognitive biases were assessed using self-report 
questionnaires only. Also, only 20 participants were included in the UHR group and 
this group consisted mainly of females. Our psychosis sample consisted of patients with 
recent onset psychosis only and was mainly males. The differences in sex distribution 
in these groups are consistent with previous research102,105 and may have influenced 
the results in the high psychosis liability group. This study used the facial expressions 
of the avatars to convey hostility; however, since facial affect recognition impairments 
are found in patients with a first episode of psychosis107, this may have affected the 
results in our high-liability group. Difficulty with interpreting the avatars’ hostile 
faces may have caused additional anxiety or may have influenced the effect between 
social hostility and paranoid interpretation. Also, although the categories of cognitive 
biases were based on exploratory factor analysis87 and replicated in confirmatory factor 
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analysis in another sample88, it is important to note that these biases likely interact 
and possibly partially overlap. Moreover, this study is limited to four cognitive biases. 
For example, we did not include interpretation bias, which is the tendency to draw 
negative conclusions when presented with ambiguous information108. Interpretation 
bias occurs in a nonpsychiatric population with higher psychosis vulnerability and may 
be associated with paranoid ideations109. Prevalence and severity of cognitive biases were 
too small in the low-liability group to analyze high- and low-liability groups separately. 
The effects remained statistically significant when psychosis liability was included as 
a covariate in the regression models, suggesting that cognitive biases predict paranoid 
response to social stressors independent of psychosis liability. Further research is needed 
to investigate this issue. Last, we only included patient groups with UHR or a diagnosis 
of psychotic disorder, whereas paranoid ideations are also common in other psychiatric 
disorders. Inclusion of a broader range of psychiatric disorders may help to increase the 
understanding of paranoia.
Clinical implications
Both attention to threat bias and external attribution bias are viable targets for 
interventions in cognitive behavioral therapy, aiming to mitigate the effect of these biases 
on paranoid appraisal of the social environment. Patients could be trained to normalize 
their attention to threat bias. However, as findings on the effect of specific techniques are 
not consistent further development is needed110-112. External attribution can be explored 
and competing explanations may be generated and tested with behavioral experiments. 
Interestingly, these procedures implicitly address belief inflexibility by contrasting 
several different beliefs with an event. In patients suffering from paranoid ideation, belief 
inflexibility has indeed been found to improve with cognitive behavioral therapy113. 
Psychological therapy in a VR social environment would allow us to integrate exposure 
to social situations with an active correction of dysfunctional cognitions. Such cognitive 
behavioral therapy enhanced by VR (VR-CBT) is currently under investigation114,115.
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The use of virtual reality (VR) in psychological treatment is expected to increase. 
Cybersickness (CS) is a negative side effect of VR exposure and is associated with 
treatment dropout. This study aimed to investigate the following: (a) if gender 
differences in CS can be replicated, (b) if differences in anxiety and CS symptoms 
between patients and controls can be replicated, and (c) whether the relationship 
between exposure to VR and CS symptoms is mediated by anxiety. A sample (N = 
170) of participants with different levels of psychosis liability was exposed to VR 
environments. CS and anxiety were assessed with self-report measures before and 
after the VR experiment. This study replicated gender differences in CS symptoms, 
most of which were present before exposure to VR. It also replicated findings 
that a significant correlation between anxiety and CS can be found in healthy 
individuals, but not in patients. In a VR environment, anxiety partially mediated 
CS symptoms, specifically nausea and disorientation. A partial explanation for the 
differences found between patients and controls may lie in a ceiling effect for the 
symptoms of CS. A second explanation may be the partial overlap between CS 
symptoms and physiological anxiety responses. CS symptoms reported at baseline 
cannot be explained by exposure to VR, but are related to anxiety. Caution is 
required when interpreting studies on both CS and anxiety, until the specificity 
in measurements has been improved. Since anxiety mediated the CS symptoms, 









The use of virtual reality (VR) in psychological treatment is expected to increase now 
that affordable technologies are available for clinical implementation6. VR can be more 
effective and less burdensome for patients116 and more practical for therapists117 than in 
vivo (real-life) exposure therapies. The use of VR in treating psychological disorders was 
introduced about 20 years ago5. This led to studies on VR treatment for various anxiety 
disorders7, eating and weight disorders118, depression119, autism spectrum disorders120, 
and substance-related disorders121, as well as paranoid ideation115 and hearing voices122 
in psychotic disorders. An important factor contributing to the effect of VR treatment 
is immersion, that is, the sense of being present in the virtual environment123. However, 
a common drawback of using head-mounted displays as a medium for immersive 
VR environments is the experience of cybersickness (CS)2, also known as simulator 
sickness. CS is the occurrence of motion sickness-like symptoms when using VR and 
is related to increased treatment dropout6. As CS symptoms occur in 60 to 70 percent 
of participants124, this has a negative impact on treatment effects. CS is an unintended 
negative side effect and efforts should be made to limit negative effects while preserving 
the therapeutic effect of VR125. Four factors are reported to influence the occurrence 
of CS: (1) hardware and software choices for the VR system, (2) design of the virtual 
environment, (3) task characteristics, and (4) user characteristics125,126. Examples of 
hardware and software characteristics influencing CS are visual surround of the display127 
and navigation (e.g., a mouse, joystick or treadmill)128. The design of the virtual 
environment can influence CS by using dynamic auditory stimulation129 and allowed 
movement (active vs. passive)125. Task characteristics known to influence CS are duration 
of exposure to the virtual environment130 and training131. User characteristics that can 
influence CS include gender, affective symptoms, and mental health. Susceptibility 
to CS is increased for women and varies over the menstrual cycle due to hormonal 
variation; however, explanations for this gender difference are incomplete132. Affective 
symptoms (e.g., feeling stressed or anxious) may increase the experience of CS133,134 
but the nature of this relationship remains unclear. VR treatment is used to expose 
patients to a virtual representation of their feared stimuli. During VR treatment patients 
will therefore experience high levels of anxiety. Physiological symptoms of anxiety and 
CS overlap and may confound both scientific research134 and clinical practice. Anxiety 
disorders are much more prevalent in women135, making gender-specific relationships 
between CS, anxiety, and VR used in psychological treatment, an area of interest. It is also 
unclear why different findings emerge in healthy individuals and patients. For example, 
significant correlations between levels of experienced anxiety and CS were found in 
healthy controls136, but not in patients diagnosed with persecutory delusions exposed to 
a neutral VR environment137. High levels of CS symptoms were found in patients with 
an anxiety disorder even before immersion in VR138. Correlations were found between 
some CS symptoms and reported anxiety in a sample with both healthy controls and 
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patients with an anxiety disorder139. Some CS symptoms may reflect anxiety more than 
side effects140. Thus, more clarity is required as to which user characteristics influence 
CS. The present study aimed to investigate the following: (a) if gender differences in CS 
can be replicated, (b) if differences in anxiety and CS symptoms between patients and 
controls can be replicated, and (c) whether the relationship between exposure to VR and 
CS symptoms is mediated by anxiety (figure 4.1).
Figure 4.1. Mediation hypothesis.












A total of 170 participants aged 18–35 years were earlier recruited for a large VR study100. 
From these, we defined a high liability patient group based on phenotype, that is, the 
experience of (subclinical) psychotic symptoms. This group consisted of two categories:
•	 Fifty-five patients with a psychotic disorder according to the DSM-IV, 
with the exception of substance-induced psychotic disorder, and psychotic 
disorder due to a medical condition. These patients were recruited at five 
outpatient departments.
•	 Twenty patients with an at-risk mental state (ARMS), recruited among 
patients seeking help for nonpsychotic psychiatric problems at two 
outpatient departments.
The low psychosis liability control group consisted of:
•	 Forty-two siblings of people diagnosed with a psychotic disorder who had 








•	 Fifty-three control persons recruited from the general population; they had 
no history of psychotic disorder nor a first-degree relative with a psychotic 
disorder.
Our previous study in this cohort found no difference in reported symptoms between the 
siblings and healthy controls100, allowing to combine both groups for the analysis. The 
exclusion criteria were poor command of the Dutch language, epilepsy, and intelligence 
quotient (IQ) < 75.
Ethical approval
This study was approved by the Medical Ethics Committee of the Leiden University 
Medical Center (NL37356.058.12/ P12.182). Written informed consent was obtained 
from all participants.
VR setting
The virtual environment used in this experiment was a cafe. Participants could navigate 
the virtual environment using a Logitech F310 Gamepad. The Sony HMZ-T1 head 
mounted display used for VR display of the cafe had a high-density resolution of 
1280·720 (per eye), with 51.6 diagonal field of view, and built-in headphones. A 3DOF 
tracker (UM7 Orientation Sensor; CH-Robotics) was added to the Sony HMZ-T1 
for head rotation. The researcher controlled the VR system and actions in the virtual 
environment using a graphical user interface. Detailed information on the conditions 
is already published100. The social stressors used in this virtual social environment 
(population density, ethnic density, and hostility) were found to elicit feelings of 
anxiety100. All participants participated in five conditions, each with different levels of 
social stress. Exposure to each condition lasted 4 min. The order of the five conditions 
was randomized to prevent a sequence effect.
Measurement instruments
Diagnostic instruments. The Comprehensive Assessment of At-Risk Mental States61 
was used to assess ARMS before participation. Psychotic disorder was diagnosed with 
either the Comprehensive Assessment of Symptoms and History60 or the Schedules for 
Clinical Assessment in Neuropsychiatry59. Anxiety was assessed by self-rated momentary 
subjective fear in units on an analog scale (subjective unit of distress [SUD]), ranging 
from 0 (no distress at all) to 100 (worst possible distress). Anxiety was first assessed 
before the experiments. Participants also rated their maximum anxiety during VR 
immediately after each of the five experiments. The mean of these five maximum anxiety 
scores was calculated and used for the analyses. The self-report Simulator Sickness 
Questionnaire (SSQ)141 was administered before and after the VR experiments. The 
SSQ measure’s three distinct symptom clusters were labeled as Oculomotor (eyestrain, 
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difficulty focusing, blurred vision, headache), Disorientation (dizziness, vertigo), and 
Nausea (nausea, stomach awareness, increased salivation, burping).The SSQ was scored 
according to the procedures by Kennedy et al.141.
Analyses
Analyses were conducted with IBM SPSS version 23. For sociodemographic 
characteristics, differences in continuous variables between the groups were analyzed 
using t tests. If the distribution of a continuous variable was skewed a Wilcoxon rank-
sum test was used. Group differences in categorical variables were tested using v2 
analysis. Pearson’s correlation coefficient (two-tailed) was used for correlations. We used 
the MEMORE method142 for two-condition within-participant statistical mediation 
analysis. The single test path-analytic approach by MEMORE eliminates the need for 
multiple discrete hypothesis tests about components of the mediation model, as the 
previous dominant approach143 requires. A single test decreases the probability of an error 
occurring. The conditions were no exposure (baseline) and exposure to VR. MEMORE 
can be used to estimate the total (c), direct (c’), and indirect (ab) effects of exposure 
to VR on CS and its subscales through anxiety in a two-condition repeated measures 
design. Bootstrapping (5,000 samples) was used. Fixed covariates such as gender (or 
other stable individual differences) are accounted for in the MEMORE model.
Results
Demographics
A total of 170 participants were included: 95 controls in the low-liability group and 75 
patients in the high-liability group. Sociodemographic characteristics of the participants 
as well as anxiety and CS scores are presented in table 4.1. Controls had a higher level of 
education and a lower use of psychiatric medication. There was a trend of more female 
participants in the control group.
Gender
At baseline, 90 percent of women and 86 percent of men reported at least one symptom 
of CS. Women reported more CS symptoms than men, both overall and for each CS 
subscale. These differences were present both before and after exposure to VR. No 
significant gender difference was found in the increase in total CS symptoms when 
exposed to VR (ranksum Z = 1.19; P = .24), or for oculomotor and disorientation 
separately. Women reported a stronger increase in nausea than men (rank sum Z = 2.31; 
P = .02) when exposed to VR. Results for both overall CS and for each of the three 
symptom categories separately are presented in figure 4.2. No differences were found 
























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































At baseline, 81 percent of the controls and 96 percent of the patients reported at least 
one symptom of CS. Patients reported significantly more symptoms of CS at baseline 
than the controls. After exposure to VR, there was no significant difference in nausea and 
disorientation between the two groups. Results for both overall CS and for each of the 
three symptom categories separately are presented in figure 4.3. At baseline, there was 
a significant correlation between anxiety and CS for patients (r = .33, P < .01), whereas 
this was not found for the controls (r = -.03, P = .74). In contrast, after exposure to VR, 
patients no longer showed a significant correlation between anxiety and CS (r = .19, 
P = .11), whereas the controls did (r = .53, P < .01).
Anxiety as mediator variable
For all 170 participants, a significant correlation was found between anxiety and CS at 
baseline (r = .33, P < .01) and after exposure to VR (r = .34, P < .01). Mediation results 
are presented in table 4.2. Anxiety mediated the relationship between exposure to a 
VR environment and the experience of CS. The direct effect (c’) remained significant, 
implying that the mediation effect of anxiety on CS was partial. Examination of the CS 
subscales revealed that the relationship between exposure to VR and nausea was partially 
mediated by anxiety. The relationship between exposure to VR and disorientation was 
Table 4.2. Effect of the mediator variable ‘anxiety’ on the relationship between Virtual Reality exposure and cyber-
sickness, both overall and for each of its three subscales in all participants (n = 170)
Effect SD P CI [95%]
Cybersickness total
Total effect (c) -13.77 2.87 < .001** -19.44 -8.08
Direct effect (c’) -9.13 3.40 .008** -15.85 -2.41
Indirect effect (ab) -4.64 2.11 .018a* -9.06 -.79
Oculomotor 
Total effect (c) -.58 2.15 .787 -4.82 3.66
Nausea
Total effect (c) -17.10 3.01 < .001** -23.05 -11.15
Direct effect (c’) -11.73 3.55 .001** -18.74 -4.73
Indirect effect (ab) -5.37 2.20 .009a** -10.22 -1.43
Disorientation
Total effect (c) -26.26 3.83 < .001** -33.84 -18.69
Direct effect (c’) -20.45 4.56 < .001** -29.45 -11.44
Indirect effect (ab) -5.82 2.96 .027a* -12.12 -.41
Notes. SD = standard deviation; a Sobel test was used to estimate P-value of indirect effects. Cybersickness was measured 
by the self-report Simulator Sickness Questionnaire (SSQ). Anxiety was assessed by self-rated momentary subjective fear 
(SUD). MEMORE was used for two-condition within-participant statistical mediation analysis. The conditions were no 
exposure (baseline) and exposure to virtual reality. Fixed covariates, such as gender, are accounted for in the MEMORE 









































































































































































































































































also partially mediated by anxiety. Oculomotor symptoms had no direct relationship (c) 
with exposure to VR.
Discussion
In this VR study, the large majority of patients and controls reported at least one 
symptom of CS. We replicated both gender differences in CS and differences in CS 
between patients and controls. The relationship between exposure to VR and CS was 
partially mediated by anxiety. This implies that part of the relationship between exposure 
to VR and CS symptoms, more specifically nausea and disorientation, was explained by 
anxiety as an intermediary variable. Women reported more CS symptoms than men, but 
most of these differences were already present at baseline. When exposed to VR, women 
had a steeper increase in nausea symptoms. The gender difference in severity of CS 
symptoms is in accordance with others132. However, gender differences in oculomotor 
and disorientation symptoms existed before VR exposure and cannot be explained by 
either exposure to VR or anxiety levels. Our results replicate both findings about CS 
symptoms being present before exposure to VR in patients with an anxiety disorder138, 
and associations found between anxiety and CS symptoms139,140. Our results replicate 
findings that significant correlations between anxiety and CS were found in controls136 
but not in patients137,138. Our study indicates that a partial explanation may lie in a 
ceiling effect for CS symptoms, that is, CS symptoms were already high in patients 
before VR and remained high, whereas they were low in healthy controls before VR 
and increased during VR. A second explanation may be the partial overlap between 
CS symptoms and physiological anxiety responses. CS symptoms reported at baseline 
cannot be explained by exposure to VR, but are related to anxiety. The present study 
found that anxiety was a mediating factor for nausea and disorientation symptoms of 
CS, but not oculomotor symptoms.
This suggests that anxiety may impact some, but not all symptoms of CS. This is 
in line with studies showing five individual symptoms of CS (general discomfort, 
fatigue, headache, difficulty concentrating, and fullness of head) to correlate with 
reported anxiety139,140. Especially two CS symptoms, general discomfort and difficulty 
concentrating, may reflect anxiety symptoms as they significantly load on the anxiety 
factor140. This is also in line with a study demonstrating that nausea symptoms are affected 
by reported anxiety134. We found no increase in oculomotor symptoms after exposure to 
VR; previous research on the profile of CS found that oculomotor symptoms are the least 
likely to occur144, which may have influenced the statistical power. It is also possible that 
oculomotor symptoms (e.g., eyestrain and blurred vision) are physiologically less related 
to anxiety symptoms. The fact that mediation by anxiety is partial and is consistent with 




The primary strength of the study is that the CS symptoms were measured before and 
after exposure to VR. Also, three different CS subscales were measured instead of only 
nausea, or using a single-sickness scale. Second strength is that the inclusion of both 
patients and controls allowed examining group differences. Thirdly, the MEMORE 
method simultaneously used the CS and anxiety scores before exposure to VR, as well as 
scores after exposure, to estimate mediation effects. On the contrary, the statistical power 
of this study was limited, as many participants reported little CS and little or no anxiety 
symptoms; this impeded more detailed analysis of the subgroups. Four of the SSQ items 
load on two subscales instead of one, which inflate the contribution of these items on 
the total score. As two of these items, general discomfort and difficulty concentrating, 
are known to be correlated with anxiety140, this might have affected analysis. Only two 
specific patient groups were included and all participants were relatively young; both 
these factors limit the generalizability of our findings. Also, this study examined state 
anxiety only, whereas additional affect states should be explored in future research. As 
a stable individual difference trait, anxiety is accounted for in the MEMORE model. 
However, as it can influence both the anxiety response and the CS symptoms, more 
research is required to clarify its potential role. Another limitation is that anxiety was 
measured with self-report. Finally, this study used the diagnostic criteria of the DSM-IV 
instead of the current DSM-V; however, as there are only marginal differences in the 
categories of psychotic disorders145 the effect on the individual diagnosis of each patient 
in the present study can be considered negligible. 
Clinical implications and future directions
This study indicates that caution is required when interpreting studies on both CS and 
anxiety, until the specificity in measurements has been improved. Gender differences 
in CS should also be taken into account. Findings on CS based on controls cannot be 
generalized to patients. Reported anxiety symptoms may partially reflect CS symptoms 
and vice versa. The relationship between VR exposure and CS symptoms is partially 
explained by anxiety as an intermediary variable. When VR therapy reduces anxiety, the 
nausea and disorientation symptoms are expected to decline. In addition, CS symptoms 
decrease after repetitive use of VR146. If a patient reports anxiety and CS during the 
first stages of VR treatment and can tolerate this, we recommend to continue with VR 
treatment. Future research should include patients diagnosed with an anxiety disorder, 
and measure both state and trait anxiety. Replication with a larger sample size of a broad 
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Background: Many patients with a psychotic disorder participate poorly in 
society. When psychotic disorders are in partial remission, feelings of paranoia, 
delusions of reference, social anxiety and self-stigmatization often remain at 
diminished severity and may lead to avoidance of places and people. Virtual 
reality exposure therapy (VRET) is an evidence-based treatment for several anxiety 
disorders. For patients with a psychotic disorder, the VRETp was developed to 
help them experience exposure to feared social situations. The present study aims 
to investigate the effects of VRETp on social participation in real life among 
patients with a psychotic disorder. 
Methods/Design: The study is a single-blind randomized controlled trial with 
two conditions: the active condition in which participants receive the virtual 
reality treatment together with treatment as usual (TAU), and the waiting list 
condition in which participants receive TAU only. The two groups are compared at 
baseline, at 3-months posttreatment and at 6-months follow-up. All participants 
on the waiting list are also offered the virtual reality treatment after the follow-
up measurements are completed. The primary outcome is social participation. 
Secondary outcomes are quality of life, interaction anxiety, depression and social 
functioning in general. Moderator and mediator analyses are conducted with 
stigma, cognitive schemata, cognitive biases, medication adherence, simulator 
sickness and presence in virtual reality. If effective, a cost-effectiveness analysis will 
be conducted.
Discussion: Results from the posttreatment measurement can be considered 
strong empirical indicators of the effectiveness of VRETp. The 6-month follow-up 
data may provide reliable documentation of the long-term effects of the treatment 
on the outcome variables. Data from pre-treatment and mid-treatment can be 
used to reveal possible pathways of change.
Trial registration: Current Controlled Trials: ISRCTN12929657 
http://www.isrctn.com/ISRCTN12929657








A large number of patients with a psychotic disorder participate poorly in society, even if 
their psychotic symptoms have been treated successfully. Unemployment is high at 80–
85%147 and about 75% does not have a relationship with a partner148. A study comparing 
the social network of young people with early psychosis and matched controls, showed 
that the psychosis group had smaller networks, fewer friends, fewer people to turn to 
in a crisis, and a greater likelihood of service providers as members149. Social network 
size is also associated with the likelihood of in-patient treatment and with the number 
of services used by psychotic patients150. Social isolation hinders patients in multiple 
areas of functioning, such as developing and maintaining a social network, the ability 
to function in work-related environments, and even in performing daily tasks needed 
for independent living (e.g. shopping for groceries). When psychotic disorders are in 
partial remission, the remaining feelings of paranoia and delusions of reference often 
cause patients to avoid places and people. Moreover, this conditioned avoidance does 
not improve with antipsychotic medication151.
Exposure 
The evidence-based psychological treatment for experiencing fear and paranoia in social 
situations is cognitive behavioral therapy (CBT) with exposure in vivo, such as the 
therapist taking a patient shopping or exposing the patient to public transportation. 
This form of treatment in vivo has several limitations. First, the social world in which 
in vivo exposure takes place cannot be experimentally manipulated. Second, exposure 
therapy in vivo is costly and not readily available in most mental healthcare institutes. 
Thirdly, therapy sessions are used to prepare exposure exercises, which the patient 
is expected to perform between sessions; however, even with careful tailoring to the 
patients’ capabilities, it is often difficult for patients to do these exercises as planned. 
Fourthly, not all patients tolerate exposure in vivo.
Anxiety disorders and VRET 
Virtual reality exposure therapy (VRET) is an evidence-based treatment for several 
anxiety disorders152. It has the potential to be an affordable and accessible form of 
treatment to enhance social participation and wellbeing for patients suffering from a 
psychotic disorder and social withdrawal. In virtual worlds fear is experienced similar to 
the in vivo experience. It is the experience of being there (known as ‘presence’) which the 
three-dimensional virtual reality (VR) environment creates, together with a narrative 
about the environment, that enables people to feel and behave as they would in real life. 
This principle makes it possible to overcome fear and practice new behavior in a virtual 
environment153. An advantage of VR is that people find it easier to start exposure, since 
they know there is no real threat to their safety154. In students suffering from fear of 
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spiders, 81–89% chose VR exposure over in vivo exposure155. A study comparing VR 
exposure vs. in vivo exposure in specific phobias showed that 76% of the patients chose 
VR exposure over in vivo exposure156. The refusal rate for in vivo exposure (27%) was 
higher than that for the VRET (3%). In total, 90.4% of the patients that preferred VR 
exposure said they did so because they were too afraid to confront the real situation or 
to object. These results suggest that the availability of VR exposure may increase the 
number of patients who are willing to engage in exposure-based therapy.   
VRET in psychosis 
In a VRET treatment protocol, patients are gradually exposed to controlled social 
environments that induce fear and in which individually-tailored exposure exercises can 
be designed. The ability to provide fear-inducing VR social environments is partially 
dependent on the availability of anxiety-provoking stimuli in the software of the virtual 
worlds. The present study will assess whether the currently used anxiety-provoking 
stimuli sufficiently match the stimuli asked for by patients during treatment.   
An experimental virtual world was developed. The ecological validity of the VR 
environment has been demonstrated. For patients suffering from psychosis a significant 
correlation was found between paranoia and social interaction anxiety in real life and 
paranoid thoughts about the avatars in the VR world62. A higher degree of paranoia was 
found when more avatars were present, when avatars had hostile facial expressions, and 
when more of the avatars had a different ethnicity157. 
Preliminary findings using VRET with psychosis show that patients experiencing 
paranoia are willing to participate in VR environments, that they report paranoid 
thoughts about the virtual people (avatars), but at the same time are willing to confront 
the fearful situation62,158. Social virtual environments have the potential to enhance CBT 
by helping patients recovering from psychosis to understand the role of avoidance and 
safety behaviors in the maintenance of interaction anxiety and paranoia. Additionally, it 
can enhance their confidence to carry out real-life behavioral experiments159.
Side-effects and safety 
A phenomenon called simulator sickness (also known as cyber sickness) can occur when 
using VR applications. Symptoms are similar to those of motion-induced sickness, but 
tend to be less severe and have a lower incidence160. It is suggested that simulator sickness 
sensations can be at least partially explained by an overlap with anxiety symptoms10. A 
pilot study on Virtual Reality and Psychosis showed low symptoms of simulator sickness, 
and no significant increase between pre- and post-measurement62. Since simulator 
sickness is known to increase with the duration of exposure161, measurement of these 
symptoms will be included in the study protocol.  







No adverse effects were found in studies using VR to expose psychotic patients to virtual 
social environments. A study with 20 psychotic patients diagnosed with first-episode 
psychosis experiencing at least moderate paranoia found that VR did not lead to more 
anxiety or physical complaints directly after the experiments; follow-up one week later 
showed that no patients reported an increase in intrusive negative thoughts, unpleasant 
emotions or behavioral changes as a consequence of the VR experience10. Similar results 
were found in a study of 21 patients with at-risk mental state for psychosis154. Our 
own pilot study confirmed that patients did not become more psychotic as a result of 
exposure to our virtual social environment62. 
Objectives
As this is a new form of treatment for social withdrawal in psychosis, the first step 
is to demonstrate the effect of VRET compared to a waiting list condition on social 
participation in real life. Objective social participation is defined as the time spent in 
social situations with other people and the time spent interacting with other people 
in everyday life. Subjective social participation is how patients experience these social 
situations; this experience is expressed as momentary paranoia, perceived social threat 
and event stress, as experienced in situations with other people. 
We hypothesize that, after applying the intervention for patients suffering from paranoia 
(VRETp), they will show improved social participation. 
Primary objective
To determine the effectiveness of VRETp in patients with psychosis, defined as improved 
social participation. 
Hypothesis 1: The amount of time spent with other people will increase, as measured 
60 times a week in real life.
Hypothesis 2: Momentary paranoia, perceived social threat and event stress as experi-
enced in social situations will decline, as measured 60 times a week in real life.
Secondary objectives
Secondary objectives are to investigate: 
a) the acceptability of VRETp for patients and therapists




c) the moderating and mediating effects of stigma, schemata about the self 
and others, cognitive biases, medication adherence, simulator sickness and 
experienced presence in the VR environment
d) the cost-effectiveness of VRETp
Methods
Participants
Included are patients diagnosed with a psychotic disorder at seven mental health 
institutions in the Netherlands: a list of study sites can be obtained from the corresponding 
author. Written Informed consent is obtained from each participant.
Inclusion criteria
To be eligible to participate, patients must meet all of the following criteria: 
•	 DSM IV diagnosis of a psychotic disorder according to the MINI.
•	 Avoiding either shops, streets, public transportation or bars/restaurants as 
assessed by the Safety Behavior Questionnaire (SBQ). 
•	 A paranoia score (> 40) as assessed by the Green Paranoid Thoughts Scale 
(GPTS) 
•	 Age 18–65 years  
Exclusion criteria
•	 IQ ≤ 70. IQ must be established by a valid instrument, such as the WAIS of 
WISC. Information on IQ can be found in the status chart of the patient. 
In case of doubt, the short form of the WAIS III is used to assess IQ
•	 Insufficient command of the Dutch language 
•	 Epilepsy. If no epilepsy is mentioned in the patient status, this is checked 
with the patient. 
Measurement instruments
Social participation (primary outcome)
Social participation is measured with the PsyMate experience sampling device. This 
form of Experience Sampling Measurement (ESM) has high ecological validity162. ESM 
is a self-assessment technique using random time sampling, and has the advantage that it 
can assess mental state and social context in everyday life as it occurs. Because the ESM 
assesses ‘at the moment’ it is less vulnerable for recall bias and a valuable instrument 







to assess clinical phenomena in the real world163. ESM is effective for patients with 
a psychotic disorder with current symptoms, as well as for patients with a psychotic 
disorder in remission164. A review of studies using the ESM it to be valid for measuring 
situational characteristics, such as social environment30. Event stress, social environment 
and company (time spent in company with others and the kind of company) are 
operationalized in accordance with the work of Collip et al.164. Research on the (social) 
context of delusions in schizophrenia shows the ESM to be a valid aid in collecting 
data of daily life social situations165. Momentary paranoia, using four established ESM 
items, is a valid measure to assess state paranoia166. Perceived social threat, using four 
established ESM items, is a valid measure to assess perceived social threat as a more 
subtle indicator of paranoia164.
Eligibility measurements
Psychotic disorders
The MINI-Plus interview is used for diagnosing lifetime psychotic disorders. This 
interview provides a reliable DSM diagnosis for psychotic disorders. The good 
psychometric characteristics of the MINI (-Plus) make it a good choice for research 
purposes167-169.
Paranoid thoughts
Paranoia symptoms are assessed with the GPTS170. The GPTS consists of 32 items 
divided into two 16-item scales, assessing ideas of social reference and persecution. 
Good internal consistency and validity are established for both of the scales and their 
dimensions170.
Safety behavior
The Safety Behavior Questionnaire – persecutory delusions (SBQ) is used to assess 
safety behaviors (such as avoidance) for social situations171. An action was considered 
to be safety behavior if the patient reported that it had been carried out with the aim 
to reduce a persecutory threat. The patient was asked to rate the frequency of the safety 
behavior over the last month on a 4-point scale. Psychometric properties of the SBQ 
range from poor to excellent171.
Secondary outcome measures
Quality of  life
The Manchester Short Assessment of Quality of Life (MANSA) is a brief instrument 
used to assess quality of life, focusing on satisfaction with life as a whole and with life 




Interaction anxiety symptoms were assessed with the Social Interaction Anxiety Scale 
(SIAS)173. The SIAS consists of 19 items that assess the tendency to fear and avoid social 
situations. Responses can range from 0 (not at all) to 4 (extremely). The SIAS has good 
psychometric properties173,174.
Social functioning
The Social and Occupational Functioning Assessment Scale (SOFAS) is used to subjectively 
assess and rate social and occupational functioning, but not psychological symptoms175,176.
Depression
The Beck Depression Inventory (BDI-II) consists of 21 items assessing symptoms and 




The Internalized Stigma of Mental Illness (ISMI) is a 29-item questionnaire that measures 
self-stigma among persons with psychiatric disorders. The ISMI shows reliability and 
validity178. 
Schemata
Schemata of self and others (BCSS) has 24 items concerning beliefs about the self and 
others that are assessed on a 5-point rating scale (0–4). The BCSS has good psychometric 
properties179. 
Cognitive biases
The Davos Assessment of Cognitive Biases Scale (DACOBS) has seven independent 
subscales each with six items; jumping to conclusions, belief inflexibility bias, attention 
for threat bias, external attribution bias, social cognition problems, subjective cognitive 
problems and safety behavior. The DACOBS is reliable and valid for use in clinical 
practice and research180.
Medication adherence
The Brief Adherence Rating Scale (BARS) is an instrument used to assess the antipsychotic 
medication adherence of patients with a psychotic disorder. The BARS consists of four 
items: three questions and an overall visual analog rating scale to assess the proportion of 
doses taken by the patient in the past month (0%–100%). The psychometric properties 
are adequate181. 







Participants and their psychiatrists are asked not to change any medication during the 
trial. 
Simulator sickness
The Simulator Sickness Questionnaire (SSQ) was developed to accommodate symptoms 
specific to simulator technology. The SSQ requires the user to report the subjective 
severity of symptoms such as general discomfort, headache, eyestrain and fatigue160. 
Although its psychometric properties are adequate, there is room for improvement182.
Presence
The Igroup Presence Questionnaire (IPQ) consists of 14 items assessing sense of presence 
in virtual environments. Responses are made on a 7-point Likert scale. The IPQ has 
demonstrated good psychometric properties183.
Cost-effectiveness
The Trimbos/iMTA questionnaire for costs associated with psychiatric Illness (the 
TiC-P) is designed for self-report by patients with a mental disorder. The questionnaire 
focuses on establishing direct medical costs and productivity costs during paid or unpaid 
work. The psychometric properties are reported to be adequate184. 
Design
The study is a single blind randomized controlled trial (RCT) with two conditions: i) 
the active condition in which subjects receive the VR treatment besides treatments as 
usual (TAU) and ii) the waiting list condition during which subjects receive TAU only. 
All participants on the waiting list are also offered the VR treatment after follow-up 
measurements have been completed. The two groups are compared at baseline, at 3 
months post treatment and at 6 months follow-up. The waiting list condition receives 
the VRET treatment after 6 months. An overview of measurements can be found in 
Table 5.1. 
Power and sample size calculation
In this RCT, the effect of VRETp on social participation is investigated by comparing 
this treatment with a waiting list condition. Social participation is assessed with the 
PsyMate experience sampling method (ESM; see Measurements). Self-assessments 
are rated on a 7-point Likert scale. Main outcome items are social environment and 
company, perceived social threat in company, event stress, and momentary paranoia. 
Estimated mean scores and standard deviations (SD) are not readily available because 
there are no previous VRETp studies with psychotic patients.   
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Using an estimated (moderate) effect size of 0.5 with a power of 0.8, an alpha of 0.05 
and a two-sided independent t-test, yields n = 64 in each group. Therefore, at least 64 
participants need to be included in each arm (total n = 128 patients). As attrition is 
estimated at about 20%, 80 participants need to be included in each condition (total n 
= 160 patients).
Procedure
Patients with a chart diagnosis of schizophrenia, schizophreniform disorder, schizo-
affective disorder, delusional disorder or psychotic disorder NOS, will be informed 
about the study by their treating specialist and asked to participate. Each patient is 
asked for written permission to be contacted by the researchers if eligible for VRETp. 
If eligible, the treating specialist discusses participation of the patient in the study with 
the remainder of the team and gives permission to the researchers to contact the patient. 
When permission is given, additional information is provided and patients have two 
weeks to consider whether they really wish to participate. The VRETp treatment is 
additional to current treatment and declining to participate has no negative consequences 
at all for patients. For each of the participating organizations an independent specialist is 
available for patients to contact. Contact information of this specialist is available in the 
information letter given to the patients of the participating organizations.  
Informed consent from all participants is obtained before assessment by the researcher. 
The MINI-Plus interview is used to diagnose psychotic disorders. Patients who are 

















Social participation Experience Sampling Method (s) x x x
Paranoia GPTS (s) x x x x x
Interaction anxiety SIAS (s) x x x x x
Depression BDI-II (s) x x x
Stigma ISMI (s) x x x
schemas BCSS (s) x x x
Safety behavior SBQ (i) x x x
Cognitive biases DACOBS (s) x x x
Social functioning SOFAS (i) x x x
Quality of life MANSA (i) x x x
Cost-effectiveness TIC-P (i) x x x
Cyber sickness SSQ (s) x x
Presence IPQ (s) x x
Medication adherence BARS (i) x x x x x







willing to participate are screened for avoidance behavior (SBQ) and for paranoia using 
the GPTS (cut-off > 40)63. Baseline measurements are obtained. Randomization is used 
to allocate a patient to either the VRETP or to the waiting list condition. Patients 
allocated to the VRETp group start their treatment, which consists of a maximum of 16 
sessions with a maximum duration of 60 min each.  
At baseline (T0) the research assistant assesses the baseline measurement of all primary 
and secondary variables. At two weeks (T1) and four weeks (T2) into treatment, 
respectively, participants in the treatment condition are assessed for their scores 
on paranoia, interaction anxiety, cyber sickness, presence in the virtual world and 
medication adherence, using self-report questionnaires handed out by the therapist, or 
interview questions (medication adherence).
At the end of treatment (T3) and at follow-up (T6), the research assistant assesses the 
primary and secondary measures. The flow diagram can be seen in Figure 5.1.
Figure 5.1. Flow diagram VRETP.















































A block of 12 random assignments will be made for each participating mental health 
center. Each block has 6 assignments for each condition: VRETp or waiting list. If a center 
includes more patients, new blocks of 12 random assignments will be made available. 
The blocks are made using a scientific randomization program (www.randomizer.org) by 
the independent randomization bureau of Parnassia Psychiatric Institute. Participants 
and therapists are informed about the randomization by mail and e-mail, respectively.
Interventions 
Participants in both the VRETp and the waiting list condition receive TAU, consisting 
of antipsychotic medication, and treatment and/or supportive counseling by therapists, 
caseworkers or coaches. TAU is considered to be equal in both conditions as a result of 
the randomization procedure used (see Randomization). During the trial participants 
are not allowed to receive any therapy aimed at improving social participation. 
Virtual reality exposure therapy (VRET)
VRETp treatment has a maximum of 16 treatment sessions of 60 min each. This 
number of sessions is somewhat larger than is usual for CBT in anxiety disorders. Our 
rationale for this is our expectation that treating paranoia requires more time compared 
with treating regular anxiety. People suffering from a psychotic disorder often show 
severity and durance in their social avoidance. Negative symptoms make it difficult 
to motivate people for therapy and this is a continuing process during treatment. 
The treatment protocol states that the therapists receive 16 h of training; all therapy 
sessions are recorded. A selection of the sessions is rated for treatment fidelity using 
the Cognitive Therapy Rating Scale (CTRS). The CTRS is a reliable185 and valid186 
instrument to measure treatment fidelity when following a CBT protocol. Monthly 4-h 
group supervision serves to guide the therapists throughout the intervention period.  
Existing CBT protocols will be adapted for VRET treatment in one area: exposure in 
vivo will be replaced by VR exposure. The remainder of the treatment protocol consists 
of well-known, evidence-based CBT elements, e.g. providing treatment rationale, 
behavioral experiments, reducing safety behavior, and attention training. Starting with 
exposure exercises for social situations which are lowest in the patient’s anxiety hierarchy, 
the exposure exercises take place during the therapy session using the Virtual Reality 
system. Participants are not allowed to receive any other form of therapy aimed at 
improving social participation during the trial. At all times the therapist is in control of 
the VRETp intervention and is able to immediately change/stop the virtual environment 
if necessary.   








A participant is considered an early completer of treatment when the subjective 
units of distress on a scale of 0 (no stress at all) to 100 (extremely stressful) in all the 
virtual situations that are part of the case conceptualization are reduced to zero in two 
consecutive sessions. This criteria is restrictive and was chosen to prevent therapies being 
ended prematurely, since no point of reference has been established for treating paranoia 
using VR exposure.
Discontinuation 
Participation is completely voluntary and participants can withdraw from participation 
at any time for any reason. Participants who drop-out or otherwise deviate from the 
intervention protocol are requested to continue to participate in the measurements.  
Fidelity checks
Audiotapes are made of all sessions and a selection of them is rated for treatment fidelity. 
All therapists are supervised by a highly skilled professional (MvdG) to evaluate, guide 
and approve the case conceptualization. Every six weeks, 4-h group supervision supports 
the therapist for the duration of the intervention. By means of a questionnaire, for each 
session the therapist reports on the elements and steps in the treatment protocol. Any 
deviation from the protocol is reported to the supervisor. 
Unblinding
The study is single-blinded, meaning that research assistants who do the measurements 
are kept blinded regarding randomization of the participants. Participants are regularly 
instructed not to tell the research assistants which group they are allocated to; if a 
research assistant is accidentally unblinded during a measurement, that measurement 
is stopped. A new appointment is then made with another blinded research assistant. 
Adverse events
The rules and regulations of the Medical Ethics Committee concerning adverse events 




All data are directly coded with a number. Data and personal information of the 
participants are kept separately and safely stored to ensure privacy. All data entry is 
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double-checked. A data monitor from Parnassia Psychiatric Institute is appointed for 
the study. 
Data analysis 
Multilevel linear mixed modeling is used to analyze the data according to the intention-
to-treat principle. Completer analysis is conducted with ANCOVA. Moderator and 
mediator analysis are conducted to assess the effects of moderators and mediators. Cost-
effectiveness is conducted with social participation as the outcome.
Ethics
Ethical approval of the protocol was granted by ‘De Medisch Ethische Toetsingscommissie 
VU medisch centrum’ (METC number: NL37356.058.12). 
Discussion
The main goal of the study is to investigate the effect of VRETp on improving social 
participation in patients with psychosis in real life. We hypothesize that VRETp will 
increase social participation objectively (time spent in company) and subjectively 
(experience less anxiety and paranoia during in social situations). Comparison between 
VRETp treatment and a waiting list condition will provide information about 
the effectiveness of VR exposure therapy for this population. This should make an 
important contribution to treatment options for people suffering from psychosis and 
social isolation. Improving social participation is of great personal value to patients with 
psychosis who suffer from the consequences of avoiding social situations in daily life. 
In addition to social participation, the effect of VRETp on psychological, emotional and 
social well-being, especially paranoia and Interaction anxiety, is explored. Studying these 
variables may help disentangle the complex phenomena related to social participation 
in patients with psychosis. 
Another aspect of the study is cost-effectiveness. If social participation improves it is 
expected that patients will become more independent, consume less care and, thereby, 
diminish costs related to extended health care. 
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Background: Many patients with psychotic disorders have persistent paranoid 
ideation and avoid social situations because of suspiciousness and anxiety. We 
investigated the effects of virtual-reality-based cognitive behavioral therapy (VR-
CBT) on paranoid thoughts and social participation.
Methods: In this randomized controlled trial at seven Dutch mental health centers, 
outpatients aged 18–65 years with a DSM-IV-diagnosed psychotic disorder and 
paranoid ideation in the past month were randomly assigned (1:1) via block 
randomization to VR-CBT (in addition to treatment as usual) or the waiting list 
control group (treatment as usual). VR-CBT consisted of 16 individual therapy 
sessions (each 1 h long). Assessments were done at baseline, after treatment (i.e., 
3 months from baseline), and at a 6-month follow-up visit. The primary outcome 
was social participation, which we operationalized as the amount of time spent 
with other people, momentary paranoia, perceived social threat, and momentary 
anxiety. Analysis was by intention to treat. This trial was retrospectively registered 
with ISRCTN, number 12929657.
Findings: Between April 1, 2014, and Dec 31, 2015, 116 patients with a psychotic 
disorder were randomly assigned, 58 to the VR-CBT group and 58 to the waiting 
list control group. Compared with the control, VR-CBT did not significantly 
increase the amount of time spent with other people at the post-treatment 
assessment. Momentary paranoid ideation (b = -0.331 [95% CI -0.432 to -0.230], 
P < .0001; effect size -1.49) and momentary anxiety (-0.288 [-0.438 to -0.1394]; 
P = .0002; -0.75) were significantly reduced in the VR-CBT group compared 
with the control group at the post-treatment assessment, and these improvements 
were maintained at the follow-up assessment. Safety behavior and social cognition 
problems were mediators of change in paranoid ideation. No adverse events were 
reported relating to the therapy or assessments.
Interpretation: Our results suggest that the addition of VR-CBT to standard 
treatment can reduce paranoid ideation and momentary anxiety in patients with 
a psychotic disorder.








People with psychotic disorders often avoid public and social activities. Their social 
networks are generally small and they spend more time alone than people without a 
psychotic disorder24. Many people with psychotic disorders do not have romantic 
partners, and the unemployment rate is high25,26. As many as 90% of patients have 
paranoid ideation to some degree18. Often, such ideation is strong and manifests as 
paranoid delusions, which are characterized by unfounded anticipation of intentional 
harm inflicted by other people. The anxiety resulting from paranoid ideation strongly 
contributes to social avoidance. This conditioned avoidance is not always affected by use 
of antipsychotic medication18. Cognitive behavioral therapy (CBT) is the most effective 
psychological treatment for people with psychotic disorders187. The effect sizes of CBT on 
paranoid delusions and social functioning are small to medium, but can be improved by 
more emphasis on behavioral rather than cognitive change, and by more person-specific 
exposure187—a key element of CBT. Exposure-based therapeutic exercises for paranoid 
ideation have several limitations. First, the social environment and reactions of others 
cannot be controlled by the therapist—relevant events might not occur, or unwanted 
events can suddenly occur. Second, exposure takes place between therapy sessions, and 
thus therapist feedback is retrospective and based on patient reports, which could be 
inaccurate because of biases14. Finally, many patients are reluctant or unable to undergo 
exposure because of strong paranoid fears or negative symptoms. These limitations could 
be overcome through virtual reality. The virtual social world is a controlled environment 
and exercises are done with the guidance of a therapist. Virtual reality is effective and safe 
for treating anxiety188. It is safe to use in people with psychotic disorders137, and studies 
suggest promising results for several virtual reality interventions, including for social skills 
training, auditory hallucinations, and paranoid ideation12,189. These findings suggest that 
virtual-reality-based CBT (VR-CBT) could be an effective, affordable, acceptable, and 
accessible form of treatment for patients with paranoid ideation and social withdrawal.
We did a randomized controlled trial to establish the effectiveness of VR-CBT, 
compared with treatment as usual, in improving the quantity and quality of social 
participation in patients with psychotic disorders who experience paranoid ideation and 
social avoidance. The primary hypothesis was that VR-CBT would lead to more time 
spent with other people, and a decrease in momentary paranoia, perceived social threat, 
and anxiety during real-life social activities. Our secondary hypotheses were that safety 
behaviors and paranoid ideation would be reduced by VR-CBT, that levels of social 
anxiety, depression, stigma, cognitive biases, and cognitive limitations would decline, 
and that social functioning, quality of life, and schematic beliefs would improve. 
Furthermore, we hypothesized that changes in safety behavior and cognition (biases and 
mental schemas) would mediate the reduction in paranoia. Cost-effectiveness analyses 




Study design and participants 
We did a single-blind randomized controlled trial of VR-CBT plus treatment as usual 
versus treatment as usual only in outpatients at seven Dutch mental health centers. 
Details of the study protocol have been published114. Inclusion criteria were a DSM-
IV diagnosis of a psychotic disorder based on the Mini-International Neuropsychiatric 
Interview190, the Schedules for Clinical Assessment in Neuropsychiatry59, or the 
Comprehensive Assessment of Symptoms and History60 (varied by center); avoidance of 
either shops, streets, public transport, or bars or restaurants; paranoid ideation in the past 
month (defined as a score greater than 40 on the Green et al Paranoid Thoughts Scale63); 
and age 18–65 years. Exclusion criteria were an IQ of 70 or lower (established by a valid 
instrument such as the Wechsler Adult Intelligence Scale or the Wechsler Intelligence 
Scale for Children); insufficient mastery of the Dutch language; and history of epilepsy. 
The protocol was approved by the medical ethical committee of VU University Medical 
Center Amsterdam (METC number NL37356.058.12). Patients were informed about 
the study by their treating psychiatrist, psychologist, or psychiatric nurse. If a patient 
was eligible and willing to participate, written informed consent was obtained.
Randomization and masking
After a baseline assessment, patients were randomly assigned. Research assistants blinded 
to treatment allocation did the post-treatment and follow-up assessments. Assessors were 
instructed to stop the assessment in case of unblinding, and the assessment was repeated 
by another research assistant. (An assessor had to be replaced on three occasions.) Block 
randomization was used to allocate patients (1:1) to the VR-CBT or control group. 
Each block had six assignments per condition. If a center had more patients, a second 
randomized block was allocated. Blocks were made with the scientific randomization 
program Research Randomizer by the independent randomization bureau of Parnassia, 
which also allocated patients to groups.
Procedures
The two groups were compared at baseline, after treatment (3 months after baseline), 
and at follow-up (6 months after baseline). Participants who dropped out of treatment 
were asked to complete the post-treatment and follow-up assessments. Instructions 
were given to psychiatrists not to change patients’ medication during the study. When 
patients reported medication changes, these changes were checked with their clinician. 
No additional psychological treatments for paranoid ideation or social participation 
were allowed. Participants in the control group were offered VR-CBT after follow-up. 
Four virtual social environments (a street, bus, café, and supermarket) were created 
with Vizard software (appendix). Within the environment, participants could move 







by operating a Logitech F310 Gamepad. They used a Sony HMZ-T1/T2/T3 Head 
Mounted Display with a high-definition resolution of 1280×720 per eye, with 51·6 
diagonal field of view, and a 3DOF tracker for head rotation. Therapists could vary 
the number of human avatars (0–40), the characteristics of the avatars (including sex 
and ethnicity), and the avatars’ responses to the patient (neutral or hostile, eye contact) 
to match the paranoid fears of the patient. Therapists could also make the avatars say 
pre-recorded sentences. Because these stimuli were directly controlled by the therapist, 
personalized treatment exercises were created for each patient.
VR-CBT consisted of 16 sessions over 8–12 weeks. Sessions lasted 1 h, 40 min of which 
comprised virtual-reality exercises. The remaining 20 min were used to plan and reflect 
on exercises. An individualized case formulation guided exposure to idiosyncratic social 
environmental cues that elicited fear, paranoid thoughts, and safety behaviors. Patients 
and therapists communicated during virtual-reality sessions to explore and challenge 
suspicious thoughts during social situations, drop safety behaviors during social 
situations (such as avoiding eye contact with, keeping distance from, and refraining from 
communication with avatars), and test harm expectancies. No homework exercises were 
given between sessions to test the effects of the in-virtuo exposure without the effects 
of structured in-vivo exposure. VR-CBT therapists were psychologists with at least 
basic CBT training. They received 2 days’ training in VR-CBT. The VR-CBT manual 
described a structured treatment plan for all 16 sessions. Therapists were supervised 
in a group for 4 h every month. All therapy sessions were recorded on audiotapes. 
Experienced CBT psychologists anonymously rated a random selection of sessions (two 
per therapist) for treatment fidelity with the Cognitive Therapy Rating Scale191. Patients 
in the waiting list control group received treatment as usual—antipsychotic medication, 
regular contact with a psychiatrist to control symptoms, and regular contact with a 
psychiatric nurse to improve self-care, daytime activities, and social and community 
functioning.
Outcomes
The primary outcome was social participation—a multidimensional construct with 
a behavioral, objective dimension and a subjective, experiential dimension. We 
operationalized objective social participation as the amount of time spent with others 
and subjective social participation as momentary paranoia, perceived social threat, and 
momentary anxiety in company.
The experience sampling method (ESM)—a structured diary method in which individuals 
are asked in daily life to report their momentary thoughts, feelings, symptoms, social 
contexts, and appraisal of social contexts—was used to assess momentary outcomes. 
ESM has been used by patients with psychotic disorder, with or without symptoms53. 
The method used in this study, PsyMate, has high ecological validity192. All participants 
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carried a PsyMate electronic device for assessments, which beeped at quasi-random 
moments ten times a day during 6 days. At each beep, the device collected self-assessments 
on a seven-point Likert scale, ranging from 1 (“not at all”) to 7 (“very”). Reports had 
to be completed within 15 min of the beep. To be included in the analysis, participants 
had to complete diary entries for at least one-third of the beeps (i.e., a minimum of 20 
measurements). For ESM, items from previous studies were used. Principal component 
analyses have been done previously for ESM affect items, and identified the following 
factors: negative affect, positive affect, momentary paranoia193, and perceived social 
threat53. A principal component analysis with oblique rotation and Kaiser normalization 
for the person-centered data from our study identified these four factors according to 
the Kaiser criterion (eigenvalue > 1). We used the momentary paranoia and perceived 
social threat subscales. The principal component analysis confirmed the perceived social 
threat factor for all four items (factor loadings ranging from 0.57 to 0.80) and partly 
confirmed momentary paranoia for three items (factor loadings ranging from 0.52 to 
0.83). The three-item momentary paranoia subscale was used. Time spent with others 
was measured by the proportion of beeps that participants reported to be in company 
of other people (not mental health professionals). Momentary paranoia was calculated 
as the mean score of the three items: “I feel that others might hurt me”, “I feel that 
others dislike me”, and “I feel suspicious”. Perceived social threat was calculated as the 
mean score on the items “I like this company [reversed score]”, “In this company, I 
feel accepted [reversed score]”, “I would rather be alone”, and “In this company, I feel 
threatened”. Scores on the item “I feel anxious” when in the presence of other people 
were used to establish momentary anxiety.
Secondary outcomes for symptom measures were the Safety Behaviour Questionnaire-
Persecutory Delusions194, the Green et al Paranoid Thoughts Scale63, the Social Interaction 
Anxiety Scale64, and the Beck Depression Inventory177. Functional outcomes were rated 
with the Social and Occupational Functioning Assessment Scale101 and the Manchester 
Short Assessment of Quality of Life195. Stigma was assessed with the Internalized Stigma 
of Mental Illness questionnaire196. To examine putative working mechanisms of the 
therapy, cognitive constructs were assessed with the Brief Core Schema Scales197 and the 
self-reported Davos Assessment of Cognitive Biases Scale87. Medication adherence was 
measured with the Brief Adherence Rating Scale198. After the fourth and eighth sessions, 
presence in virtual reality was assessed with the Igroup Presence Questionnaire199, and 
cybersickness symptoms with the Simulator Sickness Questionnaire141.
Statistical analyses
Because, to our knowledge, VR-CBT has never been tested before and ESM had not 
previously been used as a primary outcome in intervention studies, we conservatively 
estimated sample size by assuming a moderate effect size of 0.5 with a power of 0.8, 
an α of 0.05 and a two-sided independent t test. The estimated sample size was 64 for 







each group. We postulated an attrition rate of 20%, and thus set 160 as the total sample 
size. For primary outcomes, we applied the Bonferroni correction for four tests, with a 
significance level of 0.0125. For all other outcomes, the significance level was .05. Group 
characteristics were compared at baseline with t tests, non-parametric Mann-Whitney U 
tests, or χ² tests. All data had a hierarchical structure, with repeated measurements (level 
1) nested within individuals (level 2). Multilevel analyses were done to take into account 
that intra-individual observations are more similar than inter-individual observations. 
Logistic multi-level regression analyses were done for objective social participation; 
multilevel regression analyses were done for all other outcomes. All models included 
a random intercept for participant. We used the maximum-likelihood method and 
the covariance structure identity for estimation. All data were analyzed by intention to 
treat. The treatment effect was established with the group by time interaction for the 
post-treatment and follow-up assessments separately. Post-treatment and follow-up data 
were each compared to baseline. In all analyses age, sex, ethnicity, and education were 
included as covariates. If baseline differences between groups were noted, this variable 
was included as a covariate in all analyses. We calculated effect sizes for group by time 
interaction effects with the z test statistics to determine r200. To facilitate interpretation, 
we transformed r into Cohen’s dpp (the superscript shows that the effect size was based 
on pre–post measures)201.
Two parallel multiple mediation analyses were done to examine the mediating effects 
of VR-CBT on paranoid ideation at the post-treatment assessment. The analyses had 
different outcome measures—paranoid ideation (Green et al Paranoid Thoughts Scale 
total score) and momentary paranoia (ESM; appendix). Selection of potential mediators 
was based on the results of our multilevel analysis. We used a significance level of 0.10 
for the post-treatment treatment effect variables as the cutoff for inclusion in the 
mediation analysis. Analyses were done with the PROCESS macro202, which uses linear 
regression to estimate indirect effects according to the methods recommended by Hayes 
and Rockwood for clinical studies203. This method is based on a modern framework, 
and, by contrast with the causal and steps approach, in which a series of criteria are 
required to establish mediation204, it focuses solely on quantification of indirect effects. 
Hayes and Rockwood also emphasize the value of mediation analysis for research if only 
two measurement moments are used. Post-treatment scores were added as mediators, 
and baseline scores for the outcome variables and mediators were added to the models 
as covariates. Least-square path analysis was used and the bootstrap confidence interval 
(5,000 permutations) was applied to estimate indirect effects. We used Stata (version 
13.1) and SPSS (version 24.0.0.0) for all analyses. Because of an oversight, prospective 
trial registration was overlooked, but the trial was registered retrospectively with 




Role of  the funding source
The study funders had no role in the study design; data collection, analysis, or 
interpretation; or writing of the Article. RMCAP-K, CNWG, WV, PAEGD, and MvdG 
had full access to all study data, and RMCAP-K, the corresponding author, had final 
responsibility for the decision to submit for publication.
Results
Between April 1, 2014, and Dec 31, 2015, 116 patients with a psychotic disorder were 
randomly assigned (figure 6.1). Patients who were included in the study did not differ 
significantly in terms of frequency and severity of paranoid ideation from those who 
chose not to participate (we did separate analyses for patients who were eligible but did 
not consent to be contacted about study participation, those who had no wish, need, or 
time for treatment, those who were unable to travel to the treatment location, and those 
who gave permission for contact but did not respond; data not shown).
Sociodemographic characteristics were well balanced between groups (table 6.1). Partic-
ipants who dropped out from VR-CBT did not differ from participants who completed 
VR-CBT in baseline paranoid ideation or safety behaviors (data not shown). We noted 





Male 40 (69%) 42 (72%)
Age in years 36.5 (10) 39.5 (10)
Non-Dutch origin 15 (26%) 25 (43%)
Education
No/primary 16 (28%) 16 (28%)
Vocational 18 (31%) 24 (41%)
Secondary 9 (16%) 9 (16%)
Higher 15 (26%) 9 (16%)
DSM-IV diagnosis 
Schizophrenia 46 (79%) 49 (85%)
Schizoaffective disorder 1 (2%) 5 (9%)
Delusional disorder 1 (2%) 0 (0%)
Psychotic disorder NOS 10 (17%) 4 (7%)
Duration of illness in years 13.3 (10.6) 14.9 (9.5)
Medication use 
Antipsychotics 54 (93%) 57 (98%)
Olanzapine equivalent of prescribed antipsychotic medication (mg/day) 10.5 (6.8) 11.0 (8.3)
Antidepressants 15 (26%) 17 (29%)
Note. Data are n (%) or mean (SD). VR-CBT = virtual reality based cognitive behavioral therapy. NOS = Not Otherwise 
Specified.







no differences in baseline paranoid ideation or safety behavior between participants who 
refrained from follow-up measurements and those who completed all measurements 
(data not shown). Cybersickness was recorded (appendix), but only one participant 
dropped out because of nausea, rendering further statistical investigation irrelevant. No 
adverse events relating to either VR-CBT or the assessments were reported.








































11 patients (19%) in the VR-CBT group dropped out of therapy (including four who 
never started treatment). Seven patients discontinued treatment: one was too afraid 
(completed one session), one had no time (one session), one was not willing to travel 
to therapy location (two sessions), one had nausea (two sessions), one was unable to 
attend sessions sober (three sessions), and two found the head-mounted display too 
uncomfortable to tolerate (five and six sessions, respectively). Participants felt sufficiently 
present in the virtual environments on all three subscales of the Igroup Presence 
Questionnaire (range 0–6): spatial presence (mean 3.79), involvement (mean 3.16), and 
realness (mean 2.96). 28 sessions were rated for treatment fidelity. Therapists had “good” 
to “very good” adherence to the protocol and CBT quality (mean 4.5 [range 2.4–5.9]).
The VR-CBT group reported 17 changes of anti-psychotics: ten doses were lowered, 
three doses were raised, and four patients changed medication. 18 changes were reported 
in the control group: 11 doses were lowered, six doses were raised, and one person 
changed medication. No significant differences were noted between patients who had 
any medication changes and those who had no changes at baseline, at 3 months after 
treatment, or at follow-up (data not shown).
At baseline, no significant differences were noted between the VR-CBT and control 
groups, except in use of safety behaviors (table 6.2), which was significantly lower in the 
control group (24.1) than in the VR-CBT group (28.8; z = -2·09; P = .036). Baseline 
level of safety behaviors was thus included as a covariate in analyses. All participants 
completed ESM measurements at baseline (mean number of completed self-assessments 
46.1 [SD 13.3]), 96 participants completed the post- treatment assessment sufficiently 
(43.1 [10.1]), and 87 participants completed the follow-up (43.2 [11.1]).
For amount of time spent with others, the treatment effect at the post-treatment visit 
compared with baseline was not significant (dpp 0.25; P = .178), but the treatment effect 
at follow-up compared with baseline was (dpp 0.50; P = .0090; table 6.3). Time spent 
with others decreased by 2.4% in the control group between baseline and the follow-up 
assessment, whereas the amount of time marginally increased by 0.3% in the VR-CBT 
group.
Between baseline and the post-treatment assessment, a large reduction was noted in 
momentary paranoia (-0.350) in the VR-CBT group, whereas a slight increase was 
noted in the control group (0.162; dpp -1.49; P < .0001; table 6.3). A significantly larger 
decrease in momentary anxiety was noted in the VR-CBT group than in the control 
(dpp 0.75; P = .0002; table 6.3). The effect sizes for momentary paranoia and anxiety 
remained significant at follow-up. When the mean of the original four-item subscale 
was used (instead of the three-item subscale), the pattern of results for momentary 
paranoia was identical (data not shown). No significant interaction effects were noted 
for perceived social threat at the post-treatment (dpp -0.33) or follow-up (dpp 0.36) 
assessments (table 6.3).

























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Compared with the control group, use of safety behaviors decreased significantly in the 
VR-CBT group at both the post-treatment and follow-up assessment (table 6.3). The 
largest reduction at the post-treatment visit was for the in-situ safety behaviors subscale 
(binteraction – 3.7 [95% CI -6.2 to -1.2]; z -2.93, P = .0033).
Treatment effects on paranoid ideation were significant: at the post-treatment and 
follow-up assessments, levels of ideas of persecution and social reference were lower in 
the VR-CBT group than in the control group (table 6.3). Depression and anxiety were 
not significantly lower in the intervention than in the control group (table 6.3). The VR-
CBT group had improvements in self-stigmatization and social functioning at follow-
up whereas the control group did not (table 6.3). Quality of life at the post-treatment or 
follow-up assessments did not differ significantly between groups (table 6.3).
Significant interaction effects were noted for attention for threat and social cognitive 
problems at the post-treatment assessment (table 6.3). No significant treatment effects 
were found for positive and negative beliefs of self or others (table 6.3).
Mediation analysis showed that part of the treatment effect on paranoid ideation 
(measured by the Green et al Paranoid Thoughts Scale) at the post-treatment assessment 
was mediated by change in safety behavior (percentage mediated 33.7%) and change 
in social cognitive problems (percentage mediated 19.2%; table 6.3). Individuals 
who received VR-CBT used less safety behavior and reported fewer social cognition 
problems than did those in the control group, and in turn experienced less paranoid 
ideation. Jumping to conclusions and attention for threat did not mediate the effect 
of treatment on paranoid ideation (table 6.4). The direct effect of the treatment on 
paranoid ideation was no longer significant after inclusion of the mediators in the 
model (P = .060). The indirect effect of safety behavior was not significantly larger than 
the indirect effect of social cognition problems (bootstrap CI of the contrast -3.4 to 
7.5). None of the included mediators significantly mediated the effect of VR-CBT on 
momentary paranoia as measured with ESM (table 6.4). The total effect (independent of 
mediators) and direct effect (including the mediators) of treatment were both significant 
for momentary paranoia (table 6.4).
Discussion
To our knowledge, ours is the first randomized controlled trial of VR-CBT to treat 
paranoid ideation and social avoidance in patients with psychotic disorders. Although 
the amount of time spent with others did not increase after VR-CBT compared with 
the control, VR-CBT resulted in large reductions in momentary paranoia and anxiety 
during social interactions, not only at the post-treatment assessment, but also at the 
6-month follow-up assessment. Significant improvements were also noted for ideas of 
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persecution, ideas of social reference, and use of safety behavior. The therapeutic effect 
of VR-CBT for paranoid ideation was mediated by improvements in safety behaviors 
and social cognition, but mediation effects were not noted for momentary paranoia. 
Our findings suggest that VR-CBT does not immediately lead to spending more time 
with others, but helps patients to learn how to drop safety behaviors and to have social 
interactions more positively, with less anxiety and paranoia after therapy. In turn, these 
positive experiences seem to lead to fewer paranoid thoughts and fewer ideas of social 
reference in general. This interpretation was supported by the results of the mediation 
analysis, which showed that reductions in safety behavior accounted for 34% of the 
change in paranoid ideation, and improvements in social cognition for 19%.
How do these mechanisms contribute to reductions in paranoid ideation? Safety 
behaviors interfere with the development of new associations and prevent gathering of 
social information. For example, during the first sessions, many participants looked at 
avatars from the neck down only, avoiding eye contact. When such safety behavior is 
dropped, the patient receives more social information. Improvements in social cognition 
can result in more adequate interpretations of that information, thereby reducing the 
chance of incorrect paranoid appraisals. Safety behavior was targeted explicitly during 
sessions, because people practiced within virtual recreations of situations that they 
would usually avoid. Cognition was actively challenged and discussed during virtual 
reality exposures, although in a less structured fashion than safety behavior, which could 
explain the absences of findings for several cognitive biases.
Table 6.4. Results mediation analyses*
Paranoid ideation (GPTS) Momentary paranoia (ESM)
N = 101 N = 95
Effect P 95% boot CI Effect P 95% boot CI
Total effect c 13.72 0.0024 0.38 0.012
Direct effect c' 6.83 0.060 0.28 0.042
Indirect effect safety 
behaviour
ab1 4.62 0.62 to 10.21 0.02 -0.01 to 0.26
Indirect effect attention for 
threat
ab2 -0.35 -3.86 to 1.71 0.06 -0.01 to 0.23
Indirect effect social 
cognitive problems
ab3 2.63 0.05 to 8.01 0.05 -0.03 to 0.25
Indirect effect jumping to 
conclusions
ab4 -0.01 -1.49 to 1.49 -0.03 -0.17 to 0.01
Note. Boot CI = bootstrap confidence interval. ESM = Experience Sampling Method. GPTS = Green et al. Paranoid 
Thoughts Scale.
* Mediation analysis was performed by the method described by Hayes and Rockwood203. Baseline and posttreatment 
values were used, baseline values of outcome and mediator variables were added as covariates to the model.







No mediating effects were identified for momentary paranoia as measured by ESM. 
Although this finding seems contradictory to the results for paranoid ideation on the 
Green et al Paranoid Thoughts Scale, it could be explained by the nature of the scales. The 
Green et al Paranoid Thoughts Scale assesses paranoia with 32 items, whereas momentary 
paranoia is composed of three items. Thus, variation in ESM scores tends to be lower, and 
the ESM scale might be less sensitive to changes. Additionally, retrospectively measured 
paranoid ideation could capture different constructs from those captured by measurement 
of momentary state paranoia. ESM is ecologically valid, but also seems to be complementary 
to retrospective measures rather than a measurement of the same constructs205.
Overall, expansion of social activities and improvement of social functioning seem to 
require more time and are mainly accomplished in the period after therapy. Patients 
in symptomatic remission do not immediately spend more time with others206. When 
patients increasingly feel more comfortable in social situations and learn that other 
people are less threatening than anticipated, they might try and succeed to make and 
maintain social contacts and find hobbies and jobs. At the follow-up assessment in our 
study, a positive effect of VR-CBT was noted for stigma and social and occupational 
functioning. Furthermore, resolution of symptoms might not automatically improve 
social functioning—negative symptoms and deficient social skills could get in the way. 
Additional training might be needed.
Our results are in line with a virtual reality experimental study115 for treatment of 
ideas of persecution, in which significant reductions in delusional conviction and real-
world distress were noted after one session. Similar to virtual reality interventions for 
social skills and job interview training for people with schizophrenia, our intervention 
was generalizable to everyday life12. Although many virtual reality studies have a 
high frequency of dropouts due to cybersickness6, in our study only one participant 
had cybersickness to the extent that he quit treatment. SSQ data can be found in 
supplementary table S6.1. Cybersickness might become less of a problem as a result 
of improvements in technology. Perception of social threat, as measured by ESM, was 
not significantly affected by VR-CBT. Collip and colleagues53 noted that perceived 
social threat was more often reported in the company of less familiar people than in 
the presence of familiar people. However, the term social threat could be misleading, 
because the items on the ESM could also express the wish to enjoy company versus a 
preference for being alone. This scale thus needs further validation.
A strength of our study is the use of ESM to assess treatment effects in the flow of daily 
life. Another strength is the pragmatic effectiveness design of the study. The study was 
done in seven mental health centers, and treatment was delivered within standard services 
by regularly employed therapists. Therapists’ experience with exposure therapy and CBT 
varied. Our results suggest the effectiveness of VR-CBT in real-world conditions in a 
sample of patients who are representative of standard clinical practice.
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Our study also had several limitations. First, we did not use an active control group, 
such as CBT with exposure in vivo. Thus, we cannot rule out a dose-effect of therapeutic 
contacts. Second, the long-term effects of VR-CBT remain unknown, because follow-
up was restricted to 6 months. Third, technological limitations restricted conversational 
interaction possibilities between participants and avatars. Therefore VR-CBT could not 
sufficiently address conversational issues. Fourth, a potential limitation of VR-CBT is 
that patients are not exposed to unexpected surprises that can occur in life. Although 
this criticism is valid, many patients with psychosis become too frightened in real-life 
situations, preventing them from dropping safety behaviors or causing them to avoid 
exposure. To prevent the risk that the presence of the therapist becomes a safety signal, 
as therapy progresses the therapist should become less prominently present and should 
guide the patient less. Fifth, some eligible patients did not participate because they 
were too frightened to travel to the therapy location. Thus, our sample might have been 
biased, because some of the most paranoid and avoidant patients could not participate. 
Additionally, little is known about the patients who seemed eligible on the basis of 
screening but did not consent to be contacted, or about the people who provided 
consent to be contacted, but did not respond. Further-more, we could not recruit the 
aimed number of participants within our financial and time limits. The study is thus 
somewhat underpowered. Finally, the temporal order of the mediation analysis was 
based on the assumed mechanisms of VR-CBT, but reverse causality cannot be ruled 
out. That said, we agree with Hayes and Rockwood203 that mediation analysis, despite 
limitations, provides useful insights into clinical research findings. Although no final 
conclusions can be drawn, our findings support the predetermined hypothesis.
In conclusion, in patients with a psychotic disorder, our findings support the hypothesis 
that VR-CBT strongly reduces paranoid ideation, momentary anxiety, and safety 
behaviors in real-life social situations. This study shows that targeting safety behavior 
and social cognitive appraisals in psychotherapy with virtual reality can effectively reduce 
paranoid thoughts. Future research should compare VR-CBT with standard cognitive 
behavioral therapy in terms of both treatment effects and cost-effectiveness.
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Evidence before this study
Paranoid ideation is common in patients with a psychotic disorder. The anxiety 
resulting from paranoid ideation strongly contributes to social avoidance. Cognitive 
behavioural therapy is the best-documented effective psychological treatment for 
this, but effects are small to medium at best. The positive results of using virtual 
reality in treating anxiety disorders suggest virtual reality might be used to improve 
treatment for anxiety and avoidance of social situations resulting from paranoid 
ideation. We searched for the use of virtual reality in treating paranoid ideation. 
Research showed it is safe to expose patients with a psychotic disorder to immersive 
virtual environments. It also showed virtual reality can be used to elicit paranoid 
ideation and anxiety in patients with a psychotic disorder, indicating feasibility of 
creating virtual environments for treatment. 
On 14 september 2017, we searched the entire archive (i.e., using no date or 
language restrictions) of MedLine for (Virtual Reality) AND (Delus* OR Paranoi* 
OR Psychosis OR Psychotic OR Schizophren*). Ninety-four peer reviewed papers 
were identified, and only one was a randomised controlled trial of virtual reality 
therapy for reducing paranoid ideation. This small (n = 30) experimental study 
found large reductions in delusional conviction and real-world distress. 
Added value of  this study
We undertook the first randomised controlled trial to date of virtual reality therapy 
to improve daily life social functioning and to reduce paranoid ideation in patients 
with a psychotic disorder. We found that virtual reality based cognitive behavioural 
therapy strongly reduces paranoid ideation, anxiety and use of safety behaviours 
in social situations. Results of the mediation analysis support the importance of 









SSQ total score 57.5 (38.3)
SSQ – Oculomotor subscale 49.9 (31.1)
SSQ – Nausea subscale 42.9 (34.1)
SSQ – Disorientation subscale 59.6 (50.8)
Session 8
SSQ total score 52.9 (41.9)
SSQ – Oculomotor subscale 45.5 (35.1)
SSQ – Nausea subscale 42.0 (32.3)
SSQ – Disorientation subscale 50.6 (55.0)
Note. Data are mean (SD). VR-CBT = virtual reality based cognitive behavioral therapy. SSQ = Simulator sickness 
questionnaire.
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Background: Evidence was found for the effectiveness of virtual reality-based 
cognitive behavioral therapy (VR-CBT) for treating paranoia in psychosis, but 
health-economic evaluations are lacking. 
Objective: This study aimed to determine the short-term cost-effectiveness of VR-
CBT. 
Methods: The health-economic evaluation was embedded in a randomized 
controlled trial evaluating VR-CBT in 116 patients with a psychotic disorder 
suffering from paranoid ideation. The control group (n = 58) received treatment as 
usual (TAU) for psychotic disorders in accordance with the clinical guidelines. The 
experimental group (n = 58) received TAU complemented with add-on VR-CBT 
to reduce paranoid ideation and social avoidance. Data were collected at baseline 
and at 3 and 6 months postbaseline. Treatment response was defined as a pre-
post improvement of symptoms of at least 20% in social participation measures. 
Change in quality-adjusted life years (QALYs) was estimated by using Sanderson 
et al.’s conversion factor to map a change in the standardized mean difference 
of Green’s Paranoid Thoughts Scale score on a corresponding change in utility. 
The incremental cost-effectiveness ratios were calculated using 5000 bootstraps of 
seemingly unrelated regression equations of costs and effects. The cost-effectiveness 
acceptability curves were graphed for the costs per treatment responder gained and 
per QALY gained. 
Results: The average mean incremental costs for a treatment responder on social 
participation ranged between €8,079 and €19,525, with 90.74%–99.74% 
showing improvement. The average incremental cost per QALY was €48,868 over 
the 6 months of follow-up, with 99.98% showing improved QALYs. Sensitivity 
analyses show costs to be lower when relevant baseline differences were included 
in the analysis. Average costs per treatment responder now ranged between €6,800 
and €16,597, while the average cost per QALY gained was €42,030. 
Conclusions: This study demonstrates that offering VR-CBT to patients with 
paranoid delusions is an economically viable approach toward improving patients’ 
health in a cost-effective manner. Long-term effects need further research.








Psychotic disorders impose a large disease burden—morbidity plus mortality—on the 
population, and in its wake, substantial economic costs occur for society and health care 
systems. The main drivers of societal costs of schizophrenia are health care costs and 
productivity losses, but patients and their families also incur substantial costs207. Low 
participation rates of individuals with psychosis in the labor market are an important 
cause of productivity losses, while the main contributor to health care costs are in-patient 
psychiatric admissions208. All in all, treatment costs of psychotic disorders consume a 
significant part of health care budgets in European countries209.
Paranoid ideation is a common delusion in individuals with a psychotic disorder. 
Even when medicinal treatment is successful, paranoid thoughts and anxiety often 
remain because of conditioned avoidance and other acquired safety behaviors in social 
situations18. Social avoidance hinders recovery in social participation for patients and 
keeps unemployment rates as high as 70%–85%26,210. A poor social network contributes 
to stigma and a lack of empowerment, resulting in more depressive symptoms and lower 
quality of life211. A smaller social network size is associated with more severe overall 
psychiatric and negative symptoms212. Virtual reality-based cognitive behavioral therapy 
(VR-CBT) was found to be an effective treatment for paranoid ideation in individuals 
with a psychotic disorder115,213. The use of virtual reality (VR) treatment in clinical 
practice is expected to become more widespread as VR technology becomes more readily 
available6. Therefore, information on the cost-effectiveness of this kind of treatment is 
required. This study was designed to evaluate whether adding VR-CBT to treatment as 
usual (TAU) would be effective in treating paranoid ideation in a cost-effective way with 
respect to improving social participation. A trial-based cost-effectiveness analysis (CEA) 
was conducted using data collected in seven outpatient mental health care services in 
the Netherlands, comparing add-on VR-CBT with TAU alone. This paper aims to 




The health-economic evaluation was embedded in a randomized controlled trial 
evaluating VR-CBT in 116 patients with a psychotic disorder suffering from paranoid 
ideation213. The VR-CBT study was a randomized, controlled, single-blind multicenter 
trial in two parallel groups, comparing add-on VR-CBT to TAU alone over a period of 
6 months213. This study was approved by the Vrije Universiteit (VU University) Medical 
Ethics Committee for mental health service research and was registered retrospectively 
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at the ISRCTN (International Standard Randomized Controlled Trial Number) registry 
(ISRCTN12929657). The trial protocol is provided elsewhere114. Four virtual social 
environments—a street, bus, café, and supermarket—were created with Vizard software 
(WorldViz). Within the environment, participants could move by operating a Logitech 
F310 Gamepad. They used a Sony HMZ-T1/T2/T3 head-mounted display with a high-
definition resolution of 1280 × 720 per eye, a 51.6 diagonal field of view, and a 3DOF 
(3 degrees of freedom) tracker for head rotation. VR-CBT therapists were psychologists 
with at least basic cognitive behavioral therapy (CBT) training. They received 2 days of 
training in VR-CBT. The VR-CBT manual described a structured treatment plan for 
all 16 sessions. Therapists were supervised in a group for 4 hours every month by two 
VR-CBT specialists. 
Recruitment 
Participants were recruited at seven treatment centers in the Netherlands between April 
1, 2014, and December 31, 2015. To be included, participants had to meet the following 
criteria: (1) 18–65 years of age; (2) DSM-IV (Diagnostic and Statistical Manual of 
Mental Disorders, Fourth Edition) diagnosis of schizophrenia, schizophreniform 
disorder, schizoaffective disorder, delusional disorder, or psychotic disorder not otherwise 
specified; (3) suffering from at least mild paranoia, as assessed by Green’s Paranoid 
Thoughts Scale (GPTS) (score of > 40); and (4) self-report of avoiding at least one 
social situation. Exclusion criteria were as follows: (1) insufficient competency of Dutch 
language; (2) IQ below 70; and (3) a concurrent diagnosis of epilepsy. Assessments were 
performed at baseline and at 3 and 6 months postbaseline.
Interventions 
All participants continued to receive TAU (i.e., antipsychotic medication, regular contact 
with a psychiatrist to manage symptoms, and regular contact with a psychiatric nurse). 
Participants in the experimental condition also received therapist-led VR-CBT. VR-
CBT treatment consisted of 16 biweekly sessions of 60 minutes each, using 40 minutes 
for exposure and behavioral exercises in virtual social environments. The therapist used 
an individual case formulation to help patients falsify their harm expectancies. No 
homework exercises were given between VR-CBT sessions. The treatment protocol, in 
Dutch, is available from the corresponding author.
Outcome measures
Overview 
We conducted both a CEA with three measures of improved social participation as 
outcome and a cost-utility analysis (CUA) with quality-adjusted life years (QALYs) 
gained as outcome. The outcome measures are described in more detail below.








The outcome of interest in the CEA was social participation. Social participation was 
operationalized in three ways: (1) objective social participation as the amount of time 
spent with others, (2) subjective social participation as momentary anxiety, and (3) 
subjective social participation as momentary paranoia. Momentary in this context meant 
that it was measured in real life during social company. All three outcomes were assessed 
in real time using the ecological sampling method (ESM). ESM is a structured diary 
method in which individuals are asked in daily life to report their thoughts, feelings, 
and symptoms, as well as the appraisal of the present social context. To that end, all 
participants carried an electronic device (PsyMate) for the ESM assessments. The device 
beeped at semirandom moments 10 times a day over 6 days. At each beep, the device 
collected self-assessments on a 7-point Likert scale ranging from 1 (not at all) to 7 (very). 
A positive treatment response on each of the three outcome measures was defined as an 
improvement of at least 20% at 6 months follow-up relative to the patient’s baseline 
score.
Quality-adjusted life year 
The outcome in the CUA was the QALY derived from the GPTS63. The GPTS is an 
established broad measure of paranoid-delusional functioning that has long been used 
as an outcome measure. This instrument was chosen to be able to compare results with 
earlier CUA research on the subject. Mean GPTS scores at each measurement were first 
converted into the standard mean difference (SMD) by dividing the raw mean change 
scores by the SD of the GPTS at baseline in the control condition. In a next step, we 
used Sanderson et al.’s conversion factor214 of 0.1835 (i.e., the average of 0.209 using 
a rating scale and 0.158 using time trade-off), such that a change of 1 standard unit 
(i.e., SMD) on the GPTS is equal to a corresponding change of 0.18 utility. The utility 
is a quality of life valuation and is needed to compute QALY gains in the VR-CBT 
condition relative to the TAU condition over the full 6 months between baseline and 
follow-up.
Resource use and costing 
Societal costs were computed by adding (1) the direct medical costs of health care services 
use including the costs of antipsychotic medication and, in the experimental condition, 
the additional costs of adjunctive VR-CBT treatment; (2) direct nonmedical costs of 
travel; and (3) indirect costs stemming from lower productivity. For each participant, 
cost data over the last 3 months were collected at each of three measurement points. 
Resource use data, for costing, were collected using the Trimbos Institute and Institute 
of Medical Technology Assessment Questionnaire for Costs Associated with Psychiatric 
Illness (TiC-P)215. The TiC-P is the most widely used health service interview in the 
Netherlands. It consists of questions on the number of contacts by type of health care 
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provider and questions on productivity losses. A health service questionnaire is a valid and 
reliable method for quantifying costs in trial-based economic evaluations in health care216. 
A cross-validation sample comparing TiC-P self-report to electronic patient files showed 
all data to be reliable, except for the number of reported sessions with a psychologist 
(data available upon request from first author). Not all patients had understood that 
they needed to incorporate the 16 VR-CBT sessions into their TiC-P self-report. This 
information was, therefore, 100% cross-checked using electronic patient files. The main 
cost driver was admission to psychiatric hospitals, so the number of days admitted to 
a psychiatric hospital was also 100% cross-checked against electronic patient files and 
corrected where needed. Direct medical costs were calculated by multiplying health 
service units (e.g., sessions, visits, and hospital days) with their standard economic cost 
price (see supplementary table S7.1). We also added the medication costs, consisting of 
antipsychotic and antidepressant medication. Corresponding costs were calculated as the 
cost price per standard daily dose, as reported in the Dutch Pharmaceutical Compass217, 
multiplied by the number of prescription days, plus the pharmacist’s dispensing costs of 
€6 per monthly prescription or €12 for a first-time prescription218.
Virtual Reality Costs for VR therapy hardware, software and training costs were 
calculated. Total yearly costs for one VR system was €23,995, according to CleVR 
BV, a company who builds VR sets. Yearly costs for training and supervision of the 
psychologists was €13,400. Per-patient costs per 16 VR-CBT treatment sessions was 
€373.95.
Travel Costs Travel costs arose when participants had to make return trips for receiving 
health care at health services. Travel costs were computed as the average distance to a 
health service (7 km) multiplied by the costs per km (€0.21)218.
Productivity Costs Research assistants monitored changes in the participants’ work 
status at baseline and at 3 and 6 months postbaseline using the TiC-P. Productivity losses 
in paid work were calculated according to the human capital approach219, reflecting 
changes in the contractual number of hours worked per week and adjusting these for 
work-loss days arising from sick leave over the full period of 6 months using gender-
specific hourly productivity costs218. Costs were originally expressed in Euros for the 
reference year 2014, but indexed to 2015 using the consumer price index as reported by 
Statistics Netherlands. In the reference year 2015, 1 Euro in the Netherlands equaled 
1.235 US$.
Statistical analysis
Imputation Following the CONSORT (Consolidated Standards of Reporting Trials) and 
CHEERS (Consolidated Health Economic Evaluation Reporting Standards) guidelines, 
all our analyses adhered to the intention-to-treat principle. To that end, missing values 







were imputed using multiply imputed chained equations (MICE) for nonparametric 
data with M of 100 bootstraps for each incomplete variable. Baseline variables 
predictive of effects (i.e., QALYs and treatment response) were used for imputation, 
such as baseline data of the variable with missing values, treatment condition, ethnicity, 
education, sex, age, and safety behaviors at baseline. Safety behaviors, such as avoiding 
eye contact or escaping from social situations, were measured using the Safety Behaviour 
Questionnaire-Persecutory Delusions (SBQ-PD)194. Time spent with others showed a 
large difference at baseline despite randomization and was added as covariate in the CEA 
where time spent with others was used as the treatment response outcome of interest. 
Main Analysis Both the CUA and CEA were conducted from the societal perspective. In 
each of these analyses, the incremental cost-effectiveness ratios (ICERs) were calculated 
as the between-group cost difference divided by the between-group effect difference. The 
ICER is interpreted as the additional costs per additional unit effect (i.e., per additional 
treatment responder; per QALY gained). Cost and effect differences were obtained 
from seemingly unrelated regression equations of costs and effects, thus allowing for 
correlated residuals in the equations. The seemingly unrelated regression equations 
(SURE) models were bootstrapped 5,000 times. In each bootstrap step, the mean cost 
differences and the mean outcome differences were computed and these were plotted 
on the cost-effectiveness plane. Finally, cost-effectiveness acceptability curves (CEACs) 
were graphed. CEACs inform decision makers about the likelihood that an intervention 
is deemed cost-effective, given a range of willingness-to-pay ceilings for gaining 1 QALY 
and gaining 1 treatment responder. All analyses were conducted in Stata, version 13.1 
(StataCorp).
Sensitivity analyses 
The following sensitivity analyses were carried out. First, a sensitivity analysis was done 
including safety behavior at baseline as a covariate because despite randomization 
there was a significant difference at baseline, and it was found to be the main mediator 
in reducing paranoid ideation213. Second, a sensitivity analysis was done including 
psychiatric admission costs at baseline as a covariate because there was a large difference 
between groups at baseline. Third, a sensitivity analysis was done including both safety 




After providing informed consent, 116 participants agreed to participate: 58 (50.0%) 
in the control condition and 58 (50.0%) in the experimental condition (see figure 7.1).
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Figure 7.1. Trial flow diagram.
* Specification of participants lost to posttreatment: 6 declined further participation and 2 were lost due to clerical errors 
by therapist. ‡ Specification of participants lost to follow-up: 9 declined further participation, 1 died of unrelated causes, 
and 2 were lost due to clerical errors by therapist. First published in Lancet Psychiatry (Pot-Kolder et al., 2018). VR-CBT 













































Baseline characteristics of the sample can be found in table 7.1. Results of costs and 
outcomes can be found in table 7.2. A small group of participants was responsible for a 
large portion of the baseline costs, largely related to hospital admissions. The total days of 
psychiatric admissions were 233 days at baseline, 101 days posttreatment, and zero days 
at follow-up for the VR-CBT group. The total days of psychiatric admissions were 138 
days at baseline, 20 days posttreatment, and 68 days at follow-up for the TAU group.
Incremental effects
Time spent with others 
The treatment response rate regarding the time spent with others was 13 patients out 
of 58 (22%) in the control group and 24 patients out of 58 (41%) in the experimental 
group. The baseline-adjusted between-group difference between the response rates (i.e., 
the incremental effect) was 0.23, which was statistically significant (SE = 0.076, t113 = 
3.07, 95% CI 0.08–0.38, P = .003).





Male 40 (69%) 42 (72%)
Age in years 36.5 (10) 39.5 (10)
Non-Dutch origin 15 (26%) 25 (43%)
Education
No/primary 16 (28%) 16 (28%)
Vocational 18 (31%) 24 (41%)
Secondary 9 (16%) 9 (16%)
Higher 15 (26%) 9 (16%)
DSM-IV diagnosis 
Schizophrenia 46 (79%) 49 (85%)
Schizoaffective disorder 1 (2%) 5 (9%)
Delusional disorder 1 (2%) 0 (0%)
Psychotic disorder NOS 10 (17%) 4 (7%)
Duration of illness in years 13.3 (10.6) 14.9 (9.5)
Medication use 
Antipsychotics 54 (93%) 57 (98%)
Olanzapine equivalent of prescribed antipsychotic 
medication (mg/day) 
10.5 (6.8) 11.0 (8.3)
Antidepressants 15 (26%) 17 (29%)
Paid work 8 (14%) 5 (9%)
Safety behaviours 28.8 (14.2) 21.1 (16.0)
Note. Data are n (%) or mean (SD). VR-CBT = virtual reality based cognitive behavioral therapy. TAU = Treatment As 
Usual. NOS = Not Otherwise Specified. GPTS = Green et al. Paranoid Thoughts Scale. QALY = Quality-adjusted life 

















































































































































































































































































































































































































































































































The treatment response rate with regard to momentary anxiety was 17 patients out of 58 
(29%) in the control group and 24 patients out of 58 (41%) in the experimental group. 
The between-group difference between the treatment response rates (i.e., incremental 
effect) was 0.12, but this difference was not statistically significant (SE = 0.089, t114 = 
1.36, 95% CI -0.055 to 0.290, P = .18).
Momentary paranoia 
The treatment response rate in momentary GPTS paranoia was 11 patients out of 
58 (19%) in the control group and 28 patients out of 58 (48%) in the experimental 
group. The between-group difference in the response rates was 0.29 and was statistically 
significant (SE = 0.0841, t114 = 3.48, 95% CI 0.126–0.460, P = .001).
Quality-adjusted life years 
The SMD of GPTS paranoia was 0.523, which was statistically significant (SE = 0.120, 
t114 = 4.37, 95% CI 0.285–0.760, P < .001). Using Sanderson et al.’s conversion factor 
[14] of 0.1835 and taking into account a follow-up period of half a year, this became a 
QALY gain of 0.048 (0.523 × 0.1835 × 0.5) favoring the VR-CBT condition and this 
was statistically significant (SE = 0.011, t114 = 4.37, 95% CI 0.026–0.069, P < .001).
Incremental costs
Incremental health care costs 
As can be seen in table 7.2, the average per-patient health care costs in the TAU group 
was €1,396 at baseline, €648 at posttreatment, and €1,039 at follow-up. The average 
per-patient health care costs in the VR-CBT group was €1,918 at baseline, €3,031 at 
posttreatment, and €887 at follow-up. This includes €373.95 per patient for VR-related 
costs included in the posttreatment costs.
The cumulative costs per patient between baseline and follow-up, including the costs of 
VR-CBT, were €1,686 and €3,917 in the TAU and VR-CBT conditions, respectively. 
The between-group difference was €2,231 (€3,917–€1,686) and was statistically 
significant (SE = 663, t114 = 3.36, P = .001) when not adjusted for the initial cost 
difference between the conditions at baseline. After adjustment for baseline costs, the 
incremental health care costs became slightly less at €2,170 and retained statistical 
significance (SE = 661, t113 = 3.28, P = .001).
Incremental costs stemming from productivity losses 
A total of 11.2% (13/116) of the participants had paid work. The average costs stemming 
from productivity losses per person for the TAU group was €224 at baseline, €214 at 
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posttreatment, and €104 at follow-up. The average costs stemming from productivity 
losses per person for the VR-CBT group was €553 at baseline, €359 posttreatment and 
€28 at follow-up. The cumulative costs per patient between baseline and follow-up were 
€317 and €387 in the TAU and VR-CBT conditions, respectively. The between-group 
difference was €70 (€387–€317) and was not statistically significant (SE = 274, t114 = 
-0.26, P = .80).
Travel costs 
The average costs stemming from travel per person for the TAU group was €29 at 
baseline, €23 at posttreatment, and €24 at follow-up. The average travel costs per person 
for the VR-CBT group was €31 at baseline, €60 at posttreatment, and €28 at follow-up. 
The cumulative travel costs per patient between baseline and follow-up were €47 and 
€88 in the TAU and VR-CBT conditions, respectively. The between-group difference 
was €41 (€88–€47) and was statistically significant (SE = 6, t114 = -6.73, P < .001).
Incremental costs from the societal perspective 
The cumulative societal costs per patient between baseline and follow-up were €2,050 
and €4,393 in the TAU and VR-CBT conditions, respectively. The between-group 
difference was €2,343 (€4,293–€2,050) and was statistically significant (SE = 747, t114 
= -3.14, P = .002).
Incremental cost-effectiveness ratios from the societal perspective 
The mean incremental costs for a positive treatment responder was as follows:
1. Time spent with others: €2,343/0.23=€10,069. 
2. Momentary anxiety: €2,343/0.12=€19,525. 
3. Momentary paranoia: €2,343/0.29=€8,079. 
4. The mean incremental cost per QALY: €2,343/0.048=€48,868.
Figures 7.2 to 7.4 depict the distribution of the 5,000 bootstrapped ICERs over the 
cost-effectiveness plane for each of the social participation measures. Figure 7.2 depicts 
time spent with others, the plane illustrates 99.70% of the ICERs fall in the northeast 
quadrant, indicating that more treatment responses are gained for higher costs. Figure 
7.3 depicts momentary anxiety, the plane illustrates 90.74% of the ICERs fall in the 
northeast quadrant, indicating that more treatment responses are gained for higher 
costs. Figure 7.4 depicts momentary paranoia, the plane illustrates 99.74% of the ICERs 
fall in the northeast quadrant, indicating that more treatment responses are gained for 
higher costs.
Figure 7.5 depicts the distribution of the bootstrapped ICERs over the cost-effectiveness 
plane, with the vast majority of the ICERs in the northeast quadrant, indicating that 







Figure 7.2. Cost-effectiveness plane and willingness to pay (WTP) acceptability curve for time spent with others.
 
Figure 7.3. Cost-effectiveness plane and willingness to pay (WTP) acceptability curve for momentary anxiety.
 
Figure 7.4. Cost-effectiveness plane and willingness to pay (WTP) acceptability curve for momentary paranoia.
 
more QALYs are gained but for higher costs, while 0.02% of the simulated ICERs fall 
in the southeast quadrant (i.e., QALY gains for lower costs) for the VR-CBT group 




The mean incremental cost per QALY was €48,868. When looking at the acceptability 
curve in figure 7.5, a higher probability that the VR-CBT intervention is deemed 
cost-effective can also be calculated. For an 80% certainty of cost-effectiveness, the 
incremental cost for gaining 1 QALY is €66,161, which falls well below the willingness-
to-pay ceiling of €80,000 in the Netherlands for a severely disabling condition, such as 
schizophrenia characterized by paranoid delusions220.
Looking at the three treatment responses, at 50% probability of being cost-effective, 
the costs are as mentioned: time spent with others, €10,069; momentary anxiety, 
€19,525; and momentary paranoia, €8,079. Supposing that a decision maker needs an 
80% certainty, time spent with others will have to be valued at €14,293 per treatment 
responder; momentary anxiety at €50,000; and momentary paranoia at €11,342.
Sensitivity analysis 
When including safety behavior at baseline as a covariate, the incremental costs per 
treatment responder on time spent with others became €9,136; momentary anxiety 
became €17,535; and momentary paranoia became €7,219. When including safety 
behavior at baseline as a covariate, the incremental costs per QALY gained became 
€44,597. Overall, incremental costs were somewhat lower when the baseline difference 
of safety behaviors was included in the analysis.
When including psychiatric admission costs at baseline as a covariate, the incremental 
costs per treatment responder on time spent with others became €9,729; momentary 
anxiety became €18,879; and momentary paranoia became €7,750. When including 
psychiatric admission at baseline as a covariate, the incremental costs per QALY gained 
became €47,308. Overall, incremental costs were somewhat lower when the baseline 
difference of psychiatric admission costs was included in the analysis.
Figure 7.5. Cost-effectiveness plane and willingness to pay (WTP) acceptability curve for quality-adjusted life year 











When including both psychiatric admission costs at baseline and safety behavior at 
baseline as covariates, the incremental costs per treatment responder on time spent with 
others became €8,592; momentary anxiety became €16,597; and momentary paranoia 
became €6,800. When including both psychiatric admission costs and safety behavior at 
baseline as covariates, the incremental costs per QALY gained became €42,030. Overall, 
incremental costs were lower when the baseline differences of both safety behaviors and 
psychiatric admission costs were included in the analysis.
Discussion
Principal findings 
This study aimed to get an impression of short-term cost-effectiveness of VR-CBT for 
patients with paranoid delusions in comparison to TAU from a societal perspective. 
Data were collected 6 months after baseline at follow-up. Costs per treatment responder 
gained were estimated to be between €8,079 and €19,525 for different aspects of social 
participation, with between 90.74% and 99.74% showing improvement. Cost per 
QALY gained at follow-up was estimated to be €48,868 with 99.98% showing improved 
QALYs. Sensitivity analyses showed costs to be lower when baseline differences in both 
safety behavior and psychiatric admission costs were included in the analysis. Costs per 
treatment responder gained were then estimated to be between €6,800 and €16,597, 
with cost per QALY gained at €42,030.
Results in context 
How much a society values solidarity with people burdened by disease will determine if 
guidelines are translated to actual treatment of patients. While the VR-CBT treatment 
condition is more expensive than TAU only, that was to be expected, as the aim was to 
add to existing treatment. Results show that this addition improves social participation 
for people with a psychotic disorder suffering from paranoid ideation. We see this 
improvement for time spent with others, momentary paranoia, momentary anxiety, and 
paranoid ideation, via the GPTS.
Engaging in psychological therapy is challenging for many patients suffering from 
paranoid ideation and treatment results vary. There are several aspects that favor VR 
treatment. Person-specific behavioral exposure is an important part of increasing 
treatment effect187, which is exactly what the interactive VR social environments offer. 
Patients themselves also prefer VR over in vivo exposure treatment221 and VR improves 
treatment motivation for patients12.
Interestingly, during the follow-up we see that the VR-CBT group resulted in decreased 
health care costs and decreased costs due to productivity loss compared to the TAU-only 
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group. There were no psychiatric admission days at follow-up for the VR-CBT group. 
To determine whether this was a coincidence or a trend, a much longer follow-up period 
is needed. Short-term societal costs were between €8,079 and €19,525 for a positive 
treatment response. A disability weight of zero represents no loss of health and a weight 
of 1 represents health loss equivalent to death222. In the Netherlands, the willingness to 
pay for gaining a QALY ranges between €20,000 and €80,000 but differs per disease223. 
For a severely disabling disease such as schizophrenia, which according to the Global 
Burden of Disease study 2010 has a disability weight of 0.76, the willingness to pay is 
€80,000220,223. In this context, the VR-CBT treatment that has an ICER of €48,868 per 
QALY gained can be regarded as acceptable from the cost-effectiveness point of view.
Limitations 
The study has several limitations. First, data were collected only 6 months postbaseline. 
Any longer-term effects and costs are unknown. There are indications that cost-
effectiveness for treatment of psychotic symptoms improves with time224 as health benefits 
continue. Second, minimal treatment response was set at a 20% symptom reduction. A 
20% symptom reduction after just 8 weeks of therapy is clinically relevant in a patient 
group with an average duration of illness of 14 years with persistently high problematic 
isolation. Third, VR-CBT was compared to TAU only. The next step would be to 
compare VR-CBT directly to CBT, which is the current gold standard, as CBT without 
VR also results in additional costs to TAU. There are, however, also indications that 
VR-CBT could have positive results in fewer sessions compared to CBT115. Comparing 
VR-CBT directly to CBT also allows for the study of presumed benefits of VR therapy, 
such as better engagement and the ecological validity of VR on outcome effects. Such a 
study comparing VR-CBT and CBT on time to response and costs is currently ongoing 
(Netherlands Trial Register number NL7758). A final limitation was that QALYs 
were not measured directly. As the EQ-5D (European Quality of Life Five Dimension 
Scale) was not administered, QALYs were calculated using Sanderson et al.’s conversion 
factor214. Future research needs to include the EQ-5D for direct measurement.
Conclusions
This study found VR-CBT to be cost-effective in the short term from a societal 
perspective. However, the effect of additional VR-CBT sessions and long-term effects 
need to be determined while using direct measurement of QALYs.








Supplementary table S7.1. Direct medical costs
Price 2015 in Euro
Psychiatrist/Psychologist 112
Training WRAP Total 560,- * 





Note. Prices are from 2015 and are in Euros. * 8 (sessions) × 2.5 (hours) × 2 (therapists) × 112 (euro per contact-hour) / 







Brief summary of main findings



























of	virtual	 reality-based	cognitive	behavioral	 therapy	 for	paranoid	 ideations	and	social	
functioning	(chapter	5–7).
Chapter	 2	 explored	mechanisms	 of	 paranoid	 ideation	 using	 controlled	 virtual	 social	









stress	 in	 a	 virtual	 reality	 environment.	 Results	 showed	 an	 additive	 effect	 of	 separate	
cognitive	biases	on	paranoid	response	to	social	stress.	The	effect	of	social	environmental	







environment.	This	 study	 replicated	 gender	 differences	 in	 cybersickness	 symptoms.	 It	
also	replicated	findings	that	a	significant	correlation	between	anxiety	and	cybersickness	
can	be	 found	 in	healthy	 individuals,	 but	not	 in	patients.	Anxiety	partially	mediated	
cybersickness	 symptoms,	 particularly	 nausea	 and	 disorientation.	 Cybersickness	
symptoms	 appear	 to	 overlap	 with	 anxiety	 symptoms	 and	 are	 therefore	 expected	 to	
decline	during	treatment.
The	 second	 study	 was	 an	 intervention	 study.	 We	 developed	 a	 virtual	 reality-based	
cognitive	behavioral	therapy	for	patients	with	a	psychotic	disorder,	which	was	assessed	






showed	 that	 paranoid	 ideation	 and	 anxiety	 during	 real-life	 social	 situations	 were	
significantly	reduced	in	the	virtual	reality-based	cognitive	behavioral	treatment	group	







or	 assessments.	 Chapter	 7	 demonstrated	 that	 offering	 virtual	 reality-based	 cognitive	
behavioral	 treatment	 to	 patients	 with	 paranoid	 delusions	 is	 an	 economically	 viable	
approach	 for	 improving	 the	 patients’	 health	 in	 a	 cost-effective	manner227.	The	mean	





in	 virtual	 reality	 improves	 the	 daily	 life	 of	 patients.	 Virtual	 reality-based	 cognitive	






information	 about	 social	 environments	 and	 events.	 Momentary	 assessment	 studies	
cannot	control	occurrence	of	events.	This	study	was	the	first	to	experimentally	expose	
individuals	 to	 complex	 social	 environments	 with	 different	 degrees	 of	 social	 stressors	
that	were	completely	controlled.	The	type	and	degree	of	environmental	stress	were	both	
controlled,	meaning	that	all	participants	were	exposed	to	exactly	the	same	environmental	
conditions,	which	would	be	 impossible	 in	a	real-life	 social	 setting.	The	use	of	virtual	
reality	 also	 prevents	 unintended	 interaction	 effects	 between	 participants	 and	 other	













to	assess	 the	generalization	of	 treatment	effects	on	 the	daily	 life	of	patients.	Another	
strength	is	the	generalizability	of	the	study.	The	study	was	carried	out	in	seven	mental	
health	centers,	and	treatment	was	conducted	within	the	standard	healthcare	system	by	
regularly	 employed	 therapists	who	 received	 additional	 training	 and	 supervision.	Co-
morbid	diagnoses	of	the	participants	were	accepted	as	part	of	clinical	reality.	Our	results	
suggest	the	efficacy	and	affordability	of	virtual	reality-based	cognitive	behavioral	therapy	




than	 real	 life,	 which	may	 have	 reduced	 ecological	 validity.	 In	 the	 ecological	 validity	
study,	 there	 was	 no	 condition	 without	 any	 social	 stressors,	 i.e.	 without	 any	 virtual	
people	 or	 social	 noise	 in	 the	 virtual	 environment.	Therefore,	 it	 cannot	 be	 ruled	 out	
that	the	number	of	stimuli	in	virtual	reality	was	more	important	than	the	social	nature	
of	 the	 stressors.	However,	 the	 additional	 effect	 of	 avatars’	 hostile	 looks	 compared	 to	
a	similar	environment	with	neutral	avatars	does	suggests	 that	 the	social	aspect	of	 the	
stressors	matters.	In	this	study,	the	ultrahigh	risk	group	was	small	(n	=	20),	consisted	









term	 effects	 of	 virtual	 reality-based	 cognitive	 behavioral	 therapy	 remain	 unknown,	
because	follow-up	was	restricted	to	just	six	months	post	baseline.	Thirdly,	some	eligible	

















may	be	 impacted	by	a	history	of	 childhood	 trauma229.	Participants	with	a	history	of	
childhood	trauma	responded	to	social	stressors	with	more	distress,	and	this	effect	grew	
stronger	when	the	 level	of	social	stress	 increased.	The	effect	between	social	stress	and	
paranoid	 delusions	 is	moderated	 by	 cognitive	 biases,	 as	 shown	 in	 chapter	 3.	When	
presented	 with	 social	 stress,	 mentalizing	 accuracy	 in	 individuals	 with	 schizophrenia	
decreased	significantly230.	And	following	this	exposure	to	social	stress,	patients	reported	
significantly	 higher	 conviction	 in	 their	 paranoid	 ideas.	 Psychological	 treatment	 for	
the	modification	of	cognitive	biases	is	called	metacognitive	training	and	shows	mixed	
results110,231.	More	effective	modification	of	cognitive	biases	 is	needed,	as	 they	hinder	
corrective	 learning	 from	 exposure.	 Increased	 understanding	 of	 how	 each	 specific	
cognitive	 bias	 uniquely	 contributes	 to	 paranoid	 delusions	 could	 improve	 treatment.	
We	found	that	both	attention	to	threat	bias	and	external	attribution	bias	increase	the	
strength	 of	 the	 paranoid	 response	 to	 social	 stress.	This	 suggests	 that	 these	 biases	 are	






Virtual reality-based cognitive behavioral therapy for psychotic disorders
We	found	virtual	reality-based	cognitive	behavioral	therapy	to	be	very	effective	in	treating	







behavioral	 therapy	 yields	 clinically	 relevant	 treatment	 effects	 more	 quickly.	 Even	 if	
there	 are	 some	 additional	 costs	 to	 virtual	 reality-based	 cognitive	 behavioral	 therapy,	
















in	a	 supermarket,	 ‘the	 therapist	might	ask,	 ‘how	high’,	 to	which	the	patient	answers,	
‘7’,	 talking	about	 their	 level	of	anxiety.	 In	a	virtual	 supermarket,	 the	patient	 stays	 in	
the	privacy	of	the	therapy	room,	where	patient	and	therapist	can	talk	about	anything	
and	everything	that	is	relevant	in	that	specific	situation.	This	turned	out	to	be	a	great	
additional	 benefit.	 Instead	 of	 having	 to	 rely	 on	 retrospective	 information,	 virtual	
reality	offers	the	opportunity	to	discuss	thoughts,	feelings	and	behavior	as	they	present	
themselves.	This	 led	 to	 better	 understanding	 for	 both	 therapist	 and	patient.	A	 third	
advantage	is	the	ability	to	give	direct	feedback	to	a	patient.	In	virtual	reality	treatment,	
the	therapist	can	positively	reinforce	all	adequate	behaviors	of	the	patient.	At	the	same	










patients	do	have	 to	be	 able	 to	deal	with	unexpected	 situations	 in	 real	 life.	 In	 a	 later	
stage	of	the	treatment	process,	patient	and	therapist	can	agree	to	practice	with	virtual	
social	situations	where	the	patient	does	not	know	the	circumstances	in	advance.	A	fifth	
advantage	 is	 the	 opportunity	 to	 rehearse.	When	 doing	 exercises	 in	 vivo,	 interaction	
occurs	within	 real-world	 environments.	For	 example,	 if	 you	do	 a	 real-life	 exercise	 at	
the	 check-out	 register	 in	 a	 supermarket,	 the	patient	 interacts	with	 the	 cashier.	Now,	
imagine	that	a	rehearsal	is	necessary,	then	at	least	a	different	cashier,	or	maybe	even	a	
different	 shop	 is	needed.	 In	a	virtual	 supermarket,	 exercises	 can	be	 repeated	as	often	











researched:	 skill	 training	and	AVATAR	therapy.	A	review	on	virtual	 reality	 treatment	









course	of	 therapy.	A	 large	 randomized	controlled	 trial	 showed	that	AVATAR	therapy	
was	more	 effective	 in	 reducing	 the	 severity	 of	 verbal	 hallucinations	 than	 supportive	
counseling,	with	a	large	effect	size189.	These	findings	have	since	been	replicated,	observing	
a	strong	therapeutic	effect	on	the	distress	associated	with	the	voices242.	
Affordability of  virtual reality in mental healthcare services
While	 costs	 of	 virtual	 reality	 hardware	 and	 software	 are	 declining,	 they	 are	 still	
substantial.	 In	 the	 Netherlands,	 health	 insurers	 encourage	 the	 use	 of	 virtual	 reality	
treatment	by	supplying	an	additional	compensation.	Currently,	therapists	need	to	treat	
about	five	people	per	virtual	reality	set	per	day	to	cover	all	costs.	Anecdotal	evidence	
suggests	 five	 virtual	 reality	 treatments	 per	 day	 is	 optimistic.	 We	 asked	 in	 personal	
communication	Dutch	clinical	departments,	who	reported	treating	about	three	patients	
per	virtual	reality	set	a	day.	This	means	that	the	mental	health	institutions	need	to	invest	
several	 thousands	 of	 euros	 each	 year.	 Since	many	mental	 health	 institutions	 struggle	
financially,	 the	willingness	to	 implement	virtual	reality	therapy	remains	 limited,	even	
though	institutions	are	excited	about	the	benefits	for	patients.	It	is	our	hope	that	further	
technological	 developments	 will	 reduce	 hardware	 costs.	 In	 addition,	 competition	 in	
software	providers	may	reduce	software	costs.	Finally,	health	insurance	companies	could	
increase	 the	 additional	 compensation	 to	 further	 encourage	 the	 use	 of	 virtual	 reality	
treatment.	When	we	reach	the	point	that	all	virtual	reality	costs	are	covered	by	the	extra	
insurance	fee,	we	expect	to	see	a	quick	rise	in	implementation	of	virtual	reality	treatment	
in	mental	 healthcare	 services.	 Another	 solution	 could	 be	 to	 create	 a	 transdiagnostic	
standalone	virtual	reality	center	that	caters	to	all	patients	in	a	certain	region.	The	Dutch	




































virtual	 reality-based	 cognitive	 behavioral	 therapy	 should	 be	 investigated	 as	 a	 stand-
alone	 therapy	 and	not	 just	 as	 an	 add-on	 to	 antipsychotic	medication.	 Several	 recent	
trials	suggest	that	cognitive	behavioral	therapy	without	medication	may	be	a	safe	and	
acceptable	option	for	people	with	psychosis39,244.	The	ecological	validity	study	showed	
virtual	 reality	 to	 be	 safe	 for	 patients	with	 an	 ultrahigh	 risk	 of	 developing	 psychosis.	
Efficacy	 of	 virtual	 reality-based	 cognitive	 behavioral	 therapy	 should	 be	 investigated	
in	 these	 patients	 as	 well,	 especially	 since	 the	 use	 of	 antipsychotic	medication	 is	 not	
recommended	for	ultrahigh	risk	patients245,246.	A	proactive	cognitive	behavior	therapy	











A	 meta-analysis	 of	 randomized	 controlled	 trials	 for	 virtual	 reality	 exposure	 therapy	
for	 anxiety	 and	 related	disorders	 showed	 that	 virtual	 reality	 exposure	 therapy	 and	 in	
vivo	 exposure	 therapy	 did	 not	 have	 significantly	 different	 effect	 sizes221.	 However,	













360-degree	 videos	 as	 ‘evidence-based’	 virtual	 reality-based	 cognitive	 behavioral	
treatment.	However,	no	research	has	been	conducted	yet	on	360-degree	virtual	reality	






the	patient,	making	 it	 a	more	passive	 experience.	A	 study	 in	healthy	 controls	 shows	
that	 active	 virtual	 reality	 scenarios	 are	more	 effective	 in	 eliciting	 social	 anxiety	 than	
passive	virtual	reality	scenarios252.	Overall,	we	expect	 the	effects	of	360-degree	videos	
to	be	 less	 than	the	effects	of	 interactive	computer-generated	virtual	environments	 for	
virtual	reality-based	cognitive	behavioral	therapy.	The	one	exception	could	be	the	use	
of	personalized	3D-video,	i.e.	filming	a	specific	situation	that	is	important	and	relevant	



































clinical	 practice,	 behavioral	 experiments	 and	 exposure	 exercises	 are	 mostly	 prepared	
during	the	session,	while	the	patient	is	expected	to	perform	these	on	their	own	between	






were:	 the	 individual	 e-health	 technology,	 the	outer	 setting,	 the	 inner	 setting	and	 the	
individual256.	The	lack	of	acceptance	by	health	professionals	is	one	of	the	most	important	
barriers257.	However,	little	is	known	about	the	barriers	specific	to	virtual	reality	therapy.	





trained	 in	 virtual	 reality	 treatment.	Additionally,	we	 saw	 that	 this	 group	was	 already	




working	 in	 the	field	 of	 psychosis.	However,	 research	 on	 implementation	barriers	 for	
virtual	reality	therapy	is	needed	to	move	beyond	anecdotal	experience.	
Using virtual reality to increase treatment frequency
Frequency	of	treatment	sessions	is	a	variable	for	treatment	effect,	but	research	on	this	
subject	is	surprisingly	limited.	In	clinical	practice	in	the	Netherlands,	the	most	common	
therapy	 frequency	 is	 one	 forty-five-minute	 session	 a	 week.	 However,	 clinical	 effect	
trials	generally	offer	two	sixty-minute	therapy	sessions	a	week,	as	was	the	case	with	the	
Dutch	trial	on	virtual	reality	for	social	phobia258	and	the	virtual	reality-based	cognitive	






For	 the	 treatment	 of	 PTSD,	 intensive	 short-term	 therapy	 is	 becoming	 increasingly	
common	in	the	Netherlands,	and	one	study	found	that	73%	of	patients	recovered	from	











Stand-alone virtual reality-based cognitive behavioral therapy 
Not	everyone	can	afford	to	go	see	a	therapist	for	psychological	treatment.	In	countries	










more	 readily	 available	 for	 many	 people.	 While	 there	 are	 initial	 development	 costs,	
implementation	on	personal	consumer	hardware	should	keep	overall	costs	per	person	
low	 if	 many	 people	 get	 access	 to	 the	 treatment.	 For	 relatively	 simple	 psychological	
disorders,	 i.e.	specific	phobia’s	such	as	fear	of	heights	and	fear	of	spiders,	stand-alone	
virtual	reality	treatments	are	already	being	developed.	ZeroPhobia	is	a	fully	self-guided,	
phone	 app-based	 virtual	 reality	 cognitive	 behavior	 therapy	 for	 fear	 of	 heights,	 using	
cardboard	 virtual	 reality	 goggles.	ZeroPhobia	 showed	 large	 symptom	 reduction	 after	
three	 months262.	 OxfordVR	 is	 also	 dedicated	 to	 developing	 automated	 treatments,	
using	a	virtual	coach.	They	currently	offer	programs	for	fear	of	heights263	and	for	social	



















For	 this	option	 to	become	readily	available	 in	 the	 future,	 two	conditions	need	 to	be	
met.	Firstly,	virtual	 reality	hardware	needs	 to	become	a	common	household	 item,	or	
at	least	easy	and	inexpensive	to	obtain	when	needed.	Secondly,	patients	should	be	able	
to	download	 the	virtual	 reality	 software	online,	as	 is	already	common	 in	 the	gaming	
industry.	The	 software	 should	allow	patients	 to	 create	 automated	virtual	 scenarios	 to	
practice	with.	Developing	 several	 automated	 scenarios	 in	 advance,	 together	with	 the	
therapist,	can	become	part	of	the	treatment	protocol.	Since	no	such	automated	virtual	











to	 develop	 full	 stand-alone	 virtual	 reality	 treatment	 for	more	 complex	 psychological	




therapy266,267.	Personalization	of	 the	agent’s	 feedback	messages	was	 found	particularly	
important	when	symptoms	were	getting	worse.	For	example:	‘I see you indicate that your 
complaints have gotten substantially worse (note rising symptoms). I’m sorry to hear that 








a	 fully	 automated,	 semi-structured	 screening	 interview	with	 a	 single	user	 via	 spoken	
language.	An	analysis	of	face-to-face	interviews	informed	the	creation	of	an	AI	that	was	
ultimately	 fully-automated.	The	Computer	Expression	Recognition	Toolbox	 (CERT)	





management,	 displayed	 their	 sadness	more	 intensely	 and	were	 rated	 by	 observers	 as	
more	willing	 to	disclose	 than	participants	who	believed	 they	were	 interacting	with	a	
human269.	A	new	version	of	Ellie	as	a	mobile	phone	app	is	also	in	development,	using	
self-report	and	wearable	devices	for	biofeedback	to	inform	the	virtual	human	AI270.
In	conclusion,	 stand-alone	virtual	 reality	could	replace	psychological	 treatment	given	
by	a	therapist	for	relatively	simple	disorders	in	the	near	future.	It	does	seem	likely	that	
more	 virtual	 reality	 treatments	 will	 become	 fully	 automated	 and	 will	 even	 become	
available	as	apps.	Using	stand-alone	virtual	reality	to	treat	more	complex	disorders	poses	













of	 artificial	 intelligence	 could	 provide	more	 stand-alone	 options	 in	 the	 future,	 these	
are	 still	 quite	 a	way	 off	 for	 treatment	 of	 the	most	 complex	 disorders.	However,	 the	
aforementioned	GameChange	project	is	taking	a	first	step	in	this	direction,	and	it	will	
be	very	interesting	to	see	if	this	generates	clinical	results.		













why	we	 found	no	change	 in	 the	 factor	 ‘perceived	 social	 threat’,	 since	 this	 factor	was	
about	enjoying	company	and	feeling	accepted.	Research	on	the	subjective	experience	







New	 technologies	 related	 to	 virtual	 reality	 are	developing	 rapidly.	One	 technological	
development	 is	 augmented	 reality.	Augmented	 reality	 is	defined	by	Merriam-webster	
as:	 ‘an	enhanced	version	of	reality	created	by	the	use	of	 technology	to	overlay	digital	
information	 on	 an	 image	 of	 something	 being	 viewed	 through	 a	 device	 (such	 as	 a	
smartphone	 camera)’.	 This	 device	 can	 be	 a	 smartphone	 (think	 ‘Pokémon	 Go’),	 an	
augmented	reality	headset	or	augmented	glasses	you	can	wear	outside,	such	as	Google	




as	 part	 of	 its	 strength	 is	 that	 it	 allows	 patients	 to	 travel	 to	 different	 places	 without	
leaving	the	therapy	room.	Augmented	glasses	do	offer	interesting	additional	features	for	
therapeutic	purposes.	The	person	wearing	the	glasses	can	be	presented	with	an	additional	






situations.	When	biofeedback	shows	 increased	anxiety,	 the	virtual	 therapist	could	say	
something	similar	to	the	aforementioned	personalized	messages267:	‘I see your anxiety is 
rising (acknowledgement). I’m sorry to see that (empathy). However, that’s completely normal 









from	 multiple	 perspectives,	 increasing	 understanding	 of	 that	 virtual	 social	 scenario.	
Using	a	first-person	perspective	in	virtual	reality	also	allows	a	person	to	walk	a	mile	in	
someone	else’s	 shoes.	For	example,	Auti-Sim	 is	a	virtual	 reality	experience	of	 sensory	
overload	as	experienced	by	people	with	autism	spectrum	disorder.	After	the	experience,	
participants	reported	increased	emotional	concern,	helping	intentions,	and	willingness	
























group279.	 While	 this	 study	 underlines	 the	 possible	 impact	 of	 experiencing	 a	 virtual	













The future is mixed reality
Virtual	 reality	 brings	 daily	 life	 into	 the	 therapy	 room,	while	 experience	momentary	
sampling	 technology	 measures	 psychological	 phenomena	 in	 their	 natural	 context.	
Technology	continues	to	close	the	gap	between	the	real	life	of	patients	and	the	therapy	
room.	 This	 coincides	 with	 the	 growing	 importance	 of	 technology	 and	 multimedia	
realities	 in	western	 society.	The	 recent	 unforeseen	COVID-19	pandemic	 has	 acutely	
accelerated	the	use	and	implementation	of	E-health	in	mental	healthcare	and	may	prove	
to	be	a	turning	point254.	





to	expand	their	boundaries.	As	writer	William	Gibson	states:	“Cyberspace is everything. 
It’s interpenetrating our everyday reality to the point that on-line is our normal waking state”.	
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Addendum 1. De verwarde man
De Virtual  Reality Ervaring  De Verwarde Man  is gemaakt om mensen te laten 
ervaren hoe het is om een psychose te hebben. Tijdens de workshop met deze VR-
ervaring ontdek je al snel dat de grens tussen gezond en verward gedrag niet zo 





























Dutch summary, acknowledgements, 










Korte samenvatting van de belangrijkste bevindingen
Dit proefschrift rapporteert over twee klinische onderzoek studies. De eerste studie 
onderzocht mechanismen van paranoïde wanen, inclusief de ecologische validiteit van 
virtuele sociale omgevingen voor het uitlokken van paranoïde gedachten en gedrag, het 
de veiligheid van gebruik omtrent het optreden van cyber sickness (Hoofdstuk 2–4). 
De tweede studie was een gerandomiseerd klinisch onderzoek naar de effecten van in 
virtual reality gebaseerde cognitieve gedragstherapie voor paranoïde wanen en sociaal 
functioneren (Hoofdstuk 5–7). 
Hoofdstuk 2 onderzocht mechanismen van paranoïde wanen en maakte daarvoor gebruik 
van gecontroleerde virtuele sociale omgevingen100. We vonden dat zowel paranoïde 
gedachten als subjectieve spanning toenamen in overeenstemming met de hoeveelheid 
sociale stress die aan de virtuele sociale omgeving werd toegevoegd. Psychose gevoeligheid 
en reeds bestaande symptomen hadden een positieve invloed op de mate van achterdocht 
en stress die mensen ervaarde in reactie op de sociale stress. Deze resultaten geven 
experimenteel bewijs dat een verhoogde gevoeligheid voor sociale stress een belangrijke 
rol speelt in het ontstaan en het beloop van psychotische stoornissen. 
Cognitieve biases zijn geassocieerd met psychose gevoeligheid en paranoïde wanen225. 
Hoofdstuk 3 onderzocht de modererende relatie tussen reeds bestaande zelf-gerapporteerde 
cognitieve biases en het optreden van paranoïde gedachten in reactie op verschil lende 
niveaus van sociale stress in een virtuele sociale omgeving. De resultaten lieten een additief 
effect zien van de verschillende cognitieve biases op de mate van paranoïde response bij 
sociale stress. Dus hoe meer verschillende cognitief biases er bij één persoon aanwezig 
waren, des te sterker de paranoïde respons op sociale stress. Daarnaast lieten de resultaten 
dien dat bij de aanwezigheid van de cognitieve biases ‘Aandacht voor gevaar’ of ‘Externe 
attributie’ mensen een versterkte paranoïde respons gaven in reactie op sociale stress. 
Cybersickness is een negatief bijeffect van bloostelling aan virtual reality omgevingen, 
en het optreden ervan is gerelateerd aan het stoppen met virtual reality therapie. 
Hoofdstuk 4 onderzocht het optreden van cybersickness226. Een grote meerderheid 
van de deelnemers rapporteerde tenminste één symptoom van cybersickness nadat 
ze waren blootgesteld aan de virtual reality omgeving. Wat opviel was dat een groot 
deel van deze symptomen vooraf ook al gerapporteerd werden, dus nog voordat de 
deelnemers waren blootgesteld aan een virtual reality omgeving. Deze studie repliceerde 
gender verschillen in het optreden van cybersickness symptomen, waarbij vrouwen 
meer cybersickness symptomen rapporteren, ook al vooraf aan de blootstelling aan 
de virtual reality omgeving. Het onderzoek repliceerde ook dat een significante relatie 
tussen angst en cybersickness symptomen wel gevonden wordt bij deelnemers met 
een lage psychosegevoeligheid (‘gezonde controles’), maar niet bij deelnemers met een 
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hoge psychosegevoeligheid. Mogelijk kan dat worden verklaard omdat deelnemers 
met een hoge psychose gevoeligheid vooraf al veel meer symptomen van cybersickness 
rapporteerde. Angst bleek een gedeeltelijke mediator voor het optreden van cybersickness 
symptomen, vooral voor misselijkheid en desoriëntatie symptomen. Het lijkt er op 
dat cybersickness symptomen overlappen met de symptomen die optreden bij angst. 
De verwachting is daarom ook dat als de angst gedurende een virtual reality therapie 
afneemt, de gerapporteerde cybersickness symptomen ook een daling zullen laten zien. 
De tweede studie van dit proefschrift was een interventie onderzoek. We ontwikkelden 
een in virtual reality gebaseerde cognitieve gedragstherapie voor patiënten met een 
psychotische stoornis. De therapie is onderzocht in een enkel-blind gerandomiseerde 
gecontroleerde multicenter onderzoekstudie. 
Hoofdstuk 5 beschrijft het studie protocol dat werd ontworpen om het effect te 
onderzoeken van de therapie op sociale participatie in het dagelijks leven van patiënten 
met een psychotische stoornis114. 
Hoofdstuk 6 presenteert de belangrijkste resultaten van de klinische onderzoekstudie213. 
De meting na de virtual reality therapie liet een significante afname zien van paranoïde 
gedachten en angst tijdens sociale situaties in het dagelijks leven, vergeleken met de 
controle groep die de behandeling niet had gekregen. Deze verbeteringen bleven bestaan 
bij de follow-up meting. De meting na de virtual reality therapie liet geen significante 
toename zien van de hoeveelheid tijd doorgebracht met andere mensen. Bij de follow-
up meting was er wel een significante toename van de hoeveelheid tijd doorgebracht 
met andere mensen ten opzichte van de controle groep, alleen liet de ruwe data zien 
dat dit vooral kwam doordat de controle groep minder tijd was gaan doorbrengen met 
andere mensen. De groep die de virtual reality behandeling heeft gekregen liet verder 
bij de follow-up meting een significante verbetering zien van sociaal functioneren en 
een afname van zelf-stigmatisering, terwijl de controle groep geen verbeteringen liet 
zien. Veiligheidsgedrag (bijvoorbeeld vermijden of vluchten) en problemen met sociale 
cognitie waren mediatoren van verandering in de paranoïde symptomen. Er traden 
bij de metingen en bij de behandeling geen ongewenste onbedoelde effecten (adverse 
events) op. 
Hoofdstuk 7 toonde aan dat het aanbieden van in virtual reality gebaseerde cognitieve 
gedragstherapie aan patiënten met paranoïde wanen een economisch vatbare benadering 
is voor het verbeteren van de gezondheid van patiënten met een psychotische stoornis 
op een kosteneffectieve manier227. De gemiddelde incrementele kosten voor een 
behandeleffect op sociale participatie bedroeg tussen de €8.079 en €19.525, waarbij 
90,74%–99,74% van de patiënten een verbetering liet zien. De gemiddelde incrementele 
kosten per QALY (Quality-adjusted life year) bedroeg €48.868 over de 6 maanden tot 








Over het algeheel kan worden gezegd dat symptomen en cognitieve biases die mensen in 
het dagelijks sociale leven hebben, ook optreden in virtuele sociale omgevingen. Virtual 
reality kan goed worden gebruikt voor wetenschappelijk onderzoek naar (sociale) 
mechanismen zoals die van paranoïde wanen. Omgekeerd, zorgt een behandeling in 
virtuele sociale omgevingen voor verbeteringen in het dagelijks leven van patiënten met 
een psychotische stoornis die last hebben van angst en achterdocht. In virtual reality 
gebaseerde cognitieve gedragstherapie is ecologisch valide, veilig, effectief en economisch 
verantwoord voor implementatie in de gezondheidszorg voor de behandeling van 
patiënten met een psychotische stoornis. 
Sterke punten en beperkingen
Het belangrijkste sterke punt in het onderzoek naar mechanismen en ecologische 
validiteit in hoofdstuk 2, 3 en 4 is dat we gebruik hebben gemaakt van virtual reality 
als een middel om onderzoek te doen naar interacties tussen individuen en complexe 
sociale omgevingen. 
Omgevingsstudies worden gecompliceerd door subjectieve retrospectieve informatie 
over sociale omgevingen en gebeurtenissen. Ecologische steekproef studies (ESM) 
kunnen wel metingen doen in de sociale omgeving, maar hebben geen invloed op het 
optreden van gebeurtenissen. Deze studie was de eerste die deelnemers experimenteel 
blootstelde aan complexe sociale omgevingen met diverse niveaus van sociale stress die 
compleet gecontroleerd waren. Zowel het type sociale stress als de mate van sociale 
stress werden gecontroleerd, waardoor alle deelnemers blootgesteld werden aan exact 
dezelfde omgevingsfactoren. Dat zou volstrekt onmogelijk zijn in echte dagelijkse 
sociale omgevingen. Het gebruik van virtual reality voorkwam ook onbedoelde 
interactie effecten tussen deelnemers en andere mensen in de sociale omgeving, wat 
ons in staat stelde de mechanismen van paranoïde wanen te bestuderen welke inherent 
plaatsvinden in een sociale context. Een ander sterk punt van de eerste studie is ook het 
onderzoeken van deelnemers met verschillende maten van gevoeligheid voor psychose, 
waardoor we mechanismen onderzoek konden doen over verschillende niveaus van 
psychosegevoeligheid heen. 
Onze tweede onderzoek heeft de algemene voordelen die gepaard gaan met een gerando-
miseerde gecontroleerde studie. Een sterk punt specifiek voor deze studie is het gebruik 
van de Experience Sampling Methode naar de generalisatie van behandeleffecten naar het 
dagelijks leven van de deelnemers. Een ander sterk punt is de generaliseerbaarheid van 
de studie. De studie is uitgevoerd in de dagelijkse praktijk van zeven GGZ instellingen, 
en uitgevoerd door de psychologen in dienst van de instelling met een aanvullende 
training en supervisie. De inclusiecriteria waren ruim; alle co morbiditeit aan klachten 
en classificaties van deelnemers werden geaccepteerd als de klinische realiteit. Daarmee 
laten onze resultaten het effect en de betaalbaarheid zien van in virtual reality gebaseerde 
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cognitieve gedragstherapie in realistische omstandigheden, bij een groep patiënten die 
representatief zijn voor de dagelijkse klinische praktijk. 
Zoals ook eerder beschreven in de losse hoofdstukken, hebben beide studies verschillende 
beperkingen. De virtuele sociale omgevingen die zijn gebruikt bij beide studies zijn 
gesimuleerd en daarmee minder complex dan het echte leven, wat de ecologische 
validiteit beperkt kan hebben. 
In de eerste studie naar mechanismen en ecologische validiteit was geen conditie 
opgenomen zonder enige sociale stressoren, ofwel zonder enige virtuele mensen of sociaal 
achtergrond geluid in de virtuele omgeving. Daardoor kan niet worden uitgesloten dat 
het aantal stimuli in de virtuele omgeving belangrijker was dan de sociale aard van de 
stressoren. Echter, het additionele effect van de boze gezichtsuitdrukkingen vergeleken 
met dezelfde omgeving met neutrale gezichtsuitdrukkingen suggereert dat het sociale 
aspect van de stressoren van belang is. In deze studie was het aantal participanten in de 
ultra high risk groep klein (n = 20), bestond deze vooral uit vrouwen, en rapporteerde 
deze groep gemiddeld meer psychotische klachten dan de psychosegroep. Dit kan 
mogelijk worden verklaard doordat deze groep in een eerdere fase van behandeling 
werden geïncludeerd of omdat ze geen gebruik maakte van anti psychotische medicatie. 
Dit kan hebben geleid tot een onderschatting van het effect van de psychosegevoeligheid 
op achterdocht en angst in virtual reality. Cognitieve biases werden gemeten door 
middel van zelfrapportage en beperkt tot vier cognitieve biases. Ten slotte rapporteerden 
deelnemers slechts weinig cybersickness en weinig tot geen angstklachten, wat de 
statistische power beperkte bij deze analyses. 
De tweede studie, naar het behandeleffect van in virtual reality gebaseerde cognitieve 
gedragstherapie, heeft drie belangrijke beperkingen. We hebben geen gebruik gemaakt 
van een actieve controle conditie, waardoor we geen dosis-effect van therapeutische 
contacten kunnen uitsluiten. Ten tweede kunnen we nog niets zeggen over de lange 
termijn effecten van in virtual reality gebaseerde cognitieve gedragstherapie, want de 
follow-up meting was beperkt tot slechts zes maanden na de baseline meting. Ten slotte is 
het waarschijnlijk dat een groep patiënten die in aanmerking kwam voor de behandeling 
niet heeft deelgenomen, omdat ze te angstig waren naar de therapie-locatie af te reizen. 
Daardoor is onze steekproef bevooroordeeld, omdat veel van de meest achterdochtige en 









“I’m not crazy, my reality is just different from yours”
Cheshire Cat in ‘Alice in wonderland’ by Lewis Carroll 
Toen ik in 2013 als PhD-kandidaat startte had ik niet kunnen bedenken wat een enorm 
gaaf en totaal uit de hand gelopen avontuur dit zou gaan worden. 
Er zijn veel mensen die ik graag wil bedanken. Een aantal zal ik hier bij naam noemen, 
maar ook degenen die ik niet bij naam noem en die wel hebben geholpen, tot steun zijn 
geweest en hebben geïnspireerd wil ik bedanken. 
Beste (ridder) Mark, 
Ik had me geen betere mentor kunnen wensen tijdens dit PhD-avontuur. Ik heb zo 
veel van je geleerd de afgelopen jaren, en nog steeds. Je enthousiasme voor de psychose 
zorg is aanstekelijk en inspirerend, net als je kwaliteiten als onderzoeker. Komt er nog 
een boek met alle verhalen ‘uit de oude GGZ-doos’? Ik mis nu al de verhalen over de 
Token-economie, en over patiënten die zichzelf emanciperen van hun stemmen. Als 
zelf clinical-practitioner heb je me vanaf het begin af aan gesteund bij mijn wens om 
naast onderzoek ook klinisch werk en belangrijke opleidingen (VGCt/GZ/EMDR!) te 
kunnen blijven doen. Ook binnen het onderzoek kwamen de belangen van patiënten 
op de eerste plaats. Ik kon altijd bij je terecht voor vragen en advies. Ik waardeer ook 
hoe ik veel vrijheid kreeg om mijn werk naar eigen inzicht vorm te geven en uit te 
voeren. Tegelijk kon ik er ook op vertrouwen dat ik je om hulp kon vragen als dat 
nodig was. Dan ging je echt stevig voor mijn & onze belangen staan, waarvoor ik erg 
dankbaar was. Je hebt me daarnaast ontzettend geholpen een ‘platform’ te vinden. Door 
me te betrekken bij projecten en presentaties, door me voor te stellen aan belangrijke 
vakgenoten, door mij naar voren te schuiven wanneer als je als professor uitnodigingen 
kreeg over de VR. Wat als net beginnende onderzoeker zo ontzettend het verschil kan 
maken of het lukt hier een carrière in de vinden. Ik ben heel erg blij en dankbaar voor 




In de eerste week van mijn PhD traject zei je, ik parafraseer wat, dat het allemaal wel 
goed zou komen. Dat het nu aan het begin heel overweldigend was zo’n PhD, maar dat 
aan het einde van het traject ik zo’n specialist zou zijn dat jullie als mijn promotoren míj 
om informatie over het onderwerp zouden vragen. Je zei het een beetje ter relativering, 
en het was een enorme geruststelling die in de jaren daarna nog veel door mijn hoofd is 
gegaan als het even overweldigend leek. Ik waardeer ook erg hoe, als ik om advies vroeg, 
je eerst vroeg wat mijn ideeën er zelf over waren voor je met advies kwam. Dat leerde me 
mezelf serieus nemen als onderzoeker, omdat jij dat ook deed. 
I would like to thank the Thesis Committee for their valuable time. I really appreciate 
each of your willingness to be part of this, as I highly respect and value your professional 
work and opinions. 
Prof. Heleen Riper. A leading expert in E-health innovation for improving mental health 
and quality of life. 
Dr. Lucia Valmaggia, who’s virtual reality research is always amazingly clinically relevant 
and has been crucial for both studies. 
Prof. Emeritus Paul Emmelkamp, who first introduced and trained me in virtual reality 
exposure therapy and who’s pioneering work on virtual reality in the last few decades 
made our research possible. 
Prof. Tania Lincoln. A leading expert in understanding how and why psychotic 
symptoms develop and are maintained. 
Prof. Kees Korrelboom. A leading expert in clinically relevant transdiagnostic 
interventions such as COMET and CBT.
Lieve Wietse,
Mijn beste vriend. Een geweldige vent. De liefde van mijn leven. Mijn steun en rustpunt. 
Mijn cheerleader. Ik ben zo dankbaar dat jij mijn man bent. In de inmiddels 18 jaar 
dat we samen zijn hebben we al zo veel meegemaakt in het leven. Pieken en dalen. 
Verdrietige en zware omstandigheden. En iedere keer komen wij samen er weer sterker 
en liefdevoller uit. Ik had deze enorme PhD-achtbaan met niemand anders willen doen 
dan samen met jou naast mij. Ik had het ook nooit gekund zonder jouw voortdurende 
steun. We zijn een team. Team Awesome. Op naar ons volgende avontuur lieverd, en dat 
er nog vele mogen volgen. <3
Lieve Marion,
Zonder jou had ik hier nu niet gestaan met mijn proefschrift. Je was de onmisbare spil 








verzamelen en beheren was heel waardevol voor mij. Die kennis ga ik de rest van mijn 
onderzoekcarrière wat aan hebben. Ik herinner me een keer dat ik je advies negeerde…
en spijt kreeg want je had gelijk en ik had mezelf daarmee een paar weken extra werk 
bezorgd. Naast je inhoudelijke kennis heb ik ook enorm gewaardeerd hoe je me hielp 
goed voor mezelf te zorgen. Want grenzen stellen en zelfzorg zijn een enorme uitdaging 
in ieder PhD-traject, maar extra in onze twee mega(lomane)projecten. 
Lieve Alyssa,
Jij was volstrekt onmisbaar bij beide studies. Je hebt zo ontzettend veel mooi werk verzet 
en we hebben veel samen meegemaakt. Waar je tijdens de eerste studie begon als jonge 
en enthousiaste psycholoog in opleiding, heb ik je zien groeien naar research assistent 
en inmiddels een capabele en getalenteerde jonge onderzoeker bezig met je eigen PhD-
traject. Ik ben er trots op dat je naast mij staat als paranimf tijdens de verdediging.
Lieve Maartje,
Ik ben dankbaar voor onze bijzondere vriendschap. Ik vond het fantastisch om jou 
paranimf te mogen zijn, en geweldig dat jij nu naast mij staat als mijn paranimf. Je bent 
slim, lief en een grote steun. We zijn er goed in samen het leven te vieren, al dan niet 
op de dansvloer, het terras of met een glaasje wijn. Maar ook als het leven even niet zo’n 
feest is ben je er voor me. Dankjewel. 
Lieve Nicolien,
Ik was zó blij dat jij bij het onderzoek kwam als research assistent. Tegen deze tijd was 
het aantal deelnemende instellingen aan de behandeling opgelopen tot 7, terwijl de 
eerste studie nog uitliep. Het verbaasde me destijds hoe snel ik als controlefreak taken 
volledig aan jou durfde toe te vertrouwen. Je bent slim, capabel en consciëntieus. Het 
was super fijn om met jou samen te werken, dankjewel. 
Lieve Chani, 
Je kwam bij het onderzoek in de laatste fase, en ik was enorm blij met je komst en al 
je harde werken. Je bracht een enorme positieve energie en enthousiasme mee in het 
(inmiddels soms ietsje vermoeide) team. Ik vind het heel gaaf dat je zelf nu ook een PhD 
aan het doen bent, en hoop er nog veel over te horen op de VRET.P etentjes. 
Lieve Elsbeth,
Mijn favoriete VRET.P therapeut. Je hebt zo ontzettend veel werk en inzet voor de 
deelnemers en de studie gedaan. GGZ-Delfland was de enige site waar ik nooit eens 
kopzorgen over had, niet over de inclusies en niet over de behandelingen. Bij jou was dat in 
goede handen. Je bent een fantastisch mens, en inmiddels een van de meest ervaren virtual 




Collega onderzoeker, VRET.P therapeut en coauteur. Je bent zowel een hele goede 
onderzoeker als therapeut, en ik hoop ook in de toekomst weer met je samen te werken. 
De kosteneffectiviteit paper was vooraf best intimiderend, maar jij nam de tijd om me 
rustig uit te leggen hoe het werkt. Ik ben heel benieuwd hoe onze gezamenlijke mooie 
onderzoeksplannen en subsidieaanvragen er de komende jaren verder uit gaan zien. 
Heel erg veel zorg professionals hebben direct of indirect meegewerkt aan de onderzoeken 
zelf, of de disseminatie, en ik ga mijn best doen om er zo veel mogelijk te bedanken:
Te beginnen met Judith Rietdijk, voor het doorsturen van de PhD-vacature, waardoor 
dit hele avontuur kon gaan beginnen. Bedankt Jacqueline Counotte en Chris Geraets, 
mijn mede PhD-kandidaten op de respectievelijke studies. Bedankt Sonia Tiokhina, 
Sanne Bruijniks, Roos Jansen, Mischa van der Helm, Marleen Rietveld, Luyken 
Stouten, Jasper Blömer, Daniëlla Ham, Rachel Schuur, Lian de Bruijn, Katarina 
Korchnakova, Ivana van Berkel, Massi Aoudjan, Berber van der Vleugel, David van 
den Berg, José de Jager, Harm Gijsman, Niels Mulder, Rene Keet, Beyhan Gungormez, 
Maarten Vos, Erna van ’t Hag, Elisabeth Heutink, Edwin Timmer, Mandy van der 
Voort, Anita Berkers, Olivier Hoskam, Natalie Veen, Martijn Schut, Barbara Bender, 
Kimberley Zwaart, Rebecca Ploeg, Merve Yilmaz, Kirsten Kolder, Shantusha Bisai, 
Merve Yilmaz, Margot Kerkhoven, Petra Bervoets, Bianca Raijmakers, Aster van der 
Ploeg, Prachilla Ori, Barbara Bender, Dana-Maria Faneker, PJ Pancras/Tacker en Tape, 
Eddo Velders, Fons van de Kar, Joost Baas, Bas Labruyere.
Bedankt, Guntur Sandino, Niels ter Heijden, Huib Piguillet, Freek Jan Hamming, Joris 
Voermans en Yme Canter Visscher voor het creëren van de virtuele werelden. 
Bedankt ook alle andere coauteurs van de artikelen in dit proefschrift, voor jullie feedback 
en (statistiek)uitleg die er voor heeft gezorgd dat het mooie en degelijke artikelen zijn 
geworden: Filip Smit, Philipe Delespaul, Joran Lokkerbol, Marije van Beilen, Jim van 
Os en Tonnie Staring.
Bedankt Linda Broeder en Laraine Visser-Isles voor jullie hulp en ondersteuning met 
de Engelse taal. Bedankt Manuel van der Graaf voor het ontzettend gave design voor de 
kaft van mijn proefschrift. 
Bedankt ook lieve vrienden voor het luisteren en de steun, maar ook voor de gezellige 
afleiding en feestjes de afgelopen jaren; Peter Taverne, Linda Broeder, Manuel van der 
Graaf, Lisette Altena, Louise Misiewicz, Sebastiaan Dalmeijer, Boukje van Eck, Anne 
de Boer, Max Woldhuis, Moniek Veltman, Friso Holtkamp, Janita Terpstra, Jack Ha, 
Rishma Khubsing, Dagmar Smeink, Marije Schaap, Wouter de Vries, Sjoukje Kramer-
de Haas, Alexander Kramer, Jackson Choo, Shareen Kalicharan, Celine Boevé, Anne 








Vermaat, Iman Adan, Elisabeth Verbeeck, Cor Hekert, Lummieke IJmker, Saskia 
Caumans, Tamar Kraan, Karin Pos, Raluca Ioana Zamfir. 
Veel instellingen en organisaties hebben bijgedragen aan de in dit proefschrift beschreven 
wetenschappelijke onderzoeken, waarvoor ik erg dankbaar ben. Deze bijdragen maken 
innovaties en het verbeteren van zorg mogelijk.
De subsidiegevers die ons werk mogelijk maakte:
•	 Netherlands Organization for Health Research and Development 
•	 Fonds NutsOhra 
•	 Stichting tot Steun VCVGZ 
Bedankt GGZ-instellingen die tijd, ruimte en mankracht in de onderzoeken 
investeerde: Parnassia, Antes (voorheen BAVO), Dijk & Duin, GGZ-Delfland, GGZ-
NoordHollandNoord, ProPersona en het UMCG
Ik wil de Parnassia Bavo groep bedanken voor hun steun om ons kernteam deze onder-
zoeken uit te laten voeren, met in het bijzonder Ellen van Hummel. 
En ten slotte wil ik graag de meest essentiële medewerkers aan dit proefschrift bedanken; 
alle patiënten en andere deelnemers die vrijwillig hun tijd en energie hebben gegeven 
voor het wetenschappelijk onderzoek. Ik hoop jullie moeite recht te hebben gedaan met 
dit proefschrift. Ik kan jullie niet bij naam bedanken, maar zonder jullie hulp was er 
geen wetenschappelijk onderzoek. 
Een persoon wil ik nog persoonlijk bedanken, en dat is Edwin. De hoofdpersoon uit de 
korte film ‘Een podium voor Edwin’ gemaakt door Bas Labruyère met steun van de aan 
Mark van der Gaag toegekende ‘Ria van der Heijdenprijs’. Dankzij zijn openheid en 
bereidheid te vertellen over zijn persoonlijke ervaringen zijn vele (toekomstige) collega’s 
al opgeleid in de virtual reality therapie. En er zullen nog vele volgen. Aan het einde van 
de film is een kort stuk van het mooie gedicht te horen dat Edwin heeft voorgedragen 
in theater De Veste. Ik ben er trots op dat Edwin toestemming heeft gegeven het gehele 




Schizofrenie zo gek nog niet  !
De ziekte ontpopt zich in de puberteit.
Van een rups tot naar een vlinder.
Nog niet wetende dat deze zal zorgen voor erg veel hinder.
Het is in ieder geval een feit:  
Een schizofreen is zeker geen gespleten persoonlijkheid.
Het is ook niet de schuld van de moeder.
Wat nog niet zo lang geleden werd gedacht.
Wel is het een ernstige aandoening die zorgt voor veel: 
Angst, (over)vermoeidheid en onmacht.
De last die ik heb van de ziekte, voelt vaak als 
een blok aan mijn been.
Toch ben ik een gelukkige schizofreen.
Genieten van de kleine dingen in het leven.
Zoals een zonnige dag in Maart.
En een beperking is pas een beperking 
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